{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": []
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "code",
      "execution_count": 3,
      "metadata": {
        "id": "c0gv8AQAYfGM"
      },
      "outputs": [],
      "source": [
        "import numpy as np\n",
        "import pandas as pd\n",
        "\n",
        "\n",
        "from sklearn.model_selection import train_test_split\n",
        "from sklearn.model_selection import cross_val_score\n",
        "\n",
        "from sklearn.linear_model import LogisticRegression\n",
        "from sklearn.tree import DecisionTreeClassifier\n",
        "from sklearn.ensemble import RandomForestClassifier\n",
        "\n",
        "\n",
        "from sklearn.compose import ColumnTransformer\n",
        "from sklearn.preprocessing import FunctionTransformer\n",
        "from sklearn.metrics import accuracy_score\n",
        "\n",
        "\n",
        "from matplotlib import pyplot as plt\n",
        "import seaborn as sns"
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "50St_ssrgoB4"
      },
      "execution_count": 3,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# from google.colab import drive\n",
        "# drive.mount('/content/drive')"
      ],
      "metadata": {
        "id": "FnYbHE0kYOa4"
      },
      "execution_count": 4,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# import requests\n",
        "# from io import StringIO\n",
        "# url = \"\"\n",
        "# headers = \"User-Agent\": \"Mozilla/5.0 (Macintosh; Intel Mac OS X 10.14; rv:66.0) Gecko/20100101 Firefox/66.0\"}\n",
        "# req requests.get(url, headers=headers)\n",
        "# data = StringIO(req.text)\n",
        "# pd.read_csv(data)"
      ],
      "metadata": {
        "id": "ZTftz12mdL-X"
      },
      "execution_count": 5,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df = pd.read_csv('/content/usecase_2_.csv',on_bad_lines='skip', encoding='latin-1',quoting =3)"
      ],
      "metadata": {
        "id": "ZMTTkqt0Yxm8"
      },
      "execution_count": 6,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df.shape"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "2wgrhZgreI2e",
        "outputId": "f2a7b4a9-5584-4615-9eed-45aedb501d6b"
      },
      "execution_count": 7,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "(141683, 26)"
            ]
          },
          "metadata": {},
          "execution_count": 7
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df.sample(1)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 269
        },
        "id": "mokoSkSMYyrx",
        "outputId": "347667f6-4a80-4b36-dff0-c80c19118c6f"
      },
      "execution_count": 8,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                                                                                                       Unnamed: 0  \\\n",
              "* I have felt little interest or pleasure in do... NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN        NaN   \n",
              "\n",
              "                                                                                                                       NCT Number  \\\n",
              "* I have felt little interest or pleasure in do... NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN        NaN   \n",
              "\n",
              "                                                                                                                       Study Title  \\\n",
              "* I have felt little interest or pleasure in do... NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN         NaN   \n",
              "\n",
              "                                                                                                                       Study URL  \\\n",
              "* I have felt little interest or pleasure in do... NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN       NaN   \n",
              "\n",
              "                                                                                                                       Acronym  \\\n",
              "* I have felt little interest or pleasure in do... NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN     NaN   \n",
              "\n",
              "                                                                                                                       Study Status  \\\n",
              "* I have felt little interest or pleasure in do... NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN          NaN   \n",
              "\n",
              "                                                                                                                       Brief Summary  \\\n",
              "* I have felt little interest or pleasure in do... NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN           NaN   \n",
              "\n",
              "                                                                                                                       Study Results  \\\n",
              "* I have felt little interest or pleasure in do... NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN           NaN   \n",
              "\n",
              "                                                                                                                       Conditions  \\\n",
              "* I have felt little interest or pleasure in do... NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN        NaN   \n",
              "\n",
              "                                                                                                                       Interventions  \\\n",
              "* I have felt little interest or pleasure in do... NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN           NaN   \n",
              "\n",
              "                                                                                                                        ...  \\\n",
              "* I have felt little interest or pleasure in do... NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN  ...   \n",
              "\n",
              "                                                                                                                        Age  \\\n",
              "* I have felt little interest or pleasure in do... NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN  NaN   \n",
              "\n",
              "                                                                                                                       Phases  \\\n",
              "* I have felt little interest or pleasure in do... NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN    NaN   \n",
              "\n",
              "                                                                                                                       Enrollment  \\\n",
              "* I have felt little interest or pleasure in do... NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN        NaN   \n",
              "\n",
              "                                                                                                                       Funder Type  \\\n",
              "* I have felt little interest or pleasure in do... NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN         NaN   \n",
              "\n",
              "                                                                                                                       Study Type  \\\n",
              "* I have felt little interest or pleasure in do... NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN        NaN   \n",
              "\n",
              "                                                                                                                       Study Design  \\\n",
              "* I have felt little interest or pleasure in do... NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN          NaN   \n",
              "\n",
              "                                                                                                                       Other IDs  \\\n",
              "* I have felt little interest or pleasure in do... NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN       NaN   \n",
              "\n",
              "                                                                                                                       Locations  \\\n",
              "* I have felt little interest or pleasure in do... NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN       NaN   \n",
              "\n",
              "                                                                                                                       Study Documents  \\\n",
              "* I have felt little interest or pleasure in do... NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN             NaN   \n",
              "\n",
              "                                                                                                                       Time taken for Enrollment  \n",
              "* I have felt little interest or pleasure in do... NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN NaN                       NaN  \n",
              "\n",
              "[1 rows x 26 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-b2f24f38-1dd7-4eb0-b6b7-4a94bb30a0be\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th>Unnamed: 0</th>\n",
              "      <th>NCT Number</th>\n",
              "      <th>Study Title</th>\n",
              "      <th>Study URL</th>\n",
              "      <th>Acronym</th>\n",
              "      <th>Study Status</th>\n",
              "      <th>Brief Summary</th>\n",
              "      <th>Study Results</th>\n",
              "      <th>Conditions</th>\n",
              "      <th>Interventions</th>\n",
              "      <th>...</th>\n",
              "      <th>Age</th>\n",
              "      <th>Phases</th>\n",
              "      <th>Enrollment</th>\n",
              "      <th>Funder Type</th>\n",
              "      <th>Study Type</th>\n",
              "      <th>Study Design</th>\n",
              "      <th>Other IDs</th>\n",
              "      <th>Locations</th>\n",
              "      <th>Study Documents</th>\n",
              "      <th>Time taken for Enrollment</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>* I have felt little interest or pleasure in doing things.</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>1 rows × 26 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-b2f24f38-1dd7-4eb0-b6b7-4a94bb30a0be')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-b2f24f38-1dd7-4eb0-b6b7-4a94bb30a0be button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-b2f24f38-1dd7-4eb0-b6b7-4a94bb30a0be');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe"
            }
          },
          "metadata": {},
          "execution_count": 8
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df.shape"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "oPKUNOdSYypc",
        "outputId": "bf3766fd-d748-43c5-ca6b-466ff5ad0be0"
      },
      "execution_count": 9,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "(141683, 26)"
            ]
          },
          "metadata": {},
          "execution_count": 9
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df.info()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "CfRkA5JYYynH",
        "outputId": "77f9aaeb-d329-43f0-83df-a0127e98a414"
      },
      "execution_count": 10,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "<class 'pandas.core.frame.DataFrame'>\n",
            "MultiIndex: 141683 entries, ('0', 'NCT04841499', '\"Effects of a Seven-day BASISâ\\x84¢ Supplementation on Menopausal Syndromes and Measurements of the Urinary Vitamin B3 and Estradiol Levels in Pre-', ' Peri- and Post-menopause\"', 'https://clinicaltrials.gov/study/NCT04841499', nan, 'COMPLETED', '\"The purpose of this study is to determine whether a short supplementation (7days) with BASISâ\\x84¢ increases the natural production of estradiol', ' measured in urinary waste. The overall objective is to determine whether through increased estradiol levels', ' the undesirable menopausal effects', ' assessed via questionnaires', ' are mitigated by a short-term supplementation with BASISâ\\x84¢\"', 'NO', 'Menopause', 'DRUG: BASISâ\\x84¢ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg)', '\"Production of Estradiol', ' To determine whether a short supplementation with BASISâ\\x84¢ impacts the natural production of estradiol', ' measured in urinary waste.') to ('The aim of this study is to evaluate the cumulative incidence of CTEPH after a PE.\"', 'NO', 'Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|Pulmonary Embolism', 'DIAGNOSTIC_TEST: Study population', '\"Cumulated incidence of CTEPH', ' Cumulated incidence rate of CTEPH after pulmonary embolism', ' 30-day +/- 15 days after inclusion visit\"', '\"Cumulated incidence of CTEPH in patients without previous signs of CTEPH at the time of index PE diagnosis', ' Cumulated incidence rate of CTEPH in patients without previous signs of CTEPH at the time of index PE diagnosis', ' 30-day +/- 15 days after inclusion visit|Cumulated incidence of CTEPH in patients with previous signs of CTEPH at the time of index PE diagnosis', ' Cumulated incidence rate of CTEPH in patients with previous signs of CTEPH at the time of index PE diagnosis', ' 30-day +/- 15 days after inclusion visit|Risk factors of CTEPH', ' Hazard ratio of risk factors independently and significantly associated with the diagnosis of CTEPH after pulmonary embolism', ' 30-day +/- 15 days after inclusion visit|Complications associated with right heart catheterization', ' Complication rate of right heart catheterization', ' 30-day +/- 15 days after inclusion visit|Complications associated with pulmonary angiography', ' Complication rate of pulmonary angiography', ' 30-day +/- 15 days after inclusion visit\"')\n",
            "Data columns (total 26 columns):\n",
            " #   Column                      Non-Null Count  Dtype \n",
            "---  ------                      --------------  ----- \n",
            " 0   Unnamed: 0                  36637 non-null  object\n",
            " 1   NCT Number                  36167 non-null  object\n",
            " 2   Study Title                 34618 non-null  object\n",
            " 3   Study URL                   34259 non-null  object\n",
            " 4   Acronym                     33248 non-null  object\n",
            " 5   Study Status                32696 non-null  object\n",
            " 6   Brief Summary               31766 non-null  object\n",
            " 7   Study Results               31411 non-null  object\n",
            " 8   Conditions                  30675 non-null  object\n",
            " 9   Interventions               29998 non-null  object\n",
            " 10  Primary Outcome Measures    29331 non-null  object\n",
            " 11  Secondary Outcome Measures  28715 non-null  object\n",
            " 12  Other Outcome Measures      27770 non-null  object\n",
            " 13  Sponsor                     26986 non-null  object\n",
            " 14  Collaborators               25882 non-null  object\n",
            " 15  Sex                         24957 non-null  object\n",
            " 16  Age                         23512 non-null  object\n",
            " 17  Phases                      22013 non-null  object\n",
            " 18  Enrollment                  20539 non-null  object\n",
            " 19  Funder Type                 18828 non-null  object\n",
            " 20  Study Type                  17052 non-null  object\n",
            " 21  Study Design                15619 non-null  object\n",
            " 22  Other IDs                   13784 non-null  object\n",
            " 23  Locations                   12192 non-null  object\n",
            " 24  Study Documents             10568 non-null  object\n",
            " 25  Time taken for Enrollment   8998 non-null   object\n",
            "dtypes: object(26)\n",
            "memory usage: 68.7+ MB\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df= df.drop(['Unnamed: 0','NCT Number','Acronym','Study URL','Study Title','Brief Summary','Secondary Outcome Measures','Primary Outcome Measures','Other Outcome Measures','Other IDs','Study Documents'] , axis=1)"
      ],
      "metadata": {
        "id": "lVXfwcN8a3QA"
      },
      "execution_count": 11,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df.shape"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "E2C62hZgoNeh",
        "outputId": "542c436d-6d6d-4272-82e3-617d775e9981"
      },
      "execution_count": 12,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "(141683, 15)"
            ]
          },
          "metadata": {},
          "execution_count": 12
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df.isnull().sum()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 554
        },
        "id": "ITy_aOBQomW6",
        "outputId": "615f2cb1-45cb-4db5-ec63-d633c1358ece"
      },
      "execution_count": 13,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Study Status                 108987\n",
              "Study Results                110272\n",
              "Conditions                   111008\n",
              "Interventions                111685\n",
              "Sponsor                      114697\n",
              "Collaborators                115801\n",
              "Sex                          116726\n",
              "Age                          118171\n",
              "Phases                       119670\n",
              "Enrollment                   121144\n",
              "Funder Type                  122855\n",
              "Study Type                   124631\n",
              "Study Design                 126064\n",
              "Locations                    129491\n",
              "Time taken for Enrollment    132685\n",
              "dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>0</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>Study Status</th>\n",
              "      <td>108987</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Study Results</th>\n",
              "      <td>110272</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Conditions</th>\n",
              "      <td>111008</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Interventions</th>\n",
              "      <td>111685</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Sponsor</th>\n",
              "      <td>114697</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Collaborators</th>\n",
              "      <td>115801</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Sex</th>\n",
              "      <td>116726</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Age</th>\n",
              "      <td>118171</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Phases</th>\n",
              "      <td>119670</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Enrollment</th>\n",
              "      <td>121144</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Funder Type</th>\n",
              "      <td>122855</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Study Type</th>\n",
              "      <td>124631</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Study Design</th>\n",
              "      <td>126064</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Locations</th>\n",
              "      <td>129491</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Time taken for Enrollment</th>\n",
              "      <td>132685</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 13
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "##Remove more than 10 missing value including rows"
      ],
      "metadata": {
        "id": "UV6bElTLpeTE"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_cleaned = df[df.isnull().sum(axis=1) <10]"
      ],
      "metadata": {
        "id": "qReGmikkomUq"
      },
      "execution_count": 14,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df_cleaned.shape"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "3Z0tKVnComSU",
        "outputId": "4fabca7d-c343-4253-d6fa-935b0b3638b9"
      },
      "execution_count": 15,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "(28015, 15)"
            ]
          },
          "metadata": {},
          "execution_count": 15
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_cleaned.isnull().sum()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 554
        },
        "id": "gPF5aq0yp9c9",
        "outputId": "dcafa672-158b-44bf-a87f-f49f792fa5d7"
      },
      "execution_count": 16,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Study Status                  4199\n",
              "Study Results                 3945\n",
              "Conditions                    3804\n",
              "Interventions                 3566\n",
              "Sponsor                       2428\n",
              "Collaborators                 3258\n",
              "Sex                           3267\n",
              "Age                           4557\n",
              "Phases                        6020\n",
              "Enrollment                    7476\n",
              "Funder Type                   9187\n",
              "Study Type                   10963\n",
              "Study Design                 12396\n",
              "Locations                    15823\n",
              "Time taken for Enrollment    19017\n",
              "dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>0</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>Study Status</th>\n",
              "      <td>4199</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Study Results</th>\n",
              "      <td>3945</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Conditions</th>\n",
              "      <td>3804</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Interventions</th>\n",
              "      <td>3566</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Sponsor</th>\n",
              "      <td>2428</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Collaborators</th>\n",
              "      <td>3258</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Sex</th>\n",
              "      <td>3267</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Age</th>\n",
              "      <td>4557</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Phases</th>\n",
              "      <td>6020</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Enrollment</th>\n",
              "      <td>7476</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Funder Type</th>\n",
              "      <td>9187</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Study Type</th>\n",
              "      <td>10963</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Study Design</th>\n",
              "      <td>12396</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Locations</th>\n",
              "      <td>15823</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Time taken for Enrollment</th>\n",
              "      <td>19017</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 16
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "\n",
        "df_cleaned['Adress'] = df_cleaned['Locations'].str.split(',').str[-1].str.strip()\n",
        "\n",
        "# df_cleaned['Adress'] = df_cleaned['Locations'].str.split(r'|', expand=True).apply(lambda x: x.str.split(',').str[-1].str.strip(), axis=1)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "UfjaBv5auYGB",
        "outputId": "b6aeb008-8add-4cce-acbe-5cfec1b12df0"
      },
      "execution_count": 17,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "<ipython-input-17-75d0de7c6c50>:1: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_cleaned['Adress'] = df_cleaned['Locations'].str.split(',').str[-1].str.strip()\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_cleaned['Adress'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 489
        },
        "collapsed": true,
        "id": "Rx-3a9RXuYDI",
        "outputId": "f4e2bb2d-64f6-4ee1-aeec-6e19a7b13381"
      },
      "execution_count": 18,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Adress\n",
              "INTERVENTIONAL                                                                                                                   505\n",
              "United States\"                                                                                                                   455\n",
              "\"Study Protocol and Statistical Analysis Plan                                                                                    178\n",
              "OTHER                                                                                                                            173\n",
              "Turkey\"                                                                                                                          129\n",
              "                                                                                                                                ... \n",
              "Increase in the differentiation between up- and down-regulation of the fNIRS signal from session 1 to session 8 (for feedback      1\n",
              "\"Auckland Clinical Studies Ltd                                                                                                     1\n",
              "0446-18-EP                                                                                                                         1\n",
              "68588                                                                                                                              1\n",
              "01246000                                                                                                                           1\n",
              "Name: count, Length: 5341, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Adress</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>INTERVENTIONAL</th>\n",
              "      <td>505</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>United States\"</th>\n",
              "      <td>455</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>\"Study Protocol and Statistical Analysis Plan</th>\n",
              "      <td>178</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>OTHER</th>\n",
              "      <td>173</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Turkey\"</th>\n",
              "      <td>129</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Increase in the differentiation between up- and down-regulation of the fNIRS signal from session 1 to session 8 (for feedback</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>\"Auckland Clinical Studies Ltd</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>0446-18-EP</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>68588</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>01246000</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>5341 rows × 1 columns</p>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 18
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# df_cleaned = df_cleaned[df_cleaned['Adress'].notna() & (df_cleaned['Adress'] != '')]\n",
        "\n",
        "# # Count the frequency of each name in the column\n",
        "# name_counts = df_cleaned['Adress'].value_counts()\n",
        "\n",
        "# # Replace names that appear only once with 'Single_Name'\n",
        "# df_cleaned['Adress'] = df_cleaned['Adress'].apply(lambda x: 'Single_Name' if name_counts[x] == 1 else x)\n",
        "\n",
        "# # Recalculate name_counts to include 'Single_Name'\n",
        "# name_counts = df_cleaned['Adress'].value_counts()\n",
        "\n",
        "# # Replace names that appear twice with 'Double_Name'\n",
        "# df_cleaned['Adress'] = df_cleaned['Adress'].apply(lambda x: 'Double_Name' if name_counts[x] == 2 else x)\n",
        "\n",
        "# df_cleaned['Adress'] = df_cleaned['Adress'].apply(lambda x: 'Triple_Name' if name_counts[x] == 3 else x)\n",
        "\n",
        "# df_cleaned['Adress'] = df_cleaned['Adress'].apply(lambda x: 'Quadruple_Name' if name_counts[x] == 4 else x)\n",
        "\n",
        "# df_cleaned['Adress'] = df_cleaned['Adress'].apply(lambda x: 'Quintuple_Name' if name_counts[x] == 5 else x)\n",
        "\n",
        "# # df_cleaned['Adress'] = df_cleaned['Adress'].apply(lambda x: 'Sextuple_Name' if name_counts[x] == 6 else x)\n",
        "\n",
        "# df_cleaned['Adress'] = df_cleaned['Adress'].apply(lambda x: 'Septuple_Name' if name_counts[x] == 7 else x)\n",
        "\n",
        "# # df_cleaned['Adress'] = df_cleaned['Adress'].apply(lambda x: 'Octuple_Name' if name_counts[x] == 8 else x)\n",
        "\n",
        "# df_cleaned['Adress'] = df_cleaned['Adress'].apply(lambda x: 'Nonuple_Name' if name_counts[x] == 9 else x)\n",
        "\n",
        "# df_cleaned['Adress'] = df_cleaned['Adress'].apply(lambda x: 'Decuple_Name' if name_counts[x] == 10 else x)\n",
        "\n",
        "# df_cleaned['Adress'] = df_cleaned['Adress'].apply(lambda x: 'Undecuple_Name' if name_counts[x] == 11 else x)\n",
        "\n",
        "# df_cleaned['Adress'] = df_cleaned['Adress'].apply(lambda x: 'Duodecuple_Name' if name_counts[x] == 12 else x)\n",
        "\n",
        "# df_cleaned['Adress'] = df_cleaned['Adress'].apply(lambda x: 'Tredecuple_Name' if name_counts[x] == 13 else x)\n",
        "\n",
        "# df_cleaned['Adress'] = df_cleaned['Adress'].apply(lambda x: 'Quattuordecuple_Name' if name_counts[x] == 14 else x)\n",
        "\n",
        "# df_cleaned['Adress'] = df_cleaned['Adress'].apply(lambda x: 'Quindecuple_Name' if name_counts[x] == 15 else x)\n",
        "\n",
        "# df_cleaned['Adress'] = df_cleaned['Adress'].apply(lambda x: 'Sexdecuple_Name' if name_counts[x] == 16 else x)\n",
        "\n",
        "# df_cleaned['Adress'] = df_cleaned['Adress'].apply(lambda x: 'Septuple_Name' if name_counts[x] == 17 else x)\n",
        "\n",
        "# df_cleaned['Adress'] = df_cleaned['Adress'].apply(lambda x: 'Octodecuple_Name' if name_counts[x] == 18 else x)\n",
        "\n",
        "# df_cleaned['Adress'] = df_cleaned['Adress'].apply(lambda x: 'Novemdecuple_Name' if name_counts[x] == 19 else x)\n",
        "\n",
        "# df_cleaned['Adress'] = df_cleaned['Adress'].apply(lambda x: 'Dodecuple_Name' if name_counts[x] == 20 else x)\n",
        "\n",
        "# df_cleaned['Adress'] = df_cleaned['Adress'].apply(lambda x: 'Undodecuple_Name' if name_counts[x] == 21 else x)\n",
        "\n",
        "# df_cleaned['Adress'] = df_cleaned['Adress'].apply(lambda x: 'Dodeca_Name' if name_counts[x] == 22 else x)"
      ],
      "metadata": {
        "id": "puo2rYvUylgH"
      },
      "execution_count": 19,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df_cleaned['Adress'].value_counts()"
      ],
      "metadata": {
        "id": "XOVJ6tDKuX70",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 489
        },
        "outputId": "0bfc3ce6-0edc-41da-9314-89bc550ef245"
      },
      "execution_count": 20,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Adress\n",
              "INTERVENTIONAL                                                                                                                   505\n",
              "United States\"                                                                                                                   455\n",
              "\"Study Protocol and Statistical Analysis Plan                                                                                    178\n",
              "OTHER                                                                                                                            173\n",
              "Turkey\"                                                                                                                          129\n",
              "                                                                                                                                ... \n",
              "Increase in the differentiation between up- and down-regulation of the fNIRS signal from session 1 to session 8 (for feedback      1\n",
              "\"Auckland Clinical Studies Ltd                                                                                                     1\n",
              "0446-18-EP                                                                                                                         1\n",
              "68588                                                                                                                              1\n",
              "01246000                                                                                                                           1\n",
              "Name: count, Length: 5341, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Adress</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>INTERVENTIONAL</th>\n",
              "      <td>505</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>United States\"</th>\n",
              "      <td>455</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>\"Study Protocol and Statistical Analysis Plan</th>\n",
              "      <td>178</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>OTHER</th>\n",
              "      <td>173</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Turkey\"</th>\n",
              "      <td>129</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Increase in the differentiation between up- and down-regulation of the fNIRS signal from session 1 to session 8 (for feedback</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>\"Auckland Clinical Studies Ltd</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>0446-18-EP</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>68588</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>01246000</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>5341 rows × 1 columns</p>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 20
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_cleaned.Adress.unique()"
      ],
      "metadata": {
        "id": "Rk5vChVWuX5b",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "76d7958b-7b5d-4e93-a95d-80718ae2b7dd"
      },
      "execution_count": 21,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "array(['United States\"', nan, '19', ..., 'Gyeonggi', 'COPD_PBMT',\n",
              "       '01246000'], dtype=object)"
            ]
          },
          "metadata": {},
          "execution_count": 21
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_cleaned['Adress'] = df_cleaned['Adress'].fillna('0')"
      ],
      "metadata": {
        "id": "zOGj-nGVuX1U",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "37c4b214-e189-4c9a-99b7-e1ce2c8c9071"
      },
      "execution_count": 22,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "<ipython-input-22-eef511e9b11a>:1: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_cleaned['Adress'] = df_cleaned['Adress'].fillna('0')\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_cleaned.isnull().sum()"
      ],
      "metadata": {
        "id": "l2eoiYJD2Es1",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 585
        },
        "outputId": "b9e069c5-795f-4191-e321-13561e460aaf"
      },
      "execution_count": 23,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Study Status                  4199\n",
              "Study Results                 3945\n",
              "Conditions                    3804\n",
              "Interventions                 3566\n",
              "Sponsor                       2428\n",
              "Collaborators                 3258\n",
              "Sex                           3267\n",
              "Age                           4557\n",
              "Phases                        6020\n",
              "Enrollment                    7476\n",
              "Funder Type                   9187\n",
              "Study Type                   10963\n",
              "Study Design                 12396\n",
              "Locations                    15823\n",
              "Time taken for Enrollment    19017\n",
              "Adress                           0\n",
              "dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>0</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>Study Status</th>\n",
              "      <td>4199</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Study Results</th>\n",
              "      <td>3945</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Conditions</th>\n",
              "      <td>3804</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Interventions</th>\n",
              "      <td>3566</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Sponsor</th>\n",
              "      <td>2428</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Collaborators</th>\n",
              "      <td>3258</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Sex</th>\n",
              "      <td>3267</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Age</th>\n",
              "      <td>4557</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Phases</th>\n",
              "      <td>6020</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Enrollment</th>\n",
              "      <td>7476</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Funder Type</th>\n",
              "      <td>9187</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Study Type</th>\n",
              "      <td>10963</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Study Design</th>\n",
              "      <td>12396</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Locations</th>\n",
              "      <td>15823</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Time taken for Enrollment</th>\n",
              "      <td>19017</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Adress</th>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 23
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df['Time taken for Enrollment'].dtype"
      ],
      "metadata": {
        "id": "ImlNR8NTscs8",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "46c859d6-a59d-4057-8798-b1f0b97aaf4b"
      },
      "execution_count": 24,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "dtype('O')"
            ]
          },
          "metadata": {},
          "execution_count": 24
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "1yqYt0XltShe"
      },
      "execution_count": 24,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "(df['Time taken for Enrollment'].value_counts())"
      ],
      "metadata": {
        "id": "bIMLHmWQsoHl",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 489
        },
        "outputId": "c0206372-f8e1-4226-9b24-586fd933cb34"
      },
      "execution_count": 25,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Time taken for Enrollment\n",
              " United States\"                                                           393\n",
              "\"Study Protocol and Statistical Analysis Plan                             111\n",
              " Turkey\"                                                                  102\n",
              "3                                                                          82\n",
              " China\"                                                                    79\n",
              "                                                                         ... \n",
              "\"University of Michigan School of Dentistry                                 1\n",
              "2019.28633                                                                  1\n",
              " 60615                                                                      1\n",
              " https://cdn.clinicaltrials.gov/large-docs/78/NCT05214378/ICF_000.pdf\"      1\n",
              " Universidade Nove de Julho (UNINOVE)                                       1\n",
              "Name: count, Length: 4313, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Time taken for Enrollment</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>United States\"</th>\n",
              "      <td>393</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>\"Study Protocol and Statistical Analysis Plan</th>\n",
              "      <td>111</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Turkey\"</th>\n",
              "      <td>102</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>82</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>China\"</th>\n",
              "      <td>79</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>\"University of Michigan School of Dentistry</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2019.28633</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>60615</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>https://cdn.clinicaltrials.gov/large-docs/78/NCT05214378/ICF_000.pdf\"</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Universidade Nove de Julho (UNINOVE)</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>4313 rows × 1 columns</p>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 25
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "(df['Time taken for Enrollment'].value_counts())\n"
      ],
      "metadata": {
        "id": "ZRflmZx67jeG",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 489
        },
        "outputId": "cb226ad5-9916-4ffe-f39e-0460acaac7bc"
      },
      "execution_count": 26,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Time taken for Enrollment\n",
              " United States\"                                                           393\n",
              "\"Study Protocol and Statistical Analysis Plan                             111\n",
              " Turkey\"                                                                  102\n",
              "3                                                                          82\n",
              " China\"                                                                    79\n",
              "                                                                         ... \n",
              "\"University of Michigan School of Dentistry                                 1\n",
              "2019.28633                                                                  1\n",
              " 60615                                                                      1\n",
              " https://cdn.clinicaltrials.gov/large-docs/78/NCT05214378/ICF_000.pdf\"      1\n",
              " Universidade Nove de Julho (UNINOVE)                                       1\n",
              "Name: count, Length: 4313, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Time taken for Enrollment</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>United States\"</th>\n",
              "      <td>393</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>\"Study Protocol and Statistical Analysis Plan</th>\n",
              "      <td>111</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Turkey\"</th>\n",
              "      <td>102</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>82</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>China\"</th>\n",
              "      <td>79</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>\"University of Michigan School of Dentistry</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2019.28633</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>60615</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>https://cdn.clinicaltrials.gov/large-docs/78/NCT05214378/ICF_000.pdf\"</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Universidade Nove de Julho (UNINOVE)</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>4313 rows × 1 columns</p>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 26
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_cleaned.sample(1)"
      ],
      "metadata": {
        "collapsed": true,
        "id": "_-JCspdFp9Yb",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 482
        },
        "outputId": "60d7df61-3b74-434b-f426-6e3c02ffffdd"
      },
      "execution_count": 27,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Study Status  \\\n",
              "20006 NCT02932332 High-Flow Oxygen for Dyspnea in Hospitalized Ca... https://clinicaltrials.gov/study/NCT02932332 NaN COMPLETED \"The goal of this clinical research study is to... low-flow oxygen high-flow air and low-flow air in helping to decrease shortne... YES Cancer OTHER: High-flow Oxygen|OTHER: Low-flow Oxygen|... \"Change in Dyspnea Numeric Score Between 0 and ... We assessed dyspnea intensity 'now' using a num... 0 (baseline) minutes and at 10 minutes\" \"Change in Modified Borg Scale Intensity Betwee... We assessed dyspnea intensity 'now' using a Mod...          NaN   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Study Results  \\\n",
              "20006 NCT02932332 High-Flow Oxygen for Dyspnea in Hospitalized Ca... https://clinicaltrials.gov/study/NCT02932332 NaN COMPLETED \"The goal of this clinical research study is to... low-flow oxygen high-flow air and low-flow air in helping to decrease shortne... YES Cancer OTHER: High-flow Oxygen|OTHER: Low-flow Oxygen|... \"Change in Dyspnea Numeric Score Between 0 and ... We assessed dyspnea intensity 'now' using a num... 0 (baseline) minutes and at 10 minutes\" \"Change in Modified Borg Scale Intensity Betwee... We assessed dyspnea intensity 'now' using a Mod...        \"ADULT   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Conditions  \\\n",
              "20006 NCT02932332 High-Flow Oxygen for Dyspnea in Hospitalized Ca... https://clinicaltrials.gov/study/NCT02932332 NaN COMPLETED \"The goal of this clinical research study is to... low-flow oxygen high-flow air and low-flow air in helping to decrease shortne... YES Cancer OTHER: High-flow Oxygen|OTHER: Low-flow Oxygen|... \"Change in Dyspnea Numeric Score Between 0 and ... We assessed dyspnea intensity 'now' using a num... 0 (baseline) minutes and at 10 minutes\" \"Change in Modified Borg Scale Intensity Betwee... We assessed dyspnea intensity 'now' using a Mod...   OLDER_ADULT\"   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Interventions  \\\n",
              "20006 NCT02932332 High-Flow Oxygen for Dyspnea in Hospitalized Ca... https://clinicaltrials.gov/study/NCT02932332 NaN COMPLETED \"The goal of this clinical research study is to... low-flow oxygen high-flow air and low-flow air in helping to decrease shortne... YES Cancer OTHER: High-flow Oxygen|OTHER: Low-flow Oxygen|... \"Change in Dyspnea Numeric Score Between 0 and ... We assessed dyspnea intensity 'now' using a num... 0 (baseline) minutes and at 10 minutes\" \"Change in Modified Borg Scale Intensity Betwee... We assessed dyspnea intensity 'now' using a Mod...        PHASE2   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Sponsor  \\\n",
              "20006 NCT02932332 High-Flow Oxygen for Dyspnea in Hospitalized Ca... https://clinicaltrials.gov/study/NCT02932332 NaN COMPLETED \"The goal of this clinical research study is to... low-flow oxygen high-flow air and low-flow air in helping to decrease shortne... YES Cancer OTHER: High-flow Oxygen|OTHER: Low-flow Oxygen|... \"Change in Dyspnea Numeric Score Between 0 and ... We assessed dyspnea intensity 'now' using a num... 0 (baseline) minutes and at 10 minutes\" \"Change in Modified Borg Scale Intensity Betwee... We assessed dyspnea intensity 'now' using a Mod...  \"Allocation: RANDOMIZED|Intervention Model: CR...   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Collaborators  \\\n",
              "20006 NCT02932332 High-Flow Oxygen for Dyspnea in Hospitalized Ca... https://clinicaltrials.gov/study/NCT02932332 NaN COMPLETED \"The goal of this clinical research study is to... low-flow oxygen high-flow air and low-flow air in helping to decrease shortne... YES Cancer OTHER: High-flow Oxygen|OTHER: Low-flow Oxygen|... \"Change in Dyspnea Numeric Score Between 0 and ... We assessed dyspnea intensity 'now' using a num... 0 (baseline) minutes and at 10 minutes\" \"Change in Modified Borg Scale Intensity Betwee... We assessed dyspnea intensity 'now' using a Mod...   INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE\"   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Sex  \\\n",
              "20006 NCT02932332 High-Flow Oxygen for Dyspnea in Hospitalized Ca... https://clinicaltrials.gov/study/NCT02932332 NaN COMPLETED \"The goal of this clinical research study is to... low-flow oxygen high-flow air and low-flow air in helping to decrease shortne... YES Cancer OTHER: High-flow Oxygen|OTHER: Low-flow Oxygen|... \"Change in Dyspnea Numeric Score Between 0 and ... We assessed dyspnea intensity 'now' using a num... 0 (baseline) minutes and at 10 minutes\" \"Change in Modified Borg Scale Intensity Betwee... We assessed dyspnea intensity 'now' using a Mod...  2016-0282|NCI-2017-00186   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Age  \\\n",
              "20006 NCT02932332 High-Flow Oxygen for Dyspnea in Hospitalized Ca... https://clinicaltrials.gov/study/NCT02932332 NaN COMPLETED \"The goal of this clinical research study is to... low-flow oxygen high-flow air and low-flow air in helping to decrease shortne... YES Cancer OTHER: High-flow Oxygen|OTHER: Low-flow Oxygen|... \"Change in Dyspnea Numeric Score Between 0 and ... We assessed dyspnea intensity 'now' using a num... 0 (baseline) minutes and at 10 minutes\" \"Change in Modified Borg Scale Intensity Betwee... We assessed dyspnea intensity 'now' using a Mod...  \"The University of Texas MD Anderson Cancer Ce...   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Phases  \\\n",
              "20006 NCT02932332 High-Flow Oxygen for Dyspnea in Hospitalized Ca... https://clinicaltrials.gov/study/NCT02932332 NaN COMPLETED \"The goal of this clinical research study is to... low-flow oxygen high-flow air and low-flow air in helping to decrease shortne... YES Cancer OTHER: High-flow Oxygen|OTHER: Low-flow Oxygen|... \"Change in Dyspnea Numeric Score Between 0 and ... We assessed dyspnea intensity 'now' using a num... 0 (baseline) minutes and at 10 minutes\" \"Change in Modified Borg Scale Intensity Betwee... We assessed dyspnea intensity 'now' using a Mod...   Houston   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Enrollment  \\\n",
              "20006 NCT02932332 High-Flow Oxygen for Dyspnea in Hospitalized Ca... https://clinicaltrials.gov/study/NCT02932332 NaN COMPLETED \"The goal of this clinical research study is to... low-flow oxygen high-flow air and low-flow air in helping to decrease shortne... YES Cancer OTHER: High-flow Oxygen|OTHER: Low-flow Oxygen|... \"Change in Dyspnea Numeric Score Between 0 and ... We assessed dyspnea intensity 'now' using a num... 0 (baseline) minutes and at 10 minutes\" \"Change in Modified Borg Scale Intensity Betwee... We assessed dyspnea intensity 'now' using a Mod...      Texas   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Funder Type  \\\n",
              "20006 NCT02932332 High-Flow Oxygen for Dyspnea in Hospitalized Ca... https://clinicaltrials.gov/study/NCT02932332 NaN COMPLETED \"The goal of this clinical research study is to... low-flow oxygen high-flow air and low-flow air in helping to decrease shortne... YES Cancer OTHER: High-flow Oxygen|OTHER: Low-flow Oxygen|... \"Change in Dyspnea Numeric Score Between 0 and ... We assessed dyspnea intensity 'now' using a num... 0 (baseline) minutes and at 10 minutes\" \"Change in Modified Borg Scale Intensity Betwee... We assessed dyspnea intensity 'now' using a Mod...       77030   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Study Type  \\\n",
              "20006 NCT02932332 High-Flow Oxygen for Dyspnea in Hospitalized Ca... https://clinicaltrials.gov/study/NCT02932332 NaN COMPLETED \"The goal of this clinical research study is to... low-flow oxygen high-flow air and low-flow air in helping to decrease shortne... YES Cancer OTHER: High-flow Oxygen|OTHER: Low-flow Oxygen|... \"Change in Dyspnea Numeric Score Between 0 and ... We assessed dyspnea intensity 'now' using a num... 0 (baseline) minutes and at 10 minutes\" \"Change in Modified Borg Scale Intensity Betwee... We assessed dyspnea intensity 'now' using a Mod...   United States\"   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Study Design  \\\n",
              "20006 NCT02932332 High-Flow Oxygen for Dyspnea in Hospitalized Ca... https://clinicaltrials.gov/study/NCT02932332 NaN COMPLETED \"The goal of this clinical research study is to... low-flow oxygen high-flow air and low-flow air in helping to decrease shortne... YES Cancer OTHER: High-flow Oxygen|OTHER: Low-flow Oxygen|... \"Change in Dyspnea Numeric Score Between 0 and ... We assessed dyspnea intensity 'now' using a num... 0 (baseline) minutes and at 10 minutes\" \"Change in Modified Borg Scale Intensity Betwee... We assessed dyspnea intensity 'now' using a Mod...  \"Study Protocol and Statistical Analysis Plan   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Locations  \\\n",
              "20006 NCT02932332 High-Flow Oxygen for Dyspnea in Hospitalized Ca... https://clinicaltrials.gov/study/NCT02932332 NaN COMPLETED \"The goal of this clinical research study is to... low-flow oxygen high-flow air and low-flow air in helping to decrease shortne... YES Cancer OTHER: High-flow Oxygen|OTHER: Low-flow Oxygen|... \"Change in Dyspnea Numeric Score Between 0 and ... We assessed dyspnea intensity 'now' using a num... 0 (baseline) minutes and at 10 minutes\" \"Change in Modified Borg Scale Intensity Betwee... We assessed dyspnea intensity 'now' using a Mod...        77   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Time taken for Enrollment  \\\n",
              "20006 NCT02932332 High-Flow Oxygen for Dyspnea in Hospitalized Ca... https://clinicaltrials.gov/study/NCT02932332 NaN COMPLETED \"The goal of this clinical research study is to... low-flow oxygen high-flow air and low-flow air in helping to decrease shortne... YES Cancer OTHER: High-flow Oxygen|OTHER: Low-flow Oxygen|... \"Change in Dyspnea Numeric Score Between 0 and ... We assessed dyspnea intensity 'now' using a num... 0 (baseline) minutes and at 10 minutes\" \"Change in Modified Borg Scale Intensity Betwee... We assessed dyspnea intensity 'now' using a Mod...                       NaN   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Adress  \n",
              "20006 NCT02932332 High-Flow Oxygen for Dyspnea in Hospitalized Ca... https://clinicaltrials.gov/study/NCT02932332 NaN COMPLETED \"The goal of this clinical research study is to... low-flow oxygen high-flow air and low-flow air in helping to decrease shortne... YES Cancer OTHER: High-flow Oxygen|OTHER: Low-flow Oxygen|... \"Change in Dyspnea Numeric Score Between 0 and ... We assessed dyspnea intensity 'now' using a num... 0 (baseline) minutes and at 10 minutes\" \"Change in Modified Borg Scale Intensity Betwee... We assessed dyspnea intensity 'now' using a Mod...     77  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-4ac8567d-7676-4399-89d3-6e94d630028d\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th>Study Status</th>\n",
              "      <th>Study Results</th>\n",
              "      <th>Conditions</th>\n",
              "      <th>Interventions</th>\n",
              "      <th>Sponsor</th>\n",
              "      <th>Collaborators</th>\n",
              "      <th>Sex</th>\n",
              "      <th>Age</th>\n",
              "      <th>Phases</th>\n",
              "      <th>Enrollment</th>\n",
              "      <th>Funder Type</th>\n",
              "      <th>Study Type</th>\n",
              "      <th>Study Design</th>\n",
              "      <th>Locations</th>\n",
              "      <th>Time taken for Enrollment</th>\n",
              "      <th>Adress</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>20006</th>\n",
              "      <th>NCT02932332</th>\n",
              "      <th>High-Flow Oxygen for Dyspnea in Hospitalized Cancer Patients</th>\n",
              "      <th>https://clinicaltrials.gov/study/NCT02932332</th>\n",
              "      <th>NaN</th>\n",
              "      <th>COMPLETED</th>\n",
              "      <th>\"The goal of this clinical research study is to compare high-flow oxygen</th>\n",
              "      <th>low-flow oxygen</th>\n",
              "      <th>high-flow air</th>\n",
              "      <th>and low-flow air in helping to decrease shortness of breath in cancer patients. Researchers also want to learn if these therapies can help to improve lung function and quality of life.\"</th>\n",
              "      <th>YES</th>\n",
              "      <th>Cancer</th>\n",
              "      <th>OTHER: High-flow Oxygen|OTHER: Low-flow Oxygen|OTHER: High-flow Air|OTHER: Low-flow Air</th>\n",
              "      <th>\"Change in Dyspnea Numeric Score Between 0 and 10 Minutes</th>\n",
              "      <th>We assessed dyspnea intensity 'now' using a numeric rating scale from 0 to 10 where 0=none and 10=worst. The minimal clinically important difference was 1 point.</th>\n",
              "      <th>0 (baseline) minutes and at 10 minutes\"</th>\n",
              "      <th>\"Change in Modified Borg Scale Intensity Between 0 and 10 Minutes</th>\n",
              "      <th>We assessed dyspnea intensity 'now' using a Modified Dyspnea Borg scale. This is a 0-10 point ratio scale with a higher score indicating worse dyspnea.</th>\n",
              "      <td>NaN</td>\n",
              "      <td>\"ADULT</td>\n",
              "      <td>OLDER_ADULT\"</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>\"Allocation: RANDOMIZED|Intervention Model: CR...</td>\n",
              "      <td>INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE\"</td>\n",
              "      <td>2016-0282|NCI-2017-00186</td>\n",
              "      <td>\"The University of Texas MD Anderson Cancer Ce...</td>\n",
              "      <td>Houston</td>\n",
              "      <td>Texas</td>\n",
              "      <td>77030</td>\n",
              "      <td>United States\"</td>\n",
              "      <td>\"Study Protocol and Statistical Analysis Plan</td>\n",
              "      <td>77</td>\n",
              "      <td>NaN</td>\n",
              "      <td>77</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-4ac8567d-7676-4399-89d3-6e94d630028d')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-4ac8567d-7676-4399-89d3-6e94d630028d button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-4ac8567d-7676-4399-89d3-6e94d630028d');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "repr_error": "Out of range float values are not JSON compliant: nan"
            }
          },
          "metadata": {},
          "execution_count": 27
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "9f8pscH1p9Vp"
      },
      "execution_count": 27,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df.sample(2)"
      ],
      "metadata": {
        "collapsed": true,
        "id": "MTFwW6cPomP1",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 774
        },
        "outputId": "3f3e40c9-82ad-48d1-d363-6a191182566c"
      },
      "execution_count": 28,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Study Status  \\\n",
              "The Montreal Cognitive Assessment (MoCA) is a r...  naming  memory  language  abstraction  delayed recall and orientation. The MoCA has b...  including head trauma. Version 7.1 will be use...  higher score being a better outcome.  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  baseline|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  9 months|Global Fatigue Score as Measured by B...          NaN   \n",
              "   * Health Assessment Questionnaire - Disabili... NaN     NaN     NaN       NaN          NaN                                                NaN                                                NaN                                   NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                         NaN   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Study Results  \\\n",
              "The Montreal Cognitive Assessment (MoCA) is a r...  naming  memory  language  abstraction  delayed recall and orientation. The MoCA has b...  including head trauma. Version 7.1 will be use...  higher score being a better outcome.  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  baseline|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  9 months|Global Fatigue Score as Measured by B...           NaN   \n",
              "   * Health Assessment Questionnaire - Disabili... NaN     NaN     NaN       NaN          NaN                                                NaN                                                NaN                                   NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                          NaN   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Conditions  \\\n",
              "The Montreal Cognitive Assessment (MoCA) is a r...  naming  memory  language  abstraction  delayed recall and orientation. The MoCA has b...  including head trauma. Version 7.1 will be use...  higher score being a better outcome.  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  baseline|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  9 months|Global Fatigue Score as Measured by B...        NaN   \n",
              "   * Health Assessment Questionnaire - Disabili... NaN     NaN     NaN       NaN          NaN                                                NaN                                                NaN                                   NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                       NaN   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Interventions  \\\n",
              "The Montreal Cognitive Assessment (MoCA) is a r...  naming  memory  language  abstraction  delayed recall and orientation. The MoCA has b...  including head trauma. Version 7.1 will be use...  higher score being a better outcome.  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  baseline|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  9 months|Global Fatigue Score as Measured by B...           NaN   \n",
              "   * Health Assessment Questionnaire - Disabili... NaN     NaN     NaN       NaN          NaN                                                NaN                                                NaN                                   NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                          NaN   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sponsor  \\\n",
              "The Montreal Cognitive Assessment (MoCA) is a r...  naming  memory  language  abstraction  delayed recall and orientation. The MoCA has b...  including head trauma. Version 7.1 will be use...  higher score being a better outcome.  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  baseline|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  9 months|Global Fatigue Score as Measured by B...     NaN   \n",
              "   * Health Assessment Questionnaire - Disabili... NaN     NaN     NaN       NaN          NaN                                                NaN                                                NaN                                   NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                    NaN   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Collaborators  \\\n",
              "The Montreal Cognitive Assessment (MoCA) is a r...  naming  memory  language  abstraction  delayed recall and orientation. The MoCA has b...  including head trauma. Version 7.1 will be use...  higher score being a better outcome.  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  baseline|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  9 months|Global Fatigue Score as Measured by B...           NaN   \n",
              "   * Health Assessment Questionnaire - Disabili... NaN     NaN     NaN       NaN          NaN                                                NaN                                                NaN                                   NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                          NaN   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Sex  \\\n",
              "The Montreal Cognitive Assessment (MoCA) is a r...  naming  memory  language  abstraction  delayed recall and orientation. The MoCA has b...  including head trauma. Version 7.1 will be use...  higher score being a better outcome.  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  baseline|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  9 months|Global Fatigue Score as Measured by B...  NaN   \n",
              "   * Health Assessment Questionnaire - Disabili... NaN     NaN     NaN       NaN          NaN                                                NaN                                                NaN                                   NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                 NaN   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Age  \\\n",
              "The Montreal Cognitive Assessment (MoCA) is a r...  naming  memory  language  abstraction  delayed recall and orientation. The MoCA has b...  including head trauma. Version 7.1 will be use...  higher score being a better outcome.  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  baseline|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  9 months|Global Fatigue Score as Measured by B...  NaN   \n",
              "   * Health Assessment Questionnaire - Disabili... NaN     NaN     NaN       NaN          NaN                                                NaN                                                NaN                                   NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                 NaN   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Phases  \\\n",
              "The Montreal Cognitive Assessment (MoCA) is a r...  naming  memory  language  abstraction  delayed recall and orientation. The MoCA has b...  including head trauma. Version 7.1 will be use...  higher score being a better outcome.  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  baseline|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  9 months|Global Fatigue Score as Measured by B...    NaN   \n",
              "   * Health Assessment Questionnaire - Disabili... NaN     NaN     NaN       NaN          NaN                                                NaN                                                NaN                                   NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                   NaN   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Enrollment  \\\n",
              "The Montreal Cognitive Assessment (MoCA) is a r...  naming  memory  language  abstraction  delayed recall and orientation. The MoCA has b...  including head trauma. Version 7.1 will be use...  higher score being a better outcome.  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  baseline|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  9 months|Global Fatigue Score as Measured by B...        NaN   \n",
              "   * Health Assessment Questionnaire - Disabili... NaN     NaN     NaN       NaN          NaN                                                NaN                                                NaN                                   NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                       NaN   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Funder Type  \\\n",
              "The Montreal Cognitive Assessment (MoCA) is a r...  naming  memory  language  abstraction  delayed recall and orientation. The MoCA has b...  including head trauma. Version 7.1 will be use...  higher score being a better outcome.  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  baseline|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  9 months|Global Fatigue Score as Measured by B...         NaN   \n",
              "   * Health Assessment Questionnaire - Disabili... NaN     NaN     NaN       NaN          NaN                                                NaN                                                NaN                                   NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                        NaN   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Study Type  \\\n",
              "The Montreal Cognitive Assessment (MoCA) is a r...  naming  memory  language  abstraction  delayed recall and orientation. The MoCA has b...  including head trauma. Version 7.1 will be use...  higher score being a better outcome.  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  baseline|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  9 months|Global Fatigue Score as Measured by B...        NaN   \n",
              "   * Health Assessment Questionnaire - Disabili... NaN     NaN     NaN       NaN          NaN                                                NaN                                                NaN                                   NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                       NaN   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Study Design  \\\n",
              "The Montreal Cognitive Assessment (MoCA) is a r...  naming  memory  language  abstraction  delayed recall and orientation. The MoCA has b...  including head trauma. Version 7.1 will be use...  higher score being a better outcome.  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  baseline|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  9 months|Global Fatigue Score as Measured by B...          NaN   \n",
              "   * Health Assessment Questionnaire - Disabili... NaN     NaN     NaN       NaN          NaN                                                NaN                                                NaN                                   NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                         NaN   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Locations  \\\n",
              "The Montreal Cognitive Assessment (MoCA) is a r...  naming  memory  language  abstraction  delayed recall and orientation. The MoCA has b...  including head trauma. Version 7.1 will be use...  higher score being a better outcome.  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  baseline|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  9 months|Global Fatigue Score as Measured by B...       NaN   \n",
              "   * Health Assessment Questionnaire - Disabili... NaN     NaN     NaN       NaN          NaN                                                NaN                                                NaN                                   NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                      NaN   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Time taken for Enrollment  \n",
              "The Montreal Cognitive Assessment (MoCA) is a r...  naming  memory  language  abstraction  delayed recall and orientation. The MoCA has b...  including head trauma. Version 7.1 will be use...  higher score being a better outcome.  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  baseline|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  6 months|Global Fatigue Score as Measured by B...  The Brief Fatigue Inventory is a 9 item questi...  with \"\"0\"\" being no fatigue and \"\"10\"\" being a...  9 months|Global Fatigue Score as Measured by B...                       NaN  \n",
              "   * Health Assessment Questionnaire - Disabili... NaN     NaN     NaN       NaN          NaN                                                NaN                                                NaN                                   NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                NaN                                                                      NaN  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-829e3f5b-08d5-4120-bfa8-6579c2fa3410\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th>Study Status</th>\n",
              "      <th>Study Results</th>\n",
              "      <th>Conditions</th>\n",
              "      <th>Interventions</th>\n",
              "      <th>Sponsor</th>\n",
              "      <th>Collaborators</th>\n",
              "      <th>Sex</th>\n",
              "      <th>Age</th>\n",
              "      <th>Phases</th>\n",
              "      <th>Enrollment</th>\n",
              "      <th>Funder Type</th>\n",
              "      <th>Study Type</th>\n",
              "      <th>Study Design</th>\n",
              "      <th>Locations</th>\n",
              "      <th>Time taken for Enrollment</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>The Montreal Cognitive Assessment (MoCA) is a rapid assessment of cognition. The MoCA consists of 9 questions with the following subcategories: visuospatial/executive</th>\n",
              "      <th>naming</th>\n",
              "      <th>memory</th>\n",
              "      <th>language</th>\n",
              "      <th>abstraction</th>\n",
              "      <th>delayed recall and orientation. The MoCA has been used extensively to detect cognitive impairment in many conditions</th>\n",
              "      <th>including head trauma. Version 7.1 will be used at the Month 0 testing and Version 7.2 will be used at the Month 6 testing. Scores range from 0 to 30</th>\n",
              "      <th>higher score being a better outcome.</th>\n",
              "      <th>6 months|Global Fatigue Score as Measured by Brief Fatigue Inventory (BFI) at baseline</th>\n",
              "      <th>The Brief Fatigue Inventory is a 9 item questionnaire that assesses perceptual fatigue as well as fatigue interferences (e.g. interference with enjoyment of life)</th>\n",
              "      <th>with \"\"0\"\" being no fatigue and \"\"10\"\" being as bad as you can imagine. The Global Fatigue score is calculated by averaging the answers of all the questions. Brief Fatigue Inventory is measured in mTBI and PASC subjects at baseline.</th>\n",
              "      <th>baseline|Global Fatigue Score as Measured by Brief Fatigue Inventory (BFI) at 6 months</th>\n",
              "      <th>The Brief Fatigue Inventory is a 9 item questionnaire that assesses perceptual fatigue as well as fatigue interferences (e.g. interference with enjoyment of life)</th>\n",
              "      <th>with \"\"0\"\" being no fatigue and \"\"10\"\" being as bad as you can imagine. The Global Fatigue score is calculated by averaging the answers of all the questions. Brief Fatigue Inventory is measured in mTBI and PASC subjects after 6 months of growth hormone treatment.</th>\n",
              "      <th>6 months|Global Fatigue Score as Measured by Brief Fatigue Inventory (BFI) at 9 months</th>\n",
              "      <th>The Brief Fatigue Inventory is a 9 item questionnaire that assesses perceptual fatigue as well as fatigue interferences (e.g. interference with enjoyment of life)</th>\n",
              "      <th>with \"\"0\"\" being no fatigue and \"\"10\"\" being as bad as you can imagine. The Global Fatigue score is calculated by averaging the answers of all the questions. Brief Fatigue Inventory is measured in PASC subjects after 9 months of growth hormone treatment.</th>\n",
              "      <th>9 months|Global Fatigue Score as Measured by Brief Fatigue Inventory (BFI) at 12 months</th>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>* Health Assessment Questionnaire - Disability Index (HAQ-DI)</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <th>NaN</th>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-829e3f5b-08d5-4120-bfa8-6579c2fa3410')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-829e3f5b-08d5-4120-bfa8-6579c2fa3410 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-829e3f5b-08d5-4120-bfa8-6579c2fa3410');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-fc6b2eb4-e030-4c73-be23-ce42fdd4a4e2\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-fc6b2eb4-e030-4c73-be23-ce42fdd4a4e2')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-fc6b2eb4-e030-4c73-be23-ce42fdd4a4e2 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "repr_error": "Out of range float values are not JSON compliant: nan"
            }
          },
          "metadata": {},
          "execution_count": 28
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "##Count null value"
      ],
      "metadata": {
        "id": "fsDMt__daAFu"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df.shape\n"
      ],
      "metadata": {
        "id": "OZskh1N6fBDB",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "85339dd0-ce9a-4a2e-d116-7cb263075e89"
      },
      "execution_count": 29,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "(141683, 15)"
            ]
          },
          "metadata": {},
          "execution_count": 29
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "print(df.isnull().sum())"
      ],
      "metadata": {
        "id": "PU48L_tyYykh",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "6f62b7a4-7e3e-4bbf-c65b-bf72f5e29ae1"
      },
      "execution_count": 30,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Study Status                 108987\n",
            "Study Results                110272\n",
            "Conditions                   111008\n",
            "Interventions                111685\n",
            "Sponsor                      114697\n",
            "Collaborators                115801\n",
            "Sex                          116726\n",
            "Age                          118171\n",
            "Phases                       119670\n",
            "Enrollment                   121144\n",
            "Funder Type                  122855\n",
            "Study Type                   124631\n",
            "Study Design                 126064\n",
            "Locations                    129491\n",
            "Time taken for Enrollment    132685\n",
            "dtype: int64\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "print(df.isnull().sum().sum())"
      ],
      "metadata": {
        "id": "QJZUxGqva_EZ",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "78e7461a-6999-4d42-e989-2cbca2628267"
      },
      "execution_count": 31,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "1783887\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "byDFLfUSa5Uk"
      },
      "execution_count": 31,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "#For Age"
      ],
      "metadata": {
        "id": "8T45zVO65Ih7"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_cleaned['Age'].value_counts()"
      ],
      "metadata": {
        "id": "6qrJcrVZ5IVR",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 489
        },
        "outputId": "5f806438-ad9e-4f3d-9a9d-bd70452b07ab"
      },
      "execution_count": 32,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Age\n",
              "INTERVENTIONAL                                 1391\n",
              "OTHER                                          1017\n",
              " OLDER_ADULT\"                                   655\n",
              "ALL                                             607\n",
              " United States\"                                 541\n",
              "                                               ... \n",
              " 30144                                            1\n",
              "\"Berner Rehazentrum AG                            1\n",
              "\"Mohamed H Bakri                                  1\n",
              "ORE22635                                          1\n",
              " France|HÃ´pital europÃ©en Georges-Pompidou       1\n",
              "Name: count, Length: 8429, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Age</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>INTERVENTIONAL</th>\n",
              "      <td>1391</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>OTHER</th>\n",
              "      <td>1017</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>OLDER_ADULT\"</th>\n",
              "      <td>655</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>ALL</th>\n",
              "      <td>607</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>United States\"</th>\n",
              "      <td>541</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>30144</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>\"Berner Rehazentrum AG</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>\"Mohamed H Bakri</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>ORE22635</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>France|HÃ´pital europÃ©en Georges-Pompidou</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>8429 rows × 1 columns</p>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 32
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_cleaned = df_cleaned[df_cleaned['Age'].notna() & (df_cleaned['Age'] != '')]\n",
        "\n",
        "name_counts = df_cleaned['Age'].value_counts()\n",
        "\n",
        "df_cleaned['Age'] = df_cleaned['Age'].apply(lambda x: 0 if name_counts[x] == 1 else x)\n",
        "\n",
        "name_counts = df_cleaned['Age'].value_counts()\n",
        "\n",
        "df_cleaned['Age'] = df_cleaned['Age'].apply(lambda x: 1 if name_counts[x] == 2 else x)\n",
        "\n",
        "df_cleaned['Age'] = df_cleaned['Age'].apply(lambda x: 2 if name_counts[x] == 3 else x)\n",
        "\n",
        "df_cleaned['Age'] = df_cleaned['Age'].apply(lambda x: 3 if name_counts[x] == 4 else x)\n",
        "\n",
        "df_cleaned['Age'] = df_cleaned['Age'].apply(lambda x: 4 if name_counts[x] == 5 else x)\n",
        "\n",
        "df_cleaned['Age'] = df_cleaned['Age'].apply(lambda x: 5 if name_counts[x] == 6 else x)"
      ],
      "metadata": {
        "id": "HmhmtKaq5IRo",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 718
        },
        "outputId": "241e2822-26d6-4ee3-eb49-cb2ad28d3631"
      },
      "execution_count": 33,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "<ipython-input-33-64077a166889>:5: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_cleaned['Age'] = df_cleaned['Age'].apply(lambda x: 0 if name_counts[x] == 1 else x)\n"
          ]
        },
        {
          "output_type": "error",
          "ename": "KeyError",
          "evalue": "1",
          "traceback": [
            "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
            "\u001b[0;31mKeyError\u001b[0m                                  Traceback (most recent call last)",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/pandas/core/indexes/base.py\u001b[0m in \u001b[0;36mget_loc\u001b[0;34m(self, key)\u001b[0m\n\u001b[1;32m   3804\u001b[0m         \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 3805\u001b[0;31m             \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_engine\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mget_loc\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mcasted_key\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   3806\u001b[0m         \u001b[0;32mexcept\u001b[0m \u001b[0mKeyError\u001b[0m \u001b[0;32mas\u001b[0m \u001b[0merr\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32mindex.pyx\u001b[0m in \u001b[0;36mpandas._libs.index.IndexEngine.get_loc\u001b[0;34m()\u001b[0m\n",
            "\u001b[0;32mindex.pyx\u001b[0m in \u001b[0;36mpandas._libs.index.IndexEngine.get_loc\u001b[0;34m()\u001b[0m\n",
            "\u001b[0;32mpandas/_libs/hashtable_class_helper.pxi\u001b[0m in \u001b[0;36mpandas._libs.hashtable.PyObjectHashTable.get_item\u001b[0;34m()\u001b[0m\n",
            "\u001b[0;32mpandas/_libs/hashtable_class_helper.pxi\u001b[0m in \u001b[0;36mpandas._libs.hashtable.PyObjectHashTable.get_item\u001b[0;34m()\u001b[0m\n",
            "\u001b[0;31mKeyError\u001b[0m: 1",
            "\nThe above exception was the direct cause of the following exception:\n",
            "\u001b[0;31mKeyError\u001b[0m                                  Traceback (most recent call last)",
            "\u001b[0;32m<ipython-input-33-64077a166889>\u001b[0m in \u001b[0;36m<cell line: 11>\u001b[0;34m()\u001b[0m\n\u001b[1;32m      9\u001b[0m \u001b[0mdf_cleaned\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'Age'\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mdf_cleaned\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'Age'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mapply\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;32mlambda\u001b[0m \u001b[0mx\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0;36m1\u001b[0m \u001b[0;32mif\u001b[0m \u001b[0mname_counts\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mx\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m==\u001b[0m \u001b[0;36m2\u001b[0m \u001b[0;32melse\u001b[0m \u001b[0mx\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     10\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 11\u001b[0;31m \u001b[0mdf_cleaned\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'Age'\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mdf_cleaned\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'Age'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mapply\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;32mlambda\u001b[0m \u001b[0mx\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0;36m2\u001b[0m \u001b[0;32mif\u001b[0m \u001b[0mname_counts\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mx\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m==\u001b[0m \u001b[0;36m3\u001b[0m \u001b[0;32melse\u001b[0m \u001b[0mx\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     12\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     13\u001b[0m \u001b[0mdf_cleaned\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'Age'\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mdf_cleaned\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'Age'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mapply\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;32mlambda\u001b[0m \u001b[0mx\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0;36m3\u001b[0m \u001b[0;32mif\u001b[0m \u001b[0mname_counts\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mx\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m==\u001b[0m \u001b[0;36m4\u001b[0m \u001b[0;32melse\u001b[0m \u001b[0mx\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/pandas/core/series.py\u001b[0m in \u001b[0;36mapply\u001b[0;34m(self, func, convert_dtype, args, by_row, **kwargs)\u001b[0m\n\u001b[1;32m   4922\u001b[0m             \u001b[0margs\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0margs\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   4923\u001b[0m             \u001b[0mkwargs\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 4924\u001b[0;31m         ).apply()\n\u001b[0m\u001b[1;32m   4925\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   4926\u001b[0m     def _reindex_indexer(\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/pandas/core/apply.py\u001b[0m in \u001b[0;36mapply\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m   1425\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1426\u001b[0m         \u001b[0;31m# self.func is Callable\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1427\u001b[0;31m         \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mapply_standard\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1428\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1429\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0magg\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/pandas/core/apply.py\u001b[0m in \u001b[0;36mapply_standard\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m   1505\u001b[0m         \u001b[0;31m#  Categorical (GH51645).\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1506\u001b[0m         \u001b[0maction\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m\"ignore\"\u001b[0m \u001b[0;32mif\u001b[0m \u001b[0misinstance\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mobj\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mdtype\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mCategoricalDtype\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;32melse\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1507\u001b[0;31m         mapped = obj._map_values(\n\u001b[0m\u001b[1;32m   1508\u001b[0m             \u001b[0mmapper\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mcurried\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mna_action\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0maction\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mconvert\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mconvert_dtype\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1509\u001b[0m         )\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/pandas/core/base.py\u001b[0m in \u001b[0;36m_map_values\u001b[0;34m(self, mapper, na_action, convert)\u001b[0m\n\u001b[1;32m    919\u001b[0m             \u001b[0;32mreturn\u001b[0m \u001b[0marr\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mmap\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mmapper\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mna_action\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mna_action\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    920\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 921\u001b[0;31m         \u001b[0;32mreturn\u001b[0m \u001b[0malgorithms\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mmap_array\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0marr\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mmapper\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mna_action\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mna_action\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mconvert\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mconvert\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    922\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    923\u001b[0m     \u001b[0;34m@\u001b[0m\u001b[0mfinal\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/pandas/core/algorithms.py\u001b[0m in \u001b[0;36mmap_array\u001b[0;34m(arr, mapper, na_action, convert)\u001b[0m\n\u001b[1;32m   1741\u001b[0m     \u001b[0mvalues\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0marr\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mastype\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mobject\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mcopy\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mFalse\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1742\u001b[0m     \u001b[0;32mif\u001b[0m \u001b[0mna_action\u001b[0m \u001b[0;32mis\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1743\u001b[0;31m         \u001b[0;32mreturn\u001b[0m \u001b[0mlib\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mmap_infer\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mvalues\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mmapper\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mconvert\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mconvert\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1744\u001b[0m     \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1745\u001b[0m         return lib.map_infer_mask(\n",
            "\u001b[0;32mlib.pyx\u001b[0m in \u001b[0;36mpandas._libs.lib.map_infer\u001b[0;34m()\u001b[0m\n",
            "\u001b[0;32m<ipython-input-33-64077a166889>\u001b[0m in \u001b[0;36m<lambda>\u001b[0;34m(x)\u001b[0m\n\u001b[1;32m      9\u001b[0m \u001b[0mdf_cleaned\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'Age'\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mdf_cleaned\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'Age'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mapply\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;32mlambda\u001b[0m \u001b[0mx\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0;36m1\u001b[0m \u001b[0;32mif\u001b[0m \u001b[0mname_counts\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mx\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m==\u001b[0m \u001b[0;36m2\u001b[0m \u001b[0;32melse\u001b[0m \u001b[0mx\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     10\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 11\u001b[0;31m \u001b[0mdf_cleaned\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'Age'\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mdf_cleaned\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'Age'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mapply\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;32mlambda\u001b[0m \u001b[0mx\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0;36m2\u001b[0m \u001b[0;32mif\u001b[0m \u001b[0mname_counts\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mx\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m==\u001b[0m \u001b[0;36m3\u001b[0m \u001b[0;32melse\u001b[0m \u001b[0mx\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     12\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     13\u001b[0m \u001b[0mdf_cleaned\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'Age'\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mdf_cleaned\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'Age'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mapply\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;32mlambda\u001b[0m \u001b[0mx\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0;36m3\u001b[0m \u001b[0;32mif\u001b[0m \u001b[0mname_counts\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mx\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m==\u001b[0m \u001b[0;36m4\u001b[0m \u001b[0;32melse\u001b[0m \u001b[0mx\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/pandas/core/series.py\u001b[0m in \u001b[0;36m__getitem__\u001b[0;34m(self, key)\u001b[0m\n\u001b[1;32m   1119\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1120\u001b[0m         \u001b[0;32melif\u001b[0m \u001b[0mkey_is_scalar\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1121\u001b[0;31m             \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_get_value\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mkey\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1122\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1123\u001b[0m         \u001b[0;31m# Convert generator to list before going through hashable part\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/pandas/core/series.py\u001b[0m in \u001b[0;36m_get_value\u001b[0;34m(self, label, takeable)\u001b[0m\n\u001b[1;32m   1235\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1236\u001b[0m         \u001b[0;31m# Similar to Index.get_value, but we do not fall back to positional\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1237\u001b[0;31m         \u001b[0mloc\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mindex\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mget_loc\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mlabel\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1238\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1239\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mis_integer\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mloc\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/pandas/core/indexes/base.py\u001b[0m in \u001b[0;36mget_loc\u001b[0;34m(self, key)\u001b[0m\n\u001b[1;32m   3810\u001b[0m             ):\n\u001b[1;32m   3811\u001b[0m                 \u001b[0;32mraise\u001b[0m \u001b[0mInvalidIndexError\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mkey\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 3812\u001b[0;31m             \u001b[0;32mraise\u001b[0m \u001b[0mKeyError\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mkey\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;32mfrom\u001b[0m \u001b[0merr\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   3813\u001b[0m         \u001b[0;32mexcept\u001b[0m \u001b[0mTypeError\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   3814\u001b[0m             \u001b[0;31m# If we have a listlike key, _check_indexing_error will raise\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;31mKeyError\u001b[0m: 1"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [],
      "metadata": {
        "id": "RyIjYQXK58k8"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_cleaned['Age'].value_counts()"
      ],
      "metadata": {
        "id": "7n-S5Bwl5IPY"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df_cleaned['Age'] = df_cleaned['Age'].fillna('100')\n"
      ],
      "metadata": {
        "id": "vK7rpZww6LYg"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "P81GcOmq6LUV"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "7viiE_jX6LR9"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "ZSlBZ1TF6LP1"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "0WRw53pS6LNl"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "YIlq8yFq6LLR"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "rlkfQseP6LIv"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# df = df.drop(['Acronym','Other Outcome Measures','Collaborators' , 'Phases' , 'Study Documents'] , axis=)"
      ],
      "metadata": {
        "id": "Z947UG6mYyh1"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df.tail()"
      ],
      "metadata": {
        "id": "0-b7INmjYyfS",
        "collapsed": true
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df_cleaned.info()"
      ],
      "metadata": {
        "id": "tZ6B9bZZYycm"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "1MUviPLh8SY9"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "#Loop to comvert to int\n"
      ],
      "metadata": {
        "id": "xP9Tn-d99gBD"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_cleaned.Conditions.value_counts()"
      ],
      "metadata": {
        "id": "FioAc1V79f6w"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df_cleaned = df_cleaned[df_cleaned['Conditions'].notna() & (df_cleaned['Conditions'] != '')]\n",
        "\n",
        "# Fill missing values with '0' (if there are any left)\n",
        "df_cleaned['Conditions'] = df_cleaned['Conditions'].fillna('0')\n",
        "\n",
        "# Convert column to string explicitly to ensure consistent handling of values\n",
        "df_cleaned['Conditions'] = df_cleaned['Conditions'].astype(str)\n",
        "\n",
        "# Dynamically update values based on their frequency\n",
        "name_counts = df_cleaned['Conditions'].value_counts()\n",
        "for i in range(1, 21):  # Loop from 1 to 20\n",
        "    df_cleaned['Conditions'] = df_cleaned['Conditions'].apply(lambda x: i if name_counts[x] == i else x)\n",
        "    name_counts = df_cleaned['Conditions'].value_counts()\n",
        "\n",
        "# Convert 'Age' column to integer type\n",
        "# df_cleaned['Conditions'] = df_cleaned['Conditions'].astype(int)"
      ],
      "metadata": {
        "id": "Np5eXPfY9f4P"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "AAB0AtaR-Mas"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df_cleaned['Conditions'].value_counts()"
      ],
      "metadata": {
        "id": "pTPiFf2K9f1_",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 489
        },
        "outputId": "7996862d-b1d1-434b-f624-bebe5f2f2653"
      },
      "execution_count": 34,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Conditions\n",
              "ALL                                                                                                       1358\n",
              "OTHER                                                                                                     1212\n",
              " OLDER_ADULT\"                                                                                             1123\n",
              "INTERVENTIONAL                                                                                            1096\n",
              "\"ADULT                                                                                                    1015\n",
              "                                                                                                          ... \n",
              " 24 hours after the procedure (T5)|Range Of Motion                                                           1\n",
              "\"Sinus Center - Medical Univesity of South Carolina                                                          1\n",
              " 90-120 min|Detection rate of qualitative [18F]FES PET/CT evaluation for distant metastasis                  1\n",
              " The periodontal probe will be inserted at all predetermined sites at the gingival margin of all teeth       1\n",
              " using NCI Common Terminology Criteria for Adverse Events (CTC-AE) Version 4.03                              1\n",
              "Name: count, Length: 7906, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Conditions</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>ALL</th>\n",
              "      <td>1358</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>OTHER</th>\n",
              "      <td>1212</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>OLDER_ADULT\"</th>\n",
              "      <td>1123</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>INTERVENTIONAL</th>\n",
              "      <td>1096</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>\"ADULT</th>\n",
              "      <td>1015</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>24 hours after the procedure (T5)|Range Of Motion</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>\"Sinus Center - Medical Univesity of South Carolina</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>90-120 min|Detection rate of qualitative [18F]FES PET/CT evaluation for distant metastasis</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>The periodontal probe will be inserted at all predetermined sites at the gingival margin of all teeth</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>using NCI Common Terminology Criteria for Adverse Events (CTC-AE) Version 4.03</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>7906 rows × 1 columns</p>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 34
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_"
      ],
      "metadata": {
        "id": "P51d3UKanY7-",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 146
        },
        "outputId": "f6d8f4e0-5365-4e53-f8e5-c34139293f54"
      },
      "execution_count": 35,
      "outputs": [
        {
          "output_type": "error",
          "ename": "NameError",
          "evalue": "name 'df_clear' is not defined",
          "traceback": [
            "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
            "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
            "\u001b[0;32m<ipython-input-35-1c74ba164845>\u001b[0m in \u001b[0;36m<cell line: 1>\u001b[0;34m()\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0mdf_cleaned\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'Age'\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mdf_clear\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'Age'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
            "\u001b[0;31mNameError\u001b[0m: name 'df_clear' is not defined"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "\n"
      ],
      "metadata": {
        "id": "gHu1RbiFm4Uh"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "name_counts = df_cleaned['Age'].value_counts()\n",
        "\n",
        "df_cleaned['Age'] = df_cleaned['Age'].apply(lambda x: 0 if name_counts[x] == 1 else x)\n"
      ],
      "metadata": {
        "id": "LieWPw8_m3NI"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df_cleaned['Age'].value_counts()"
      ],
      "metadata": {
        "id": "Fzmpc3ENm3KV"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "_V09D-nGm3Hs"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "khDPmcyvm3EX"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "Zsg-9dme9fzv"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "#========================= ========================================="
      ],
      "metadata": {
        "id": "nMI56qTX-Oqb"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "#=====================  USING NEW DATASET ==========================="
      ],
      "metadata": {
        "id": "GtbD9QgChW0_"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear = df[df.isnull().sum(axis=1) <10]"
      ],
      "metadata": {
        "id": "vNaaY2zi9fw_"
      },
      "execution_count": 372,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "FVTHGq4i1LcO"
      },
      "execution_count": 372,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear.shape"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Lej4ha1u9fs2",
        "outputId": "2945f5b9-5096-4aa0-fd79-a047addb1350"
      },
      "execution_count": 373,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "(28015, 15)"
            ]
          },
          "metadata": {},
          "execution_count": 373
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear.isnull().sum()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 554
        },
        "id": "UjPzaCVv9fqN",
        "outputId": "79c8a3ba-a3a3-4f7d-e720-1963036ea7f9"
      },
      "execution_count": 374,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Study Status                  4199\n",
              "Study Results                 3945\n",
              "Conditions                    3804\n",
              "Interventions                 3566\n",
              "Sponsor                       2428\n",
              "Collaborators                 3258\n",
              "Sex                           3267\n",
              "Age                           4557\n",
              "Phases                        6020\n",
              "Enrollment                    7476\n",
              "Funder Type                   9187\n",
              "Study Type                   10963\n",
              "Study Design                 12396\n",
              "Locations                    15823\n",
              "Time taken for Enrollment    19017\n",
              "dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>0</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>Study Status</th>\n",
              "      <td>4199</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Study Results</th>\n",
              "      <td>3945</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Conditions</th>\n",
              "      <td>3804</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Interventions</th>\n",
              "      <td>3566</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Sponsor</th>\n",
              "      <td>2428</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Collaborators</th>\n",
              "      <td>3258</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Sex</th>\n",
              "      <td>3267</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Age</th>\n",
              "      <td>4557</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Phases</th>\n",
              "      <td>6020</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Enrollment</th>\n",
              "      <td>7476</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Funder Type</th>\n",
              "      <td>9187</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Study Type</th>\n",
              "      <td>10963</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Study Design</th>\n",
              "      <td>12396</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Locations</th>\n",
              "      <td>15823</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Time taken for Enrollment</th>\n",
              "      <td>19017</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 374
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "##for Study style"
      ],
      "metadata": {
        "id": "ddjr72zu_L4z"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Study Status'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 507
        },
        "id": "1rezwSaU9fn2",
        "outputId": "5158bb3e-482c-4703-d896-583ace6b5df6"
      },
      "execution_count": 375,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Study Status\n",
              "ALL                                                                                                                                                                                                1559\n",
              " OLDER_ADULT\"                                                                                                                                                                                      1313\n",
              "\"ADULT                                                                                                                                                                                              967\n",
              "OTHER                                                                                                                                                                                               895\n",
              "INTERVENTIONAL                                                                                                                                                                                      594\n",
              "                                                                                                                                                                                                   ... \n",
              " 1 year|QoL: quality of life: Percentage of partecipants changing their smoking habits                                                                                                                1\n",
              " Functionality of gastric drainage channel which will be inserted through the appropriate channel of the SGAD.                                                                                        1\n",
              " blinded sinus surgeon based on the centralized video-endoscopy review. FSO diameter estimated endoscopically by probing with a 3-mm olive-shaped frontal sinus suction tip and reported in mm.       1\n",
              " week 3|Number of Participants Who Attended the Session                                                                                                                                               1\n",
              " or SD.                                                                                                                                                                                               1\n",
              "Name: count, Length: 12803, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Study Status</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>ALL</th>\n",
              "      <td>1559</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>OLDER_ADULT\"</th>\n",
              "      <td>1313</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>\"ADULT</th>\n",
              "      <td>967</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>OTHER</th>\n",
              "      <td>895</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>INTERVENTIONAL</th>\n",
              "      <td>594</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1 year|QoL: quality of life: Percentage of partecipants changing their smoking habits</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Functionality of gastric drainage channel which will be inserted through the appropriate channel of the SGAD.</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>blinded sinus surgeon based on the centralized video-endoscopy review. FSO diameter estimated endoscopically by probing with a 3-mm olive-shaped frontal sinus suction tip and reported in mm.</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>week 3|Number of Participants Who Attended the Session</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>or SD.</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>12803 rows × 1 columns</p>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 375
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "\n",
        "# Assuming 'df_clear' is your DataFrame\n",
        "# Replace NaN and empty values\n",
        "df_clear = df_clear[df_clear['Study Status'].notna() & (df_clear['Study Status'] != '')]\n",
        "df_clear['Study Status'] = df_clear['Study Status'].fillna('0')\n",
        "\n",
        "# Convert column to string to standardize\n",
        "df_clear['Study Status'] = df_clear['Study Status'].astype(str)\n",
        "\n",
        "# Convert strings to numeric where possible (ignore errors)\n",
        "df_clear['Study Status'] = pd.to_numeric(df_clear['Study Status'], errors='coerce')\n",
        "\n",
        "# Dynamically update values based on their frequency\n",
        "name_counts = df_clear['Study Status'].value_counts()\n",
        "\n",
        "# Loop from 1 to 20 and skip NaN values explicitly\n",
        "for i in range(1, 21):\n",
        "    df_clear['Study Status'] = df_clear['Study Status'].apply(\n",
        "        lambda x: i if pd.notna(x) and name_counts.get(x, 0) == i else x\n",
        "    )\n",
        "    name_counts = df_clear['Study Status'].value_counts()\n",
        "\n",
        "# Convert back to integer (after handling non-convertible values)\n",
        "df_clear['Study Status'] = df_clear['Study Status'].fillna(0).astype(int)\n",
        "\n",
        "# Display the cleaned DataFrame\n",
        "print(df_clear)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "collapsed": true,
        "id": "R-ZMgBf-9feW",
        "outputId": "75686561-ac4f-457e-a0f1-d37135f60722"
      },
      "execution_count": 376,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Status  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re... 3 months\"                                          \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                              0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                          2 days after Emergency department visit|Frequen...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                     0   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                          exhaustion and low physical activity. 1 point f...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                      0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                           This is the thickness from the outer plexiform ...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                  0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha... Survival without needs of mechanical ventilatio...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...             0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ...   \n",
            "68945                                              NCT04776031                                        Evaluation of R:GEN as Intervention in Subjects... https://clinicaltrials.gov/study/NCT04776031       NaN                                                COMPLETED                                          The purpose of this study is to assess the safe... NO                                                 Early Age Related Macular Degeneration (Disorder)  DEVICE: R:GEN Laser System                         \"To access the safety and tolerability of the R...  Incidences of Serious Adverse Events              Serious Adverse Device Effects                      Unanticipated Serious Adverse Device Effects      up to 48 weeks\"                                    \"To evaluate the progression in severity of AMD...  Evidence of the presence of late AMD               24 weeks and 48 weeks post-treatment\"                         0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid... nmol BCE/L                                          6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...             0   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe... 4 Ã 875 nm infrared LEDs                           and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...             0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                   PFS is defined as the date from the first dose ...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...             0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl... Complication rate of right heart catheterization    30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                     0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Study Results  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re... 3 months\"                                          \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                              ADULT\"   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                          2 days after Emergency department visit|Frequen...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                                        ALL   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                          exhaustion and low physical activity. 1 point f...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                                    baseline   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                           This is the thickness from the outer plexiform ...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                       Allocation: NON_RANDOMIZED|Intervention Model:...   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha... Survival without needs of mechanical ventilatio...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                             \"ADULT   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68945                                              NCT04776031                                        Evaluation of R:GEN as Intervention in Subjects... https://clinicaltrials.gov/study/NCT04776031       NaN                                                COMPLETED                                          The purpose of this study is to assess the safe... NO                                                 Early Age Related Macular Degeneration (Disorder)  DEVICE: R:GEN Laser System                         \"To access the safety and tolerability of the R...  Incidences of Serious Adverse Events              Serious Adverse Device Effects                      Unanticipated Serious Adverse Device Effects      up to 48 weeks\"                                    \"To evaluate the progression in severity of AMD...  Evidence of the presence of late AMD               24 weeks and 48 weeks post-treatment\"                                                            NaN   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid... nmol BCE/L                                          6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                          24 months   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe... 4 Ã 875 nm infrared LEDs                           and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...                                            1 week\"   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                   PFS is defined as the date from the first dose ...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...   Approximately 2 months|Percentage of particip...   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl... Complication rate of right heart catheterization    30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                                     2003.0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Conditions  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re... 3 months\"                                          \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                       PHASE1|PHASE2   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                          2 days after Emergency department visit|Frequen...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                                      ADULT   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                          exhaustion and low physical activity. 1 point f...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                                    12 weeks   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                           This is the thickness from the outer plexiform ...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                           01.11.2018/01   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha... Survival without needs of mechanical ventilatio...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                       OLDER_ADULT\"   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68945                                              NCT04776031                                        Evaluation of R:GEN as Intervention in Subjects... https://clinicaltrials.gov/study/NCT04776031       NaN                                                COMPLETED                                          The purpose of this study is to assess the safe... NO                                                 Early Age Related Macular Degeneration (Disorder)  DEVICE: R:GEN Laser System                         \"To access the safety and tolerability of the R...  Incidences of Serious Adverse Events              Serious Adverse Device Effects                      Unanticipated Serious Adverse Device Effects      up to 48 weeks\"                                    \"To evaluate the progression in severity of AMD...  Evidence of the presence of late AMD               24 weeks and 48 weeks post-treatment\"                                                           31.0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid... nmol BCE/L                                          6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                   up to 36 months\"   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe... 4 Ã 875 nm infrared LEDs                           and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...        \"The secondary outcomes are number of steps   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                   PFS is defined as the date from the first dose ...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...   using NCI Common Terminology Criteria for Adv...   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl... Complication rate of right heart catheterization    30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                                      OTHER   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Interventions  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re... 3 months\"                                          \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                                24.0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                          2 days after Emergency department visit|Frequen...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                                     PHASE4   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                          exhaustion and low physical activity. 1 point f...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                            24 weeks|Change of Timed up and go (TUG) at 1...   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                           This is the thickness from the outer plexiform ...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                              \"Ankara University Biotechnology Institute   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha... Survival without needs of mechanical ventilatio...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                             PHASE2   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68945                                              NCT04776031                                        Evaluation of R:GEN as Intervention in Subjects... https://clinicaltrials.gov/study/NCT04776031       NaN                                                COMPLETED                                          The purpose of this study is to assess the safe... NO                                                 Early Age Related Macular Degeneration (Disorder)  DEVICE: R:GEN Laser System                         \"To access the safety and tolerability of the R...  Incidences of Serious Adverse Events              Serious Adverse Device Effects                      Unanticipated Serious Adverse Device Effects      up to 48 weeks\"                                    \"To evaluate the progression in severity of AMD...  Evidence of the presence of late AMD               24 weeks and 48 weeks post-treatment\"                                                       INDUSTRY   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid... nmol BCE/L                                          6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...         Seoul National University Bundang Hospital   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe... 4 Ã 875 nm infrared LEDs                           and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...   The 6MST aims to measure the number of steps ...   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                   PFS is defined as the date from the first dose ...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                            Approximately 2 months\"   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl... Complication rate of right heart catheterization    30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                             INTERVENTIONAL   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Sponsor  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re... 3 months\"                                          \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                           DOXYAPG18   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                          2 days after Emergency department visit|Frequen...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                          \"Allocation: RANDOMIZED|Intervention Model: PA...   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                          exhaustion and low physical activity. 1 point f...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                  24 weeks|Change of SPPB at 12 and 24 weeks   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                           This is the thickness from the outer plexiform ...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                      Turkey|Umut Arslan   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha... Survival without needs of mechanical ventilatio...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...  Allocation: RANDOMIZED|Intervention Model: PAR...   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68945                                              NCT04776031                                        Evaluation of R:GEN as Intervention in Subjects... https://clinicaltrials.gov/study/NCT04776031       NaN                                                COMPLETED                                          The purpose of this study is to assess the safe... NO                                                 Early Age Related Macular Degeneration (Disorder)  DEVICE: R:GEN Laser System                         \"To access the safety and tolerability of the R...  Incidences of Serious Adverse Events              Serious Adverse Device Effects                      Unanticipated Serious Adverse Device Effects      up to 48 weeks\"                                    \"To evaluate the progression in severity of AMD...  Evidence of the presence of late AMD               24 weeks and 48 weeks post-treatment\"              \"Centre for Eye Research Australia - Royal Vic...   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid... nmol BCE/L                                          6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                              ADULT   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe... 4 Ã 875 nm infrared LEDs                           and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...                                                NaN   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                   PFS is defined as the date from the first dose ...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                                ALL   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl... Complication rate of right heart catheterization    30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                                  BesanÃ§on   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Collaborators  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re... 3 months\"                                          \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                  \"BENRACHADI Latifa   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                          2 days after Emergency department visit|Frequen...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                  INVESTIGATOR)|Primary Purpose: TREATMENT\"   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                          exhaustion and low physical activity. 1 point f...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                            Short Physical Performance Battery (SPPB) con...   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                           This is the thickness from the outer plexiform ...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                  Ankara   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha... Survival without needs of mechanical ventilatio...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                  APHP200375-TOCIDEX|2020-001246-18   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68945                                              NCT04776031                                        Evaluation of R:GEN as Intervention in Subjects... https://clinicaltrials.gov/study/NCT04776031       NaN                                                COMPLETED                                          The purpose of this study is to assess the safe... NO                                                 Early Age Related Macular Degeneration (Disorder)  DEVICE: R:GEN Laser System                         \"To access the safety and tolerability of the R...  Incidences of Serious Adverse Events              Serious Adverse Device Effects                      Unanticipated Serious Adverse Device Effects      up to 48 weeks\"                                    \"To evaluate the progression in severity of AMD...  Evidence of the presence of late AMD               24 weeks and 48 weeks post-treatment\"                                                 East Melbourne   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid... nmol BCE/L                                          6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                       OLDER_ADULT\"   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe... 4 Ã 875 nm infrared LEDs                           and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...                                                ALL   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                   PFS is defined as the date from the first dose ...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                             \"ADULT   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl... Complication rate of right heart catheterization    30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                   France|La Cavale Blanche   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sex  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re... 3 months\"                                          \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                 Rabat   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                          2 days after Emergency department visit|Frequen...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                   2019-10026   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                          exhaustion and low physical activity. 1 point f...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                           NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                           This is the thickness from the outer plexiform ...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                  TÃ¼rkiye   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha... Survival without needs of mechanical ventilatio...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...  \"CH AndrÃ©e Rosemon   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ...   \n",
            "68945                                              NCT04776031                                        Evaluation of R:GEN as Intervention in Subjects... https://clinicaltrials.gov/study/NCT04776031       NaN                                                COMPLETED                                          The purpose of this study is to assess the safe... NO                                                 Early Age Related Macular Degeneration (Disorder)  DEVICE: R:GEN Laser System                         \"To access the safety and tolerability of the R...  Incidences of Serious Adverse Events              Serious Adverse Device Effects                      Unanticipated Serious Adverse Device Effects      up to 48 weeks\"                                    \"To evaluate the progression in severity of AMD...  Evidence of the presence of late AMD               24 weeks and 48 weeks post-treatment\"                         Victoria   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid... nmol BCE/L                                          6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...               PHASE4   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe... 4 Ã 875 nm infrared LEDs                           and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...               \"ADULT   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                   PFS is defined as the date from the first dose ...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...         OLDER_ADULT\"   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl... Complication rate of right heart catheterization    30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                        Brest   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Age  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re... 3 months\"                                          \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                      Morocco\"   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                          2 days after Emergency department visit|Frequen...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                           \"Montefiore Medical Center   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                          exhaustion and low physical activity. 1 point f...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                                   NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                           This is the thickness from the outer plexiform ...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                             06312   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha... Survival without needs of mechanical ventilatio...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                      Cayenne   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ...   \n",
            "68945                                              NCT04776031                                        Evaluation of R:GEN as Intervention in Subjects... https://clinicaltrials.gov/study/NCT04776031       NaN                                                COMPLETED                                          The purpose of this study is to assess the safe... NO                                                 Early Age Related Macular Degeneration (Disorder)  DEVICE: R:GEN Laser System                         \"To access the safety and tolerability of the R...  Incidences of Serious Adverse Events              Serious Adverse Device Effects                      Unanticipated Serious Adverse Device Effects      up to 48 weeks\"                                    \"To evaluate the progression in severity of AMD...  Evidence of the presence of late AMD               24 weeks and 48 weeks post-treatment\"                                                     3002   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid... nmol BCE/L                                          6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                         70.0   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe... 4 Ã 875 nm infrared LEDs                           and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...                                 OLDER_ADULT\"   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                   PFS is defined as the date from the first dose ...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                       PHASE2   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl... Complication rate of right heart catheterization    30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"           France|HÃ´pital europÃ©en Georges-Pompidou   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Phases  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re... 3 months\"                                          \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                               NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                          2 days after Emergency department visit|Frequen...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                    Bronx   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                          exhaustion and low physical activity. 1 point f...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                       NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                           This is the thickness from the outer plexiform ...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                               Turkey\"   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha... Survival without needs of mechanical ventilatio...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...   French Guiana\"   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ...   \n",
            "68945                                              NCT04776031                                        Evaluation of R:GEN as Intervention in Subjects... https://clinicaltrials.gov/study/NCT04776031       NaN                                                COMPLETED                                          The purpose of this study is to assess the safe... NO                                                 Early Age Related Macular Degeneration (Disorder)  DEVICE: R:GEN Laser System                         \"To access the safety and tolerability of the R...  Incidences of Serious Adverse Events              Serious Adverse Device Effects                      Unanticipated Serious Adverse Device Effects      up to 48 weeks\"                                    \"To evaluate the progression in severity of AMD...  Evidence of the presence of late AMD               24 weeks and 48 weeks post-treatment\"                   Australia\"   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid... nmol BCE/L                                          6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...            OTHER   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe... 4 Ã 875 nm infrared LEDs                           and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...              NaN   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                   PFS is defined as the date from the first dose ...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...             59.0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl... Complication rate of right heart catheterization    30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                    Paris   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Enrollment  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re... 3 months\"                                          \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                5   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                          2 days after Emergency department visit|Frequen...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                New York   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                          exhaustion and low physical activity. 1 point f...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                      NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                           This is the thickness from the outer plexiform ...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                  NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha... Survival without needs of mechanical ventilatio...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...             NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ...   \n",
            "68945                                              NCT04776031                                        Evaluation of R:GEN as Intervention in Subjects... https://clinicaltrials.gov/study/NCT04776031       NaN                                                COMPLETED                                          The purpose of this study is to assess the safe... NO                                                 Early Age Related Macular Degeneration (Disorder)  DEVICE: R:GEN Laser System                         \"To access the safety and tolerability of the R...  Incidences of Serious Adverse Events              Serious Adverse Device Effects                      Unanticipated Serious Adverse Device Effects      up to 48 weeks\"                                    \"To evaluate the progression in severity of AMD...  Evidence of the presence of late AMD               24 weeks and 48 weeks post-treatment\"                         NaN   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid... nmol BCE/L                                          6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...  INTERVENTIONAL   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe... 4 Ã 875 nm infrared LEDs                           and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...            20.0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                   PFS is defined as the date from the first dose ...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...        INDUSTRY   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl... Complication rate of right heart catheterization    30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                   75015   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Funder Type  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re... 3 months\"                                          \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                                 NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                          2 days after Emergency department visit|Frequen...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                                      10467   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                          exhaustion and low physical activity. 1 point f...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                                         NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                           This is the thickness from the outer plexiform ...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                       6   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha... Survival without needs of mechanical ventilatio...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                                 11   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68945                                              NCT04776031                                        Evaluation of R:GEN as Intervention in Subjects... https://clinicaltrials.gov/study/NCT04776031       NaN                                                COMPLETED                                          The purpose of this study is to assess the safe... NO                                                 Early Age Related Macular Degeneration (Disorder)  DEVICE: R:GEN Laser System                         \"To access the safety and tolerability of the R...  Incidences of Serious Adverse Events              Serious Adverse Device Effects                      Unanticipated Serious Adverse Device Effects      up to 48 weeks\"                                    \"To evaluate the progression in severity of AMD...  Evidence of the presence of late AMD               24 weeks and 48 weeks post-treatment\"                                                             25   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid... nmol BCE/L                                          6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe... 4 Ã 875 nm infrared LEDs                           and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...                                              OTHER   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                   PFS is defined as the date from the first dose ...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                     INTERVENTIONAL   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl... Complication rate of right heart catheterization    30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                       France|HÃ´pital Nord   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Study Type  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re... 3 months\"                                          \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                                 NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                          2 days after Emergency department visit|Frequen...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                             United States\"   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                          exhaustion and low physical activity. 1 point f...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                                         NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                           This is the thickness from the outer plexiform ...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                     NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha... Survival without needs of mechanical ventilatio...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                                NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68945                                              NCT04776031                                        Evaluation of R:GEN as Intervention in Subjects... https://clinicaltrials.gov/study/NCT04776031       NaN                                                COMPLETED                                          The purpose of this study is to assess the safe... NO                                                 Early Age Related Macular Degeneration (Disorder)  DEVICE: R:GEN Laser System                         \"To access the safety and tolerability of the R...  Incidences of Serious Adverse Events              Serious Adverse Device Effects                      Unanticipated Serious Adverse Device Effects      up to 48 weeks\"                                    \"To evaluate the progression in severity of AMD...  Evidence of the presence of late AMD               24 weeks and 48 weeks post-treatment\"                                                            NaN   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid... nmol BCE/L                                          6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                     B-1902-520-004   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe... 4 Ã 875 nm infrared LEDs                           and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...                                     INTERVENTIONAL   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                   PFS is defined as the date from the first dose ...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl... Complication rate of right heart catheterization    30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                             Saint-Ãtienne   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Study Design  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re... 3 months\"                                          \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                                 NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                          2 days after Emergency department visit|Frequen...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                              \"Study Protocol and Statistical Analysis Plan   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                          exhaustion and low physical activity. 1 point f...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                                         NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                           This is the thickness from the outer plexiform ...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                     NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha... Survival without needs of mechanical ventilatio...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                                NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68945                                              NCT04776031                                        Evaluation of R:GEN as Intervention in Subjects... https://clinicaltrials.gov/study/NCT04776031       NaN                                                COMPLETED                                          The purpose of this study is to assess the safe... NO                                                 Early Age Related Macular Degeneration (Disorder)  DEVICE: R:GEN Laser System                         \"To access the safety and tolerability of the R...  Incidences of Serious Adverse Events              Serious Adverse Device Effects                      Unanticipated Serious Adverse Device Effects      up to 48 weeks\"                                    \"To evaluate the progression in severity of AMD...  Evidence of the presence of late AMD               24 weeks and 48 weeks post-treatment\"                                                            NaN   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid... nmol BCE/L                                          6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...        \"Seoul National University Bundang Hospital   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe... 4 Ã 875 nm infrared LEDs                           and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...  \"Allocation: RANDOMIZED|Intervention Model: CR...   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                   PFS is defined as the date from the first dose ...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                              17217   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl... Complication rate of right heart catheterization    30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                                    France\"   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Locations  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re... 3 months\"                                          \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                         NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                          2 days after Emergency department visit|Frequen...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                 19   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                          exhaustion and low physical activity. 1 point f...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                 NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                           This is the thickness from the outer plexiform ...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                             NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha... Survival without needs of mechanical ventilatio...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...        NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ...   \n",
            "68945                                              NCT04776031                                        Evaluation of R:GEN as Intervention in Subjects... https://clinicaltrials.gov/study/NCT04776031       NaN                                                COMPLETED                                          The purpose of this study is to assess the safe... NO                                                 Early Age Related Macular Degeneration (Disorder)  DEVICE: R:GEN Laser System                         \"To access the safety and tolerability of the R...  Incidences of Serious Adverse Events              Serious Adverse Device Effects                      Unanticipated Serious Adverse Device Effects      up to 48 weeks\"                                    \"To evaluate the progression in severity of AMD...  Evidence of the presence of late AMD               24 weeks and 48 weeks post-treatment\"                    NaN   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid... nmol BCE/L                                          6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...   Gyeonggi   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe... 4 Ã 875 nm infrared LEDs                           and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...  COPD_PBMT   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                   PFS is defined as the date from the first dose ...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...   01246000   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl... Complication rate of right heart catheterization    30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                 44   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Time taken for Enrollment  \n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re... 3 months\"                                          \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                     NaN  \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                          2 days after Emergency department visit|Frequen...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                            NaN  \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                          exhaustion and low physical activity. 1 point f...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                             NaN  \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                           This is the thickness from the outer plexiform ...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                         NaN  \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha... Survival without needs of mechanical ventilatio...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                    NaN  \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ...  \n",
            "68945                                              NCT04776031                                        Evaluation of R:GEN as Intervention in Subjects... https://clinicaltrials.gov/study/NCT04776031       NaN                                                COMPLETED                                          The purpose of this study is to assess the safe... NO                                                 Early Age Related Macular Degeneration (Disorder)  DEVICE: R:GEN Laser System                         \"To access the safety and tolerability of the R...  Incidences of Serious Adverse Events              Serious Adverse Device Effects                      Unanticipated Serious Adverse Device Effects      up to 48 weeks\"                                    \"To evaluate the progression in severity of AMD...  Evidence of the presence of late AMD               24 weeks and 48 weeks post-treatment\"                                                NaN  \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid... nmol BCE/L                                          6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                  Korea  \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe... 4 Ã 875 nm infrared LEDs                           and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...   Universidade Nove de Julho (UNINOVE)  \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                   PFS is defined as the date from the first dose ...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                    NaN  \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl... Complication rate of right heart catheterization    30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                            NaN  \n",
            "\n",
            "[23816 rows x 15 columns]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Study Status'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "collapsed": true,
        "id": "cOfSMqOx9fbz",
        "outputId": "b9f4f673-fdda-4960-b947-0fcf174dc118"
      },
      "execution_count": 377,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Study Status\n",
              "0      21921\n",
              "1        234\n",
              "2        115\n",
              "6        110\n",
              "3         95\n",
              "4         91\n",
              "11        89\n",
              "30        78\n",
              "12        76\n",
              "8         75\n",
              "9         73\n",
              "40        71\n",
              "60        65\n",
              "20        59\n",
              "7         56\n",
              "16        52\n",
              "15        50\n",
              "5         45\n",
              "24        41\n",
              "10        40\n",
              "50        40\n",
              "13        39\n",
              "19        38\n",
              "14        36\n",
              "18        36\n",
              "17        34\n",
              "80        34\n",
              "100       28\n",
              "45        25\n",
              "32        24\n",
              "90        23\n",
              "48        23\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Study Status</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>21921</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>234</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>115</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>110</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>95</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>91</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>89</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>30</th>\n",
              "      <td>78</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>76</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>75</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>73</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>40</th>\n",
              "      <td>71</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>60</th>\n",
              "      <td>65</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20</th>\n",
              "      <td>59</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>56</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>16</th>\n",
              "      <td>52</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15</th>\n",
              "      <td>50</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>45</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>24</th>\n",
              "      <td>41</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>10</th>\n",
              "      <td>40</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>50</th>\n",
              "      <td>40</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>13</th>\n",
              "      <td>39</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>19</th>\n",
              "      <td>38</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>36</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>18</th>\n",
              "      <td>36</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>17</th>\n",
              "      <td>34</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>80</th>\n",
              "      <td>34</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>100</th>\n",
              "      <td>28</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>45</th>\n",
              "      <td>25</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>32</th>\n",
              "      <td>24</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>90</th>\n",
              "      <td>23</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>48</th>\n",
              "      <td>23</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 377
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "#For Study Result"
      ],
      "metadata": {
        "id": "2oyIk7PaYLml"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Study Results'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 489
        },
        "id": "6RSZ7CUl9fZf",
        "outputId": "ec382258-102d-4cdc-822c-ae14364be881"
      },
      "execution_count": 378,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Study Results\n",
              "INTERVENTIONAL                                                                            1614\n",
              "ALL                                                                                       1485\n",
              " OLDER_ADULT\"                                                                             1180\n",
              "OTHER                                                                                      317\n",
              "\"ADULT                                                                                     309\n",
              "                                                                                          ... \n",
              " Day 0|Median Length of Hospital Stay                                                        1\n",
              " nose                                                                                        1\n",
              " Every 3-6 months                                                                            1\n",
              " 4 weeks in cross-over design|Change in baseline gastrointestinal tolerance at 4 weeks       1\n",
              "2003.0                                                                                       1\n",
              "Name: count, Length: 10232, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Study Results</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>INTERVENTIONAL</th>\n",
              "      <td>1614</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>ALL</th>\n",
              "      <td>1485</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>OLDER_ADULT\"</th>\n",
              "      <td>1180</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>OTHER</th>\n",
              "      <td>317</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>\"ADULT</th>\n",
              "      <td>309</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Day 0|Median Length of Hospital Stay</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>nose</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Every 3-6 months</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4 weeks in cross-over design|Change in baseline gastrointestinal tolerance at 4 weeks</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2003.0</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>10232 rows × 1 columns</p>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 378
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "\n",
        "\n",
        "# Assuming 'df_clear' is your DataFrame\n",
        "# Replace NaN and empty values\n",
        "df_clear = df_clear[df_clear['Study Results'].notna() & (df_clear['Study Results'] != '')]\n",
        "df_clear['Study Results'] = df_clear['Study Results'].fillna('0')\n",
        "\n",
        "# Convert column to string to standardize\n",
        "df_clear['Study Results'] = df_clear['Study Results'].astype(str)\n",
        "\n",
        "# Convert strings to numeric where possible (ignore errors)\n",
        "df_clear['Study Results'] = pd.to_numeric(df_clear['Study Results'], errors='coerce')\n",
        "\n",
        "# Dynamically update values based on their frequency\n",
        "name_counts = df_clear['Study Results'].value_counts()\n",
        "\n",
        "# Loop from 1 to 20 and skip NaN values explicitly\n",
        "for i in range(1, 21):\n",
        "    df_clear['Study Results'] = df_clear['Study Results'].apply(\n",
        "        lambda x: i if pd.notna(x) and name_counts.get(x, 0) == i else x\n",
        "    )\n",
        "    name_counts = df_clear['Study Results'].value_counts()\n",
        "\n",
        "# Convert back to integer (after handling non-convertible values)\n",
        "df_clear['Study Results'] = df_clear['Study Results'].fillna(0).astype(int)\n",
        "\n",
        "# Display the cleaned DataFrame\n",
        "print(df_clear)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "collapsed": true,
        "id": "_RBAMs35Zkfj",
        "outputId": "77d65615-b8de-4406-c4cd-03c60788c5fd"
      },
      "execution_count": 379,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "<ipython-input-379-7301b0183a68>:4: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_clear['Study Results'] = df_clear['Study Results'].fillna('0')\n",
            "<ipython-input-379-7301b0183a68>:7: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_clear['Study Results'] = df_clear['Study Results'].astype(str)\n",
            "<ipython-input-379-7301b0183a68>:10: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_clear['Study Results'] = pd.to_numeric(df_clear['Study Results'], errors='coerce')\n",
            "<ipython-input-379-7301b0183a68>:17: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_clear['Study Results'] = df_clear['Study Results'].apply(\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Status  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                              0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                     0   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                      0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                  0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...             0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...             0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...             0   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...             0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...             0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                     0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Results  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                               0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                      0   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                       0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                   0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...              0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...              0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...              0   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...              0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...              0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                      1   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Conditions  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                       PHASE1|PHASE2   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                                      ADULT   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                                    12 weeks   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                           01.11.2018/01   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                       OLDER_ADULT\"   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                             \"ADULT   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                   up to 36 months\"   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...        \"The secondary outcomes are number of steps   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...   using NCI Common Terminology Criteria for Adv...   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                                      OTHER   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Interventions  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                                24.0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                                     PHASE4   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                            24 weeks|Change of Timed up and go (TUG) at 1...   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                              \"Ankara University Biotechnology Institute   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                             PHASE2   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                       OLDER_ADULT\"   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...         Seoul National University Bundang Hospital   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...   The 6MST aims to measure the number of steps ...   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                            Approximately 2 months\"   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                             INTERVENTIONAL   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Sponsor  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                           DOXYAPG18   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                          \"Allocation: RANDOMIZED|Intervention Model: PA...   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                  24 weeks|Change of SPPB at 12 and 24 weeks   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                      Turkey|Umut Arslan   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...  Allocation: RANDOMIZED|Intervention Model: PAR...   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                     INTERVENTIONAL   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                              ADULT   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...                                                NaN   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                                ALL   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                                  BesanÃ§on   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Collaborators  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                  \"BENRACHADI Latifa   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                  INVESTIGATOR)|Primary Purpose: TREATMENT\"   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                            Short Physical Performance Battery (SPPB) con...   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                  Ankara   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                  APHP200375-TOCIDEX|2020-001246-18   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...  Allocation: NON_RANDOMIZED|Intervention Model:...   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                       OLDER_ADULT\"   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...                                                ALL   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                             \"ADULT   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                   France|La Cavale Blanche   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sex  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                 Rabat   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                   2019-10026   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                           NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                  TÃ¼rkiye   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...  \"CH AndrÃ©e Rosemon   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...        STUDY00142039   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...               PHASE4   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...               \"ADULT   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...         OLDER_ADULT\"   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                        Brest   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Age  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                      Morocco\"   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                           \"Montefiore Medical Center   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                                   NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                             06312   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                      Cayenne   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...         \"University of Kansas Medical Center   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                         70.0   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...                                 OLDER_ADULT\"   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                       PHASE2   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"           France|HÃ´pital europÃ©en Georges-Pompidou   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Phases  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                               NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                    Bronx   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                       NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                               Turkey\"   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...   French Guiana\"   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...      Kansas City   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...            OTHER   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...              NaN   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...             59.0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                    Paris   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Enrollment  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                5   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                New York   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                      NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                  NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...             NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...          Kansas   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...  INTERVENTIONAL   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...            20.0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...        INDUSTRY   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                   75015   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Funder Type  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                                 NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                                      10467   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                                         NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                       6   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                                 11   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                              66160   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...                                              OTHER   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                     INTERVENTIONAL   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                       France|HÃ´pital Nord   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Study Type  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                                 NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                             United States\"   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                                         NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                     NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                                NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                     United States\"   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                     B-1902-520-004   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...                                     INTERVENTIONAL   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                             Saint-Ãtienne   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Study Design  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                                 NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                              \"Study Protocol and Statistical Analysis Plan   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                                         NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                     NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                                NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                                NaN   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...        \"Seoul National University Bundang Hospital   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...  \"Allocation: RANDOMIZED|Intervention Model: CR...   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                              17217   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                                    France\"   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Locations  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                         NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                 19   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                 NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                             NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...        NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...        NaN   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...   Gyeonggi   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...  COPD_PBMT   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...   01246000   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                 44   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Time taken for Enrollment  \n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                     NaN  \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                            NaN  \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                             NaN  \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                         NaN  \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                    NaN  \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ...  \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                    NaN  \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                  Korea  \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...   Universidade Nove de Julho (UNINOVE)  \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                    NaN  \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                            NaN  \n",
            "\n",
            "[20784 rows x 15 columns]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Study Results'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "WCIA3bcwZmPI",
        "outputId": "7a51a47d-0769-43cb-f045-a4a20057393c"
      },
      "execution_count": 380,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Study Results\n",
              "0      18574\n",
              "1        299\n",
              "20       123\n",
              "2        120\n",
              "4        103\n",
              "11        83\n",
              "3         80\n",
              "30        79\n",
              "6         76\n",
              "15        76\n",
              "12        74\n",
              "60        73\n",
              "5         72\n",
              "9         70\n",
              "10        65\n",
              "13        65\n",
              "16        64\n",
              "8         63\n",
              "40        61\n",
              "7         58\n",
              "50        56\n",
              "24        55\n",
              "14        54\n",
              "100       43\n",
              "18        40\n",
              "19        38\n",
              "80        33\n",
              "32        33\n",
              "90        25\n",
              "36        24\n",
              "48        24\n",
              "34        22\n",
              "22        21\n",
              "56        21\n",
              "17        17\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Study Results</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>18574</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>299</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20</th>\n",
              "      <td>123</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>120</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>103</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>83</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>80</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>30</th>\n",
              "      <td>79</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>76</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15</th>\n",
              "      <td>76</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>74</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>60</th>\n",
              "      <td>73</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>72</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>70</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>10</th>\n",
              "      <td>65</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>13</th>\n",
              "      <td>65</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>16</th>\n",
              "      <td>64</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>63</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>40</th>\n",
              "      <td>61</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>58</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>50</th>\n",
              "      <td>56</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>24</th>\n",
              "      <td>55</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>54</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>100</th>\n",
              "      <td>43</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>18</th>\n",
              "      <td>40</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>19</th>\n",
              "      <td>38</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>80</th>\n",
              "      <td>33</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>32</th>\n",
              "      <td>33</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>90</th>\n",
              "      <td>25</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>36</th>\n",
              "      <td>24</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>48</th>\n",
              "      <td>24</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>34</th>\n",
              "      <td>22</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>22</th>\n",
              "      <td>21</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>56</th>\n",
              "      <td>21</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>17</th>\n",
              "      <td>17</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 380
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "#For Conditions"
      ],
      "metadata": {
        "id": "mdGFLvAKdRZj"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Conditions'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 524
        },
        "id": "uWusJCMoZmMl",
        "outputId": "dceb6434-ae29-40b8-cb84-e597663be07a"
      },
      "execution_count": 381,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Conditions\n",
              "OTHER                                                                                                                                                                                                                                                                                                                                                                                              1476\n",
              "\"ADULT                                                                                                                                                                                                                                                                                                                                                                                             1038\n",
              "INTERVENTIONAL                                                                                                                                                                                                                                                                                                                                                                                      558\n",
              "ADULT                                                                                                                                                                                                                                                                                                                                                                                               447\n",
              " OLDER_ADULT\"                                                                                                                                                                                                                                                                                                                                                                                       425\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                   ... \n",
              " United States|City Doc Urgent Care center                                                                                                                                                                                                                                                                                                                                                            1\n",
              " Rhode Island                                                                                                                                                                                                                                                                                                                                                                                         1\n",
              " Identification of attitudes of survivors toward the physical activity program will be analyzed using descriptive statistics. Examining the data by groups will further refine understanding of the emergent themes. Discussion of the findings and suggestions for interpretation will be used to guide subsequent analyses to more fully understand the themes and patterns among the themes.       1\n",
              "\"Ablation time                                                                                                                                                                                                                                                                                                                                                                                        1\n",
              " using NCI Common Terminology Criteria for Adverse Events (CTC-AE) Version 4.03                                                                                                                                                                                                                                                                                                                       1\n",
              "Name: count, Length: 9139, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Conditions</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>OTHER</th>\n",
              "      <td>1476</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>\"ADULT</th>\n",
              "      <td>1038</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>INTERVENTIONAL</th>\n",
              "      <td>558</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>ADULT</th>\n",
              "      <td>447</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>OLDER_ADULT\"</th>\n",
              "      <td>425</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>United States|City Doc Urgent Care center</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Rhode Island</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Identification of attitudes of survivors toward the physical activity program will be analyzed using descriptive statistics. Examining the data by groups will further refine understanding of the emergent themes. Discussion of the findings and suggestions for interpretation will be used to guide subsequent analyses to more fully understand the themes and patterns among the themes.</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>\"Ablation time</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>using NCI Common Terminology Criteria for Adverse Events (CTC-AE) Version 4.03</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>9139 rows × 1 columns</p>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 381
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "\n",
        "# Assuming 'df_clear' is your DataFrame\n",
        "# Replace NaN and empty values\n",
        "df_clear = df_clear[df_clear['Conditions'].notna() & (df_clear['Conditions'] != '')]\n",
        "df_clear['Conditions'] = df_clear['Conditions'].fillna('0')\n",
        "\n",
        "# Convert column to string to standardize\n",
        "df_clear['Conditions'] = df_clear['Conditions'].astype(str)\n",
        "\n",
        "# Convert strings to numeric where possible (ignore errors)\n",
        "df_clear['Conditions'] = pd.to_numeric(df_clear['Conditions'], errors='coerce')\n",
        "\n",
        "# Dynamically update values based on their frequency\n",
        "name_counts = df_clear['Conditions'].value_counts()\n",
        "\n",
        "# Loop from 1 to 20 and skip NaN values explicitly\n",
        "for i in range(1, 21):\n",
        "    df_clear['Conditions'] = df_clear['Conditions'].apply(\n",
        "        lambda x: i if pd.notna(x) and name_counts.get(x, 0) == i else x\n",
        "    )\n",
        "    name_counts = df_clear['Conditions'].value_counts()\n",
        "\n",
        "# Convert back to integer (after handling non-convertible values)\n",
        "df_clear['Conditions'] = df_clear['Conditions'].fillna(0).astype(int)\n",
        "\n",
        "# Display the cleaned DataFrame\n",
        "print(df_clear)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "collapsed": true,
        "id": "c6osX4w1ZmKE",
        "outputId": "b0fcefeb-0f08-4c55-9494-2514dbceae6d"
      },
      "execution_count": 382,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "<ipython-input-382-d008b1d118c5>:6: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_clear['Conditions'] = df_clear['Conditions'].fillna('0')\n",
            "<ipython-input-382-d008b1d118c5>:9: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_clear['Conditions'] = df_clear['Conditions'].astype(str)\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Status  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                              0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                     0   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                      0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                  0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...             0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...             0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...             0   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...             0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...             0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                     0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Results  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                               0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                      0   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                       0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                   0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...              0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...              0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...              0   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...              0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...              0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                      1   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Conditions  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                            0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                   0   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                    0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...           0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...           0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...           0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                   0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Interventions  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                                24.0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                                     PHASE4   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                            24 weeks|Change of Timed up and go (TUG) at 1...   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                              \"Ankara University Biotechnology Institute   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                             PHASE2   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                       OLDER_ADULT\"   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...         Seoul National University Bundang Hospital   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...   The 6MST aims to measure the number of steps ...   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                            Approximately 2 months\"   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                             INTERVENTIONAL   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Sponsor  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                           DOXYAPG18   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                          \"Allocation: RANDOMIZED|Intervention Model: PA...   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                  24 weeks|Change of SPPB at 12 and 24 weeks   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                      Turkey|Umut Arslan   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...  Allocation: RANDOMIZED|Intervention Model: PAR...   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                     INTERVENTIONAL   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                              ADULT   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...                                                NaN   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                                ALL   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                                  BesanÃ§on   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Collaborators  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                  \"BENRACHADI Latifa   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                  INVESTIGATOR)|Primary Purpose: TREATMENT\"   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                            Short Physical Performance Battery (SPPB) con...   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                  Ankara   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                  APHP200375-TOCIDEX|2020-001246-18   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...  Allocation: NON_RANDOMIZED|Intervention Model:...   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                       OLDER_ADULT\"   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...                                                ALL   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                             \"ADULT   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                   France|La Cavale Blanche   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sex  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                 Rabat   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                   2019-10026   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                           NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                  TÃ¼rkiye   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...  \"CH AndrÃ©e Rosemon   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...        STUDY00142039   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...               PHASE4   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...               \"ADULT   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...         OLDER_ADULT\"   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                        Brest   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Age  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                      Morocco\"   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                           \"Montefiore Medical Center   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                                   NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                             06312   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                      Cayenne   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...         \"University of Kansas Medical Center   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                         70.0   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...                                 OLDER_ADULT\"   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                       PHASE2   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"           France|HÃ´pital europÃ©en Georges-Pompidou   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Phases  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                               NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                    Bronx   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                       NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                               Turkey\"   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...   French Guiana\"   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...      Kansas City   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...            OTHER   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...              NaN   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...             59.0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                    Paris   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Enrollment  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                5   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                New York   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                      NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                  NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...             NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...          Kansas   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...  INTERVENTIONAL   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...            20.0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...        INDUSTRY   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                   75015   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Funder Type  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                                 NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                                      10467   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                                         NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                       6   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                                 11   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                              66160   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...                                              OTHER   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                     INTERVENTIONAL   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                       France|HÃ´pital Nord   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Study Type  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                                 NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                             United States\"   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                                         NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                     NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                                NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                     United States\"   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                     B-1902-520-004   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...                                     INTERVENTIONAL   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                             Saint-Ãtienne   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Study Design  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                                 NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                              \"Study Protocol and Statistical Analysis Plan   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                                         NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                     NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                                NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                                NaN   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...        \"Seoul National University Bundang Hospital   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...  \"Allocation: RANDOMIZED|Intervention Model: CR...   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                              17217   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                                    France\"   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Locations  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                         NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                 19   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                 NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                             NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...        NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...        NaN   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...   Gyeonggi   \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...  COPD_PBMT   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...   01246000   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                 44   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Time taken for Enrollment  \n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm           â¢ Probing pockets depths were assessed to the...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                     NaN  \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                          mild                                                or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                            NaN  \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat... weakness                                            slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                             NaN  \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas... Change from baseline visual acuity at 6 months\"    \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                         NaN  \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar... Cumulative incidence of discharge alive             14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                    NaN  \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ...  \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person... the better the person's perceived adjustment.       Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                    NaN  \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le... ng/mL                                               6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                  Korea  \n",
            "68951                                              NCT03639220                                        Photobiomodulation Therapy in Exercise Capacity... https://clinicaltrials.gov/study/NCT03639220       NaN                                                COMPLETED                                          \"Chronic obstructive pulmonary disease (COPD) i...  as well as musculoskeletal and systemic manife...  light emitting diodes (LEDs)                       on muscle performance                              exercise tolerance and metabolic variables dur...  with 1 session per week. PBMT or placebo (PL) ... with a dose of 30 J per site                        using a cluster of 12 diodes: 4 Ã 905 nm supe...  4 Ã 875 nm infrared LEDs                          and 4 Ã 640 nm red LEDs; Multi Radiance Medic...  Solon - OH                                         USA). Patients will be randomized into two gro...   Universidade Nove de Julho (UNINOVE)  \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro... At week 8\"                                         \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                    NaN  \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ... Hazard ratio of risk factors independently and ...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                            NaN  \n",
            "\n",
            "[17868 rows x 15 columns]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Conditions'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 711
        },
        "id": "hgm9c3CQZmH0",
        "outputId": "2bf062b5-bd3a-436b-c31d-757606b4fa1a"
      },
      "execution_count": 383,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Conditions\n",
              "0     17020\n",
              "1       270\n",
              "3        62\n",
              "2        59\n",
              "4        54\n",
              "12       51\n",
              "6        42\n",
              "8        42\n",
              "5        31\n",
              "15       31\n",
              "7        28\n",
              "14       28\n",
              "30       26\n",
              "20       26\n",
              "10       26\n",
              "11       22\n",
              "19       19\n",
              "18       18\n",
              "13       13\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Conditions</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>17020</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>270</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>62</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>59</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>54</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>51</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>42</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>42</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>31</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15</th>\n",
              "      <td>31</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>28</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>28</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>30</th>\n",
              "      <td>26</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20</th>\n",
              "      <td>26</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>10</th>\n",
              "      <td>26</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>22</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>19</th>\n",
              "      <td>19</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>18</th>\n",
              "      <td>18</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>13</th>\n",
              "      <td>13</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 383
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "#For Interventions"
      ],
      "metadata": {
        "id": "5f3C1M_kdwK1"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Interventions'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 489
        },
        "id": "7C6Q2txUZmFU",
        "outputId": "df6d6408-2f95-43c9-9d4b-88689f1e9b4c"
      },
      "execution_count": 384,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Interventions\n",
              "INTERVENTIONAL                                                                                        1913\n",
              " OLDER_ADULT\"                                                                                         1081\n",
              "OTHER                                                                                                  301\n",
              "ALL                                                                                                    268\n",
              "INDUSTRY                                                                                               191\n",
              "                                                                                                      ... \n",
              " Kfar Saba                                                                                               1\n",
              " Up to 123 Weeks|Percentage of Participants Positive for Anti-drug Antibodies (ADAs) to Relatlimab       1\n",
              " LAT8881 is measured in plasma samples taken pre-dose and at 5 minutes                                   1\n",
              "\"Dr. Ruben Velazquez Private Practice                                                                    1\n",
              " Approximately 2 months\"                                                                                 1\n",
              "Name: count, Length: 8961, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Interventions</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>INTERVENTIONAL</th>\n",
              "      <td>1913</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>OLDER_ADULT\"</th>\n",
              "      <td>1081</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>OTHER</th>\n",
              "      <td>301</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>ALL</th>\n",
              "      <td>268</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>INDUSTRY</th>\n",
              "      <td>191</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Kfar Saba</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Up to 123 Weeks|Percentage of Participants Positive for Anti-drug Antibodies (ADAs) to Relatlimab</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>LAT8881 is measured in plasma samples taken pre-dose and at 5 minutes</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>\"Dr. Ruben Velazquez Private Practice</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Approximately 2 months\"</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>8961 rows × 1 columns</p>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 384
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "#Skip it Interventions"
      ],
      "metadata": {
        "id": "lg1Z0O8ld7ZN"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear = df_clear.drop(['Interventions'] , axis=1)"
      ],
      "metadata": {
        "id": "ZiaspYhxZmDH"
      },
      "execution_count": 385,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "#For Sponsor"
      ],
      "metadata": {
        "id": "PFrq4tL5eFJi"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Sponsor'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 489
        },
        "id": "KdWOhhGHZmAA",
        "outputId": "f12d2253-b5ba-4aae-9088-69c9fa151860"
      },
      "execution_count": 386,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Sponsor\n",
              "INTERVENTIONAL                                                                                                                                   1185\n",
              "ALL                                                                                                                                               910\n",
              "\"ADULT                                                                                                                                            480\n",
              " United States\"                                                                                                                                   368\n",
              "OTHER                                                                                                                                             262\n",
              "                                                                                                                                                 ... \n",
              "Premier Research Group plc                                                                                                                          1\n",
              " H7S1Z5                                                                                                                                             1\n",
              "Bioinformation-panc                                                                                                                                 1\n",
              " 4 and Range of movement of the hip will be measured with a goniometer. Measurements will be performed after balance measurements at baseline       1\n",
              " At 18-months corrected age\"                                                                                                                        1\n",
              "Name: count, Length: 7133, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Sponsor</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>INTERVENTIONAL</th>\n",
              "      <td>1185</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>ALL</th>\n",
              "      <td>910</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>\"ADULT</th>\n",
              "      <td>480</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>United States\"</th>\n",
              "      <td>368</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>OTHER</th>\n",
              "      <td>262</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Premier Research Group plc</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>H7S1Z5</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Bioinformation-panc</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4 and Range of movement of the hip will be measured with a goniometer. Measurements will be performed after balance measurements at baseline</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>At 18-months corrected age\"</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>7133 rows × 1 columns</p>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 386
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "\n",
        "# Assuming 'df_clear' is your DataFrame\n",
        "# Replace NaN and empty values\n",
        "df_clear = df_clear[df_clear['Sponsor'].notna() & (df_clear['Sponsor'] != '')]\n",
        "df_clear['Sponsor'] = df_clear['Sponsor'].fillna('0')\n",
        "\n",
        "# Convert column to string to standardize\n",
        "df_clear['Sponsor'] = df_clear['Sponsor'].astype(str)\n",
        "\n",
        "# Convert strings to numeric where possible (ignore errors)\n",
        "df_clear['Sponsor'] = pd.to_numeric(df_clear['Sponsor'], errors='coerce')\n",
        "\n",
        "# Dynamically update values based on their frequency\n",
        "name_counts = df_clear['Sponsor'].value_counts()\n",
        "\n",
        "# Loop from 1 to 20 and skip NaN values explicitly\n",
        "for i in range(1, 21):\n",
        "    df_clear['Sponsor'] = df_clear['Sponsor'].apply(\n",
        "        lambda x: i if pd.notna(x) and name_counts.get(x, 0) == i else x\n",
        "    )\n",
        "    name_counts = df_clear['Sponsor'].value_counts()\n",
        "\n",
        "# Convert back to integer (after handling non-convertible values)\n",
        "df_clear['Sponsor'] = df_clear['Sponsor'].fillna(0).astype(int)\n",
        "\n",
        "# Display the cleaned DataFrame\n",
        "print(df_clear)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "6JGYGnKtZl7x",
        "outputId": "78ad754a-d293-40c1-e180-4d8a8eabf120"
      },
      "execution_count": 387,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "<ipython-input-387-7145017a0801>:6: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_clear['Sponsor'] = df_clear['Sponsor'].fillna('0')\n",
            "<ipython-input-387-7145017a0801>:9: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_clear['Sponsor'] = df_clear['Sponsor'].astype(str)\n",
            "<ipython-input-387-7145017a0801>:12: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_clear['Sponsor'] = pd.to_numeric(df_clear['Sponsor'], errors='coerce')\n",
            "<ipython-input-387-7145017a0801>:19: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_clear['Sponsor'] = df_clear['Sponsor'].apply(\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Status  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                              0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                     0   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                      0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                  0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...             0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...             0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...             0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...             0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...             0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                     0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Results  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                               0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                      0   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                       0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                   0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...              0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...              0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...              0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...              0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...              0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                      1   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Conditions  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                            0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                   0   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                    0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...           0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...           0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...           0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                   0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sponsor  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                         0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                0   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                 0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                             0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...        0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...        0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...        0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...        0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...        0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Collaborators  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                  \"BENRACHADI Latifa   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                  INVESTIGATOR)|Primary Purpose: TREATMENT\"   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                            Short Physical Performance Battery (SPPB) con...   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                  Ankara   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                  APHP200375-TOCIDEX|2020-001246-18   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...                                      CARE_PROVIDER   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...  Allocation: NON_RANDOMIZED|Intervention Model:...   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                       OLDER_ADULT\"   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                             \"ADULT   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                   France|La Cavale Blanche   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sex  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                 Rabat   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                   2019-10026   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                           NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                  TÃ¼rkiye   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...  \"CH AndrÃ©e Rosemon   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...         INVESTIGATOR   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...        STUDY00142039   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...               PHASE4   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...         OLDER_ADULT\"   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                        Brest   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Age  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                            Morocco\"   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                 \"Montefiore Medical Center   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                                         NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                   06312   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                            Cayenne   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...   OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCI...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...               \"University of Kansas Medical Center   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                               70.0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                             PHASE2   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                 France|HÃ´pital europÃ©en Georges-Pompidou   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Phases  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                             NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                  Bronx   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                     NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                             Turkey\"   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                 French Guiana\"   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...  2017P000179|1R01NS095937-01A1   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                    Kansas City   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                          OTHER   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                           59.0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                  Paris   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Enrollment  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                 5   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                 New York   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                       NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                   NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                              NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...  \"Massachusetts General Hospital   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                           Kansas   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                   INTERVENTIONAL   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                         INDUSTRY   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                    75015   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Funder Type  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                                 NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                                      10467   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                                         NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                       6   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                                 11   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...                                        Charlestown   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                              66160   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                     INTERVENTIONAL   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                       France|HÃ´pital Nord   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Study Type  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                                 NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                             United States\"   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                                         NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                     NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                                NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...                                      Massachusetts   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                     United States\"   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                     B-1902-520-004   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                             Saint-Ãtienne   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Study Design  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                             NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                          \"Study Protocol and Statistical Analysis Plan   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                                     NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                 NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                            NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...                                          02129   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                            NaN   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...    \"Seoul National University Bundang Hospital   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                          17217   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                                France\"   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Locations  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                         NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                 19   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                 NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                             NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...        NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...        NaN   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...        NaN   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...   Gyeonggi   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...   01246000   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                 44   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Time taken for Enrollment  \n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                        NaN  \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                               NaN  \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                NaN  \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                            NaN  \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                       NaN  \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ...  \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...                       NaN  \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                       NaN  \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                     Korea  \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                       NaN  \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                               NaN  \n",
            "\n",
            "[16268 rows x 14 columns]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Sponsor'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 554
        },
        "id": "mD604KSvZl42",
        "outputId": "26f23452-0016-4ac6-e997-584c1d85cb2b"
      },
      "execution_count": 388,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Sponsor\n",
              "0     14686\n",
              "1       738\n",
              "2       259\n",
              "3       118\n",
              "4       106\n",
              "5        91\n",
              "6        85\n",
              "8        57\n",
              "7        42\n",
              "13       26\n",
              "20       20\n",
              "15       15\n",
              "14       14\n",
              "11       11\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Sponsor</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>14686</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>738</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>259</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>118</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>106</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>91</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>85</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>57</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>42</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>13</th>\n",
              "      <td>26</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20</th>\n",
              "      <td>20</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15</th>\n",
              "      <td>15</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>14</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>11</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 388
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "#For  Collaborators"
      ],
      "metadata": {
        "id": "FpmZJ75ZgxxW"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Collaborators'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 489
        },
        "id": "08XYpmlRgxk8",
        "outputId": "848b75e8-9855-4571-a828-8405f8646d12"
      },
      "execution_count": 389,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Collaborators\n",
              "\"ADULT                       630\n",
              " OLDER_ADULT\"                488\n",
              " United States\"              463\n",
              "INTERVENTIONAL               326\n",
              "OTHER                        256\n",
              "                            ... \n",
              "827284                         1\n",
              "Home-HIT_T1D                   1\n",
              "AOR14068                       1\n",
              " pancreatic parenchyma         1\n",
              " France|La Cavale Blanche      1\n",
              "Name: count, Length: 6177, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Collaborators</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>\"ADULT</th>\n",
              "      <td>630</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>OLDER_ADULT\"</th>\n",
              "      <td>488</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>United States\"</th>\n",
              "      <td>463</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>INTERVENTIONAL</th>\n",
              "      <td>326</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>OTHER</th>\n",
              "      <td>256</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>827284</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Home-HIT_T1D</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>AOR14068</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>pancreatic parenchyma</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>France|La Cavale Blanche</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>6177 rows × 1 columns</p>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 389
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "\n",
        "# Assuming 'df_clear' is your DataFrame\n",
        "# Replace NaN and empty values\n",
        "df_clear = df_clear[df_clear['Collaborators'].notna() & (df_clear['Collaborators'] != '')]\n",
        "df_clear['Collaborators'] = df_clear['Collaborators'].fillna('0')\n",
        "\n",
        "# Convert column to string to standardize\n",
        "df_clear['Collaborators'] = df_clear['Collaborators'].astype(str)\n",
        "\n",
        "# Convert strings to numeric where possible (ignore errors)\n",
        "df_clear['Collaborators'] = pd.to_numeric(df_clear['Collaborators'], errors='coerce')\n",
        "\n",
        "# Dynamically update values based on their frequency\n",
        "name_counts = df_clear['Collaborators'].value_counts()\n",
        "\n",
        "# Loop from 1 to 20 and skip NaN values explicitly\n",
        "for i in range(1, 21):\n",
        "    df_clear['Collaborators'] = df_clear['Collaborators'].apply(\n",
        "        lambda x: i if pd.notna(x) and name_counts.get(x, 0) == i else x\n",
        "    )\n",
        "    name_counts = df_clear['Collaborators'].value_counts()\n",
        "\n",
        "# Convert back to integer (after handling non-convertible values)\n",
        "df_clear['Collaborators'] = df_clear['Collaborators'].fillna(0).astype(int)\n",
        "\n",
        "# Display the cleaned DataFrame\n",
        "print(df_clear)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "RtPgARWDgxhl",
        "outputId": "c732a119-ffb4-4439-9dcd-5f1b2acc7478"
      },
      "execution_count": 390,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "<ipython-input-390-911f286253a0>:6: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_clear['Collaborators'] = df_clear['Collaborators'].fillna('0')\n",
            "<ipython-input-390-911f286253a0>:9: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_clear['Collaborators'] = df_clear['Collaborators'].astype(str)\n",
            "<ipython-input-390-911f286253a0>:12: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_clear['Collaborators'] = pd.to_numeric(df_clear['Collaborators'], errors='coerce')\n",
            "<ipython-input-390-911f286253a0>:19: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_clear['Collaborators'] = df_clear['Collaborators'].apply(\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Status  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                              0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                     0   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                      0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                  0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...             0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...             0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...             0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...             0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...             0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                     0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Results  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                               0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                      0   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                       0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                   0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...              0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...              0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...              0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...              0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...              0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                      1   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Conditions  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                            0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                   0   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                    0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...           0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...           0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...           0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                   0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sponsor  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                         0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                0   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                 0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                             0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...        0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...        0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...        0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...        0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...        0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Collaborators  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                               0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                      0   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                       0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                   0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...              0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...              0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...              0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...              0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...              0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                      0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sex  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                 Rabat   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                   2019-10026   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                           NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                  TÃ¼rkiye   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...  \"CH AndrÃ©e Rosemon   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...         INVESTIGATOR   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...        STUDY00142039   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...               PHASE4   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...         OLDER_ADULT\"   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                        Brest   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Age  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                            Morocco\"   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                 \"Montefiore Medical Center   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                                         NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                   06312   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                            Cayenne   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...   OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCI...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...               \"University of Kansas Medical Center   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                               70.0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                             PHASE2   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                 France|HÃ´pital europÃ©en Georges-Pompidou   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Phases  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                             NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                  Bronx   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                     NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                             Turkey\"   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                 French Guiana\"   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...  2017P000179|1R01NS095937-01A1   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                    Kansas City   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                          OTHER   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                           59.0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                  Paris   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Enrollment  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                 5   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                 New York   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                       NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                   NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                              NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...  \"Massachusetts General Hospital   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                           Kansas   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                   INTERVENTIONAL   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                         INDUSTRY   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                    75015   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Funder Type  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                                 NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                                      10467   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                                         NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                       6   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                                 11   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...                                        Charlestown   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                              66160   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                     INTERVENTIONAL   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                       France|HÃ´pital Nord   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Study Type  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                                 NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                             United States\"   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                                         NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                     NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                                NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...                                      Massachusetts   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                     United States\"   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                     B-1902-520-004   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                             Saint-Ãtienne   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Study Design  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                             NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                          \"Study Protocol and Statistical Analysis Plan   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                                     NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                 NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                            NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...                                          02129   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                            NaN   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...    \"Seoul National University Bundang Hospital   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                          17217   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                                France\"   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Locations  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                         NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                 19   \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                 NaN   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                             NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...        NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...        NaN   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...        NaN   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...   Gyeonggi   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...   01246000   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                 44   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Time taken for Enrollment  \n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                        NaN  \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                               NaN  \n",
            "13                                                 NCT04438876                                        The Effects of Functional Power Training on Fra... https://clinicaltrials.gov/study/NCT04438876       NaN                                                COMPLETED                                          To investigate the efficacy of a 12-week Functi... NO                                                 Frailty|Muscle Weakness                            OTHER: Functional Power Training|OTHER: Usual care \"Change of Frail status at 12 and 24 weeks          Cardiovascular Health Study (CHS) Frailty stat...  weakness                                           slowness                                           exhaustion and low physical activity. 1 point ...  Pre-Frail: 1-2 points                              Frail: 3-5 points.                                 baseline                                                                NaN  \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                            NaN  \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                       NaN  \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ...  \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...                       NaN  \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                       NaN  \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                     Korea  \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                       NaN  \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                               NaN  \n",
            "\n",
            "[13806 rows x 14 columns]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Collaborators'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 491
        },
        "id": "W5e3neZ9gxf0",
        "outputId": "d4d395b7-ed50-472f-a035-a2f31d14e322"
      },
      "execution_count": 391,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Collaborators\n",
              "0     12498\n",
              "1       671\n",
              "2       238\n",
              "3       121\n",
              "4        89\n",
              "5        60\n",
              "6        55\n",
              "8        27\n",
              "14       14\n",
              "12       12\n",
              "11       11\n",
              "10       10\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Collaborators</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>12498</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>671</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>238</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>121</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>89</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>60</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>55</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>27</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>14</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>12</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>11</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>10</th>\n",
              "      <td>10</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 391
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Collaborators'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 491
        },
        "id": "iO3G1V_Ygxd5",
        "outputId": "99ae1883-c38d-4aec-d64b-fc229cc031e5"
      },
      "execution_count": 392,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Collaborators\n",
              "0     12498\n",
              "1       671\n",
              "2       238\n",
              "3       121\n",
              "4        89\n",
              "5        60\n",
              "6        55\n",
              "8        27\n",
              "14       14\n",
              "12       12\n",
              "11       11\n",
              "10       10\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Collaborators</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>12498</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>671</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>238</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>121</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>89</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>60</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>55</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>27</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>14</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>12</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>11</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>10</th>\n",
              "      <td>10</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 392
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "#For Sex"
      ],
      "metadata": {
        "id": "GagMS7ilhiwh"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Sex'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 489
        },
        "id": "v8o9-6G6gxaF",
        "outputId": "2f430c91-009c-4325-ef78-cb95af6b6d03"
      },
      "execution_count": 393,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Sex\n",
              " OLDER_ADULT\"                                    675\n",
              "INTERVENTIONAL                                   316\n",
              "ALL                                              249\n",
              " United States\"                                  211\n",
              "\"ADULT                                           162\n",
              "                                                ... \n",
              " Day 5 of TMS                                      1\n",
              "HPrato-4                                           1\n",
              " 33016                                             1\n",
              " 8 weeks|Hand fine grip strength measurement:      1\n",
              " Brest                                             1\n",
              "Name: count, Length: 5896, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Sex</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>OLDER_ADULT\"</th>\n",
              "      <td>675</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>INTERVENTIONAL</th>\n",
              "      <td>316</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>ALL</th>\n",
              "      <td>249</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>United States\"</th>\n",
              "      <td>211</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>\"ADULT</th>\n",
              "      <td>162</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Day 5 of TMS</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>HPrato-4</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>33016</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8 weeks|Hand fine grip strength measurement:</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Brest</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>5896 rows × 1 columns</p>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 393
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "\n",
        "# Assuming 'df_clear' is your DataFrame\n",
        "# Replace NaN and empty values\n",
        "df_clear = df_clear[df_clear['Sex'].notna() & (df_clear['Sex'] != '')]\n",
        "df_clear['Sex'] = df_clear['Sex'].fillna('0')\n",
        "\n",
        "# Convert column to string to standardize\n",
        "df_clear['Sex'] = df_clear['Sex'].astype(str)\n",
        "\n",
        "# Convert strings to numeric where possible (ignore errors)\n",
        "df_clear['Sex'] = pd.to_numeric(df_clear['Sex'], errors='coerce')\n",
        "\n",
        "# Dynamically update values based on their frequency\n",
        "name_counts = df_clear['Sex'].value_counts()\n",
        "\n",
        "# Loop from 1 to 20 and skip NaN values explicitly\n",
        "for i in range(1, 21):\n",
        "    df_clear['Sex'] = df_clear['Sex'].apply(\n",
        "        lambda x: i if pd.notna(x) and name_counts.get(x, 0) == i else x\n",
        "    )\n",
        "    name_counts = df_clear['Sex'].value_counts()\n",
        "\n",
        "# Convert back to integer (after handling non-convertible values)\n",
        "df_clear['Sex'] = df_clear['Sex'].fillna(0).astype(int)\n",
        "\n",
        "# Display the cleaned DataFrame\n",
        "print(df_clear)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "PTLfo8LpiJPF",
        "outputId": "58c71533-dcd0-4152-8267-c5cae7121df6"
      },
      "execution_count": 394,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "<ipython-input-394-d15fa4695793>:6: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_clear['Sex'] = df_clear['Sex'].fillna('0')\n",
            "<ipython-input-394-d15fa4695793>:9: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_clear['Sex'] = df_clear['Sex'].astype(str)\n",
            "<ipython-input-394-d15fa4695793>:12: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_clear['Sex'] = pd.to_numeric(df_clear['Sex'], errors='coerce')\n",
            "<ipython-input-394-d15fa4695793>:19: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_clear['Sex'] = df_clear['Sex'].apply(\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Status  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                              0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                     0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                  0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...             0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                      0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...             0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...             0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...             0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...             0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                     0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Results  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                               0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                      0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                   0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...              0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                       4   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...              0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...              0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...              0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...              0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                      1   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Conditions  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                            0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                   0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...           0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                    0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...           0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...           0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                   0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sponsor  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                         0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                             0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...        0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                 0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...        0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...        0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...        0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...        0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Collaborators  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                               0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                      0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                   0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...              0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                       0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...              0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...              0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...              0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...              0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                      0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sex  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                     0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                            0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                         0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...    0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                             0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...    0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...    0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...    0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...    0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"            0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Age  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                            Morocco\"   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                 \"Montefiore Medical Center   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                   06312   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                            Cayenne   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                                             San Luis Potosi   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...   OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCI...   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...               \"University of Kansas Medical Center   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                               70.0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                             PHASE2   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                 France|HÃ´pital europÃ©en Georges-Pompidou   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Phases  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                             NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                  Bronx   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                             Turkey\"   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                 French Guiana\"   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                                   78990   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...  2017P000179|1R01NS095937-01A1   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                    Kansas City   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                          OTHER   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                           59.0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                  Paris   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Enrollment  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                 5   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                 New York   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                   NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                              NaN   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                                   Mexico\"   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...  \"Massachusetts General Hospital   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                           Kansas   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                   INTERVENTIONAL   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                         INDUSTRY   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                    75015   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Funder Type  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                                 NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                                      10467   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                       6   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                                 11   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                                                         NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...                                        Charlestown   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                              66160   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                     INTERVENTIONAL   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                       France|HÃ´pital Nord   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Study Type  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                                 NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                             United States\"   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                     NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                                NaN   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                                                           5   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...                                      Massachusetts   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                     United States\"   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                     B-1902-520-004   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                             Saint-Ãtienne   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Study Design  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                             NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                          \"Study Protocol and Statistical Analysis Plan   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                 NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                            NaN   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                                                     NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...                                          02129   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                            NaN   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...    \"Seoul National University Bundang Hospital   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                          17217   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                                France\"   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Locations  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                         NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                 19   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                             NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...        NaN   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                 NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...        NaN   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...        NaN   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...   Gyeonggi   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...   01246000   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                 44   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Time taken for Enrollment  \n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                        NaN  \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                               NaN  \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                            NaN  \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                       NaN  \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                                NaN  \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ...  \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...                       NaN  \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                       NaN  \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                     Korea  \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                       NaN  \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                               NaN  \n",
            "\n",
            "[11476 rows x 14 columns]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Sex'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 585
        },
        "id": "IPFoynxNiYSo",
        "outputId": "4059a696-4a5d-4843-bebe-002dea0605cd"
      },
      "execution_count": 395,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Sex\n",
              "0        9840\n",
              "1         722\n",
              "2         279\n",
              "3         138\n",
              "4         101\n",
              "5          75\n",
              "7          63\n",
              "8          57\n",
              "6          48\n",
              "11         44\n",
              "9          36\n",
              "13         26\n",
              "55905      21\n",
              "14         14\n",
              "12         12\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Sex</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>9840</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>722</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>279</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>138</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>101</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>75</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>63</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>57</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>48</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>44</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>36</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>13</th>\n",
              "      <td>26</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>55905</th>\n",
              "      <td>21</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>14</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>12</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 395
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Sex'] = df_clear['Sex'].replace(55905,15)"
      ],
      "metadata": {
        "id": "ZK_rWY1Wja4m"
      },
      "execution_count": 396,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Sex'].value_counts()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 585
        },
        "id": "QLyvp9bcjp2z",
        "outputId": "3ded86e8-3dae-4565-ca96-9d4e11de7f3e"
      },
      "execution_count": 397,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Sex\n",
              "0     9840\n",
              "1      722\n",
              "2      279\n",
              "3      138\n",
              "4      101\n",
              "5       75\n",
              "7       63\n",
              "8       57\n",
              "6       48\n",
              "11      44\n",
              "9       36\n",
              "13      26\n",
              "15      21\n",
              "14      14\n",
              "12      12\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Sex</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>9840</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>722</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>279</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>138</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>101</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>75</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>63</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>57</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>48</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>44</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>36</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>13</th>\n",
              "      <td>26</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15</th>\n",
              "      <td>21</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>14</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>12</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 397
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "#For Age"
      ],
      "metadata": {
        "id": "GIln5WPRjuBW"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Age'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 489
        },
        "id": "8VoFBPl_iYL8",
        "outputId": "317fa6a0-2440-4f30-c172-f6fd668f8a1e"
      },
      "execution_count": 398,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Age\n",
              " United States\"                                                                                      496\n",
              " OLDER_ADULT\"                                                                                        224\n",
              "\"ADULT                                                                                               184\n",
              "INTERVENTIONAL                                                                                        94\n",
              " Egypt\"                                                                                               91\n",
              "                                                                                                    ... \n",
              " Fudan University                                                                                      1\n",
              " Farmington                                                                                            1\n",
              "Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING       1\n",
              " Fine grip strength measurements will be made with finger dynamometry (Pinchmeter-Sammons Preston      1\n",
              " France|HÃ´pital europÃ©en Georges-Pompidou                                                            1\n",
              "Name: count, Length: 5046, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Age</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>United States\"</th>\n",
              "      <td>496</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>OLDER_ADULT\"</th>\n",
              "      <td>224</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>\"ADULT</th>\n",
              "      <td>184</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>INTERVENTIONAL</th>\n",
              "      <td>94</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Egypt\"</th>\n",
              "      <td>91</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Fudan University</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Farmington</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Fine grip strength measurements will be made with finger dynamometry (Pinchmeter-Sammons Preston</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>France|HÃ´pital europÃ©en Georges-Pompidou</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>5046 rows × 1 columns</p>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 398
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Age'].nunique()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "P8a6e0KBiYJa",
        "outputId": "83059717-582c-4d73-943a-e169bc48115d"
      },
      "execution_count": 399,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "5046"
            ]
          },
          "metadata": {},
          "execution_count": 399
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Age'] = df_clear['Age'].fillna('0')\n"
      ],
      "metadata": {
        "id": "6Xjw_r5zmT0n"
      },
      "execution_count": 400,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# df_cleaned['Age'] = df_cleaned['Age'].apply(lambda x: 0 if name_counts[x] == 1 else x)\n"
      ],
      "metadata": {
        "id": "PXC7_E7kmTxR"
      },
      "execution_count": 401,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "\n",
        "# Assuming 'df_clear' is your DataFrame\n",
        "# Replace NaN and empty values\n",
        "df_clear = df_clear[df_clear['Age'].notna() & (df_clear['Age'] != '')]\n",
        "df_clear['Age'] = df_clear['Age'].fillna('0')\n",
        "\n",
        "# Convert column to string to standardize\n",
        "df_clear['Age'] = df_clear['Age'].astype(str)\n",
        "\n",
        "# Convert strings to numeric where possible (ignore errors)\n",
        "df_clear['Age'] = pd.to_numeric(df_clear['Age'], errors='coerce')\n",
        "\n",
        "# Dynamically update values based on their frequency\n",
        "name_counts = df_clear['Age'].value_counts()\n",
        "\n",
        "# Loop from 1 to 20 and skip NaN values explicitly\n",
        "for i in range(1, 21):\n",
        "    df_clear['Age'] = df_clear['Age'].apply(\n",
        "        lambda x: i if pd.notna(x) and name_counts.get(x, 0) == i else x\n",
        "    )\n",
        "    name_counts = df_clear['Age'].value_counts()\n",
        "\n",
        "# Convert back to integer (after handling non-convertible values)\n",
        "df_clear['Age'] = df_clear['Age'].fillna(0).astype(int)\n",
        "\n",
        "# Display the cleaned DataFrame\n",
        "print(df_clear)\n"
      ],
      "metadata": {
        "id": "iVuklU79mTuI",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "ff5e1bba-43d2-449b-e750-b6f0959acb51"
      },
      "execution_count": 402,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Status  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                              0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                     0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                  0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...             0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                      0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...             0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...             0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...             0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...             0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                     0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Results  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                               0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                      0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                   0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...              0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                       4   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...              0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...              0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...              0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...              0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                      1   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Conditions  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                            0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                   0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...           0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                    0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...           0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...           0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                   0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sponsor  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                         0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                             0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...        0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                 0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...        0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...        0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...        0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...        0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Collaborators  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                               0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                      0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                   0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...              0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                       0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...              0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...              0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...              0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...              0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                      0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sex  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                     0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                            0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                         0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...    0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                             0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...    0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...    0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...    0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...    0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"            0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Age  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                     0   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                            0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                         1   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...    0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                             0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...    0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...    0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...    4   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...    0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"            0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Phases  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                             NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                  Bronx   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                             Turkey\"   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                 French Guiana\"   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                                   78990   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...  2017P000179|1R01NS095937-01A1   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                    Kansas City   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                          OTHER   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                           59.0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                  Paris   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Enrollment  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                 5   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                 New York   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                   NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                              NaN   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                                   Mexico\"   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...  \"Massachusetts General Hospital   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                           Kansas   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                   INTERVENTIONAL   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                         INDUSTRY   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                    75015   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Funder Type  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                                 NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                                      10467   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                       6   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                                 11   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                                                         NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...                                        Charlestown   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                              66160   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                     INTERVENTIONAL   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                       France|HÃ´pital Nord   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Study Type  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                                 NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                             United States\"   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                     NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                                NaN   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                                                           5   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...                                      Massachusetts   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                     United States\"   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                     B-1902-520-004   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                             Saint-Ãtienne   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Study Design  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                                             NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                          \"Study Protocol and Statistical Analysis Plan   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                 NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                            NaN   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                                                     NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...                                          02129   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                            NaN   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...    \"Seoul National University Bundang Hospital   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                          17217   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                                France\"   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Locations  \\\n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                         NaN   \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                 19   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                             NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...        NaN   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                 NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...        NaN   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...        NaN   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...   Gyeonggi   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...   01246000   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                 44   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Time taken for Enrollment  \n",
            "2                                                  NCT03727620                                        Doxycycline in the Treatment of Aggressive Peri... https://clinicaltrials.gov/study/NCT03727620       NaN                                                COMPLETED                                          \"The aim of the study was to compare the clinic...  three times a day for 7 days.\"                    NO                                                 Aggressive Periodontitis                           DRUG: amoxicillin plus metronidazole|DRUG: Doxy... \"Decrease of periodontal pockets â¥ 4mm            â¢ Probing pockets depths were assessed to th...  when recruiting patient at baseline and the re...  3 months\"                                         \"Plaque index decrease                              Plaque index was assessed by using Loe and sil...  3 months|Gingival index decrease                                        NaN  \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                               NaN  \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                            NaN  \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                       NaN  \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                                NaN  \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ...  \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...                       NaN  \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                       NaN  \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                     Korea  \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                       NaN  \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                               NaN  \n",
            "\n",
            "[11476 rows x 14 columns]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Age'].value_counts()"
      ],
      "metadata": {
        "id": "e3LXeP4qmTq5",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 554
        },
        "outputId": "4e43c1bd-572d-4f4a-d1f4-14360226b652"
      },
      "execution_count": 403,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Age\n",
              "0     10299\n",
              "1       486\n",
              "2       197\n",
              "3       105\n",
              "4        75\n",
              "10       50\n",
              "8        46\n",
              "12       40\n",
              "5        40\n",
              "6        37\n",
              "7        36\n",
              "9        36\n",
              "15       15\n",
              "14       14\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Age</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>10299</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>486</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>197</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>105</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>75</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>10</th>\n",
              "      <td>50</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>46</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>40</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>40</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>37</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>36</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>36</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15</th>\n",
              "      <td>15</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>14</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 403
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "#For Phases"
      ],
      "metadata": {
        "id": "pYDWY9m0ll6O"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Phases'].value_counts()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 489
        },
        "id": "8V6ZblVOlknL",
        "outputId": "e7fa291c-c909-46d6-d3d2-84956b1beaaa"
      },
      "execution_count": 404,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Phases\n",
              " United States\"                                                                                                 268\n",
              " OLDER_ADULT\"                                                                                                   202\n",
              "OTHER                                                                                                           144\n",
              "\"Study Protocol and Statistical Analysis Plan                                                                   143\n",
              "INTERVENTIONAL                                                                                                  105\n",
              "                                                                                                               ... \n",
              " Guy's and St Thomas's NHS Foundation Trust                                                                       1\n",
              " Queensland                                                                                                       1\n",
              " Before starting treatment|Joint Range of Motion (ROM) Measurement                                                1\n",
              " After 6 weeks of treatment (treatment is 18 sessions)|Functional Independence Measure for Children (WeeFIM)      1\n",
              "2017P000179|1R01NS095937-01A1                                                                                     1\n",
              "Name: count, Length: 4470, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Phases</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>United States\"</th>\n",
              "      <td>268</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>OLDER_ADULT\"</th>\n",
              "      <td>202</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>OTHER</th>\n",
              "      <td>144</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>\"Study Protocol and Statistical Analysis Plan</th>\n",
              "      <td>143</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>INTERVENTIONAL</th>\n",
              "      <td>105</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Guy's and St Thomas's NHS Foundation Trust</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Queensland</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Before starting treatment|Joint Range of Motion (ROM) Measurement</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>After 6 weeks of treatment (treatment is 18 sessions)|Functional Independence Measure for Children (WeeFIM)</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2017P000179|1R01NS095937-01A1</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>4470 rows × 1 columns</p>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 404
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "\n",
        "# Assuming 'df_clear' is your DataFrame\n",
        "# Replace NaN and empty values\n",
        "df_clear = df_clear[df_clear['Phases'].notna() & (df_clear['Phases'] != '')]\n",
        "df_clear['Phases'] = df_clear['Phases'].fillna('0')\n",
        "\n",
        "# Convert column to string to standardize\n",
        "df_clear['Phases'] = df_clear['Phases'].astype(str)\n",
        "\n",
        "# Convert strings to numeric where possible (ignore errors)\n",
        "df_clear['Phases'] = pd.to_numeric(df_clear['Phases'], errors='coerce')\n",
        "\n",
        "# Dynamically update values based on their frequency\n",
        "name_counts = df_clear['Phases'].value_counts()\n",
        "\n",
        "# Loop from 1 to 20 and skip NaN values explicitly\n",
        "for i in range(1, 21):\n",
        "    df_clear['Phases'] = df_clear['Phases'].apply(\n",
        "        lambda x: i if pd.notna(x) and name_counts.get(x, 0) == i else x\n",
        "    )\n",
        "    name_counts = df_clear['Phases'].value_counts()\n",
        "\n",
        "# Convert back to integer (after handling non-convertible values)\n",
        "df_clear['Phases'] = df_clear['Phases'].fillna(0).astype(int)\n",
        "\n",
        "# Display the cleaned DataFrame\n",
        "print(df_clear)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "lTPZRAm8lkkO",
        "outputId": "51d55c77-f0a4-4134-afd6-7a489ec2921b"
      },
      "execution_count": 405,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "<ipython-input-405-f263115d2b6a>:6: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_clear['Phases'] = df_clear['Phases'].fillna('0')\n",
            "<ipython-input-405-f263115d2b6a>:9: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_clear['Phases'] = df_clear['Phases'].astype(str)\n",
            "<ipython-input-405-f263115d2b6a>:12: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_clear['Phases'] = pd.to_numeric(df_clear['Phases'], errors='coerce')\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Status  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                     0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                  0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...             0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                      0   \n",
            "37                                                 NCT02995902                                        FLT-PET/DW-MRI for Detection of Brain Metastase... https://clinicaltrials.gov/study/NCT02995902       SIBES II                                           COMPLETED                                          \"The purpose of the study is to determine the v...  and to determine whether MRI of the brain shou... NO                                                 Small Cell Lung Cancer                             DEVICE: FLT-PET|DEVICE: MRI                        \"Overall survival                                   1 year|Disease free survival                       1 year\"                                           NaN                                                NaN                                                \"Rigshospitalet                                     Denmark\"                                                     11   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...             0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...             0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...             0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...             0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                     0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Results  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                      0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                   0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...              0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                       4   \n",
            "37                                                 NCT02995902                                        FLT-PET/DW-MRI for Detection of Brain Metastase... https://clinicaltrials.gov/study/NCT02995902       SIBES II                                           COMPLETED                                          \"The purpose of the study is to determine the v...  and to determine whether MRI of the brain shou... NO                                                 Small Cell Lung Cancer                             DEVICE: FLT-PET|DEVICE: MRI                        \"Overall survival                                   1 year|Disease free survival                       1 year\"                                           NaN                                                NaN                                                \"Rigshospitalet                                     Denmark\"                                                       0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...              0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...              0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...              0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...              0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                      1   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Conditions  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                   0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...           0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                    0   \n",
            "37                                                 NCT02995902                                        FLT-PET/DW-MRI for Detection of Brain Metastase... https://clinicaltrials.gov/study/NCT02995902       SIBES II                                           COMPLETED                                          \"The purpose of the study is to determine the v...  and to determine whether MRI of the brain shou... NO                                                 Small Cell Lung Cancer                             DEVICE: FLT-PET|DEVICE: MRI                        \"Overall survival                                   1 year|Disease free survival                       1 year\"                                           NaN                                                NaN                                                \"Rigshospitalet                                     Denmark\"                                                    0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...           0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...           0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                   0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sponsor  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                             0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...        0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                 0   \n",
            "37                                                 NCT02995902                                        FLT-PET/DW-MRI for Detection of Brain Metastase... https://clinicaltrials.gov/study/NCT02995902       SIBES II                                           COMPLETED                                          \"The purpose of the study is to determine the v...  and to determine whether MRI of the brain shou... NO                                                 Small Cell Lung Cancer                             DEVICE: FLT-PET|DEVICE: MRI                        \"Overall survival                                   1 year|Disease free survival                       1 year\"                                           NaN                                                NaN                                                \"Rigshospitalet                                     Denmark\"                                                 0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...        0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...        0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...        0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...        0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Collaborators  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                      0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                   0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...              0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                       0   \n",
            "37                                                 NCT02995902                                        FLT-PET/DW-MRI for Detection of Brain Metastase... https://clinicaltrials.gov/study/NCT02995902       SIBES II                                           COMPLETED                                          \"The purpose of the study is to determine the v...  and to determine whether MRI of the brain shou... NO                                                 Small Cell Lung Cancer                             DEVICE: FLT-PET|DEVICE: MRI                        \"Overall survival                                   1 year|Disease free survival                       1 year\"                                           NaN                                                NaN                                                \"Rigshospitalet                                     Denmark\"                                                      10   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...              0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...              0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...              0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...              0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                      0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sex  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                            0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                         0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...    0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                             0   \n",
            "37                                                 NCT02995902                                        FLT-PET/DW-MRI for Detection of Brain Metastase... https://clinicaltrials.gov/study/NCT02995902       SIBES II                                           COMPLETED                                          \"The purpose of the study is to determine the v...  and to determine whether MRI of the brain shou... NO                                                 Small Cell Lung Cancer                             DEVICE: FLT-PET|DEVICE: MRI                        \"Overall survival                                   1 year|Disease free survival                       1 year\"                                           NaN                                                NaN                                                \"Rigshospitalet                                     Denmark\"                                             0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...    0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...    0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...    0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...    0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"            0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Age  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                            0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                         1   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...    0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                             0   \n",
            "37                                                 NCT02995902                                        FLT-PET/DW-MRI for Detection of Brain Metastase... https://clinicaltrials.gov/study/NCT02995902       SIBES II                                           COMPLETED                                          \"The purpose of the study is to determine the v...  and to determine whether MRI of the brain shou... NO                                                 Small Cell Lung Cancer                             DEVICE: FLT-PET|DEVICE: MRI                        \"Overall survival                                   1 year|Disease free survival                       1 year\"                                           NaN                                                NaN                                                \"Rigshospitalet                                     Denmark\"                                             0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...    0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...    0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...    4   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...    0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"            0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Phases  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                               0   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                            0   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...       0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                1   \n",
            "37                                                 NCT02995902                                        FLT-PET/DW-MRI for Detection of Brain Metastase... https://clinicaltrials.gov/study/NCT02995902       SIBES II                                           COMPLETED                                          \"The purpose of the study is to determine the v...  and to determine whether MRI of the brain shou... NO                                                 Small Cell Lung Cancer                             DEVICE: FLT-PET|DEVICE: MRI                        \"Overall survival                                   1 year|Disease free survival                       1 year\"                                           NaN                                                NaN                                                \"Rigshospitalet                                     Denmark\"                                               26   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...       0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...       0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...       0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...       8   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"               0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Enrollment  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                 New York   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                   NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                              NaN   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                                   Mexico\"   \n",
            "37                                                 NCT02995902                                        FLT-PET/DW-MRI for Detection of Brain Metastase... https://clinicaltrials.gov/study/NCT02995902       SIBES II                                           COMPLETED                                          \"The purpose of the study is to determine the v...  and to determine whether MRI of the brain shou... NO                                                 Small Cell Lung Cancer                             DEVICE: FLT-PET|DEVICE: MRI                        \"Overall survival                                   1 year|Disease free survival                       1 year\"                                           NaN                                                NaN                                                \"Rigshospitalet                                     Denmark\"                                                                       NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...  \"Massachusetts General Hospital   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                           Kansas   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                   INTERVENTIONAL   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                         INDUSTRY   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                    75015   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Funder Type  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                                      10467   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                       6   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                                 11   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                                                         NaN   \n",
            "37                                                 NCT02995902                                        FLT-PET/DW-MRI for Detection of Brain Metastase... https://clinicaltrials.gov/study/NCT02995902       SIBES II                                           COMPLETED                                          \"The purpose of the study is to determine the v...  and to determine whether MRI of the brain shou... NO                                                 Small Cell Lung Cancer                             DEVICE: FLT-PET|DEVICE: MRI                        \"Overall survival                                   1 year|Disease free survival                       1 year\"                                           NaN                                                NaN                                                \"Rigshospitalet                                     Denmark\"                                                                                         NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...                                        Charlestown   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                              66160   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                     INTERVENTIONAL   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                       France|HÃ´pital Nord   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Study Type  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                             United States\"   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                     NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                                NaN   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                                                           5   \n",
            "37                                                 NCT02995902                                        FLT-PET/DW-MRI for Detection of Brain Metastase... https://clinicaltrials.gov/study/NCT02995902       SIBES II                                           COMPLETED                                          \"The purpose of the study is to determine the v...  and to determine whether MRI of the brain shou... NO                                                 Small Cell Lung Cancer                             DEVICE: FLT-PET|DEVICE: MRI                        \"Overall survival                                   1 year|Disease free survival                       1 year\"                                           NaN                                                NaN                                                \"Rigshospitalet                                     Denmark\"                                                                                         NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...                                      Massachusetts   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                     United States\"   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                     B-1902-520-004   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                             Saint-Ãtienne   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Study Design  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                          \"Study Protocol and Statistical Analysis Plan   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                                                 NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                                            NaN   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                                                     NaN   \n",
            "37                                                 NCT02995902                                        FLT-PET/DW-MRI for Detection of Brain Metastase... https://clinicaltrials.gov/study/NCT02995902       SIBES II                                           COMPLETED                                          \"The purpose of the study is to determine the v...  and to determine whether MRI of the brain shou... NO                                                 Small Cell Lung Cancer                             DEVICE: FLT-PET|DEVICE: MRI                        \"Overall survival                                   1 year|Disease free survival                       1 year\"                                           NaN                                                NaN                                                \"Rigshospitalet                                     Denmark\"                                                                                     NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...                                          02129   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                            NaN   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...    \"Seoul National University Bundang Hospital   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                          17217   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                                France\"   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Locations  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                 19   \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                             NaN   \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...        NaN   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                 NaN   \n",
            "37                                                 NCT02995902                                        FLT-PET/DW-MRI for Detection of Brain Metastase... https://clinicaltrials.gov/study/NCT02995902       SIBES II                                           COMPLETED                                          \"The purpose of the study is to determine the v...  and to determine whether MRI of the brain shou... NO                                                 Small Cell Lung Cancer                             DEVICE: FLT-PET|DEVICE: MRI                        \"Overall survival                                   1 year|Disease free survival                       1 year\"                                           NaN                                                NaN                                                \"Rigshospitalet                                     Denmark\"                                                 NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...        NaN   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...        NaN   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...   Gyeonggi   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...   01246000   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                 44   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Time taken for Enrollment  \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                               NaN  \n",
            "15                                                 NCT04224207                                        Management of Retinitis Pigmentosa by Mesenchym... https://clinicaltrials.gov/study/NCT04224207       WJ-MSC                                             COMPLETED                                          The aim of this study is to determine if umbili... NO                                                 Retinitis Pigmentosa|Inherited Retinal Dystrophy   BIOLOGICAL: Wharton's jelly derived mesenchymal... \"ETDRS visual acuity                                The visual acuity scores obtained from the bas...  Change from baseline visual acuity at 6 months\"   \"Outer retinal thickness                            This is the thickness from the outer plexiform...  Change from baseline outer retinal thickness a... NaN                                                Ankara Universitesi Teknokent                                            NaN  \n",
            "Uninfected; non viral RNA detected: 0 Asymptoma...  pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanica...  (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopress...  pO2/FIO2\\<150 AND vasopressors (norepinephrine...  OR Dialysis OR ECMO: 9 Dead: 10                    day 7 and day 14|Overall survival at 14            28                                                 60 and 90 days                                     Overall survival                                   14                                                 28                                                 60 and 90 days|Cumulative incidence of dischar...  Cumulative incidence of discharge alive            14 and 28 days|Survival without needs of mecha...  Survival without needs of mechanical ventilati...  day 1|Cumulative incidence of oxygen supply in...  Cumulative incidence of oxygen supply independ...  14 and 28 days|Survival without needs of venti...                       NaN  \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                                NaN  \n",
            "37                                                 NCT02995902                                        FLT-PET/DW-MRI for Detection of Brain Metastase... https://clinicaltrials.gov/study/NCT02995902       SIBES II                                           COMPLETED                                          \"The purpose of the study is to determine the v...  and to determine whether MRI of the brain shou... NO                                                 Small Cell Lung Cancer                             DEVICE: FLT-PET|DEVICE: MRI                        \"Overall survival                                   1 year|Disease free survival                       1 year\"                                           NaN                                                NaN                                                \"Rigshospitalet                                     Denmark\"                                                                NaN  \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ...  \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...                       NaN  \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                       NaN  \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                     Korea  \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                       NaN  \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                               NaN  \n",
            "\n",
            "[9540 rows x 14 columns]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Phases'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "BED90Kkdlkg9",
        "outputId": "a09bd901-46a6-44cf-9428-b9dde93253c1"
      },
      "execution_count": 406,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Phases\n",
              "0     6899\n",
              "1      633\n",
              "2      258\n",
              "3      158\n",
              "4      142\n",
              "5      130\n",
              "6      111\n",
              "12      98\n",
              "10      93\n",
              "17      93\n",
              "7       78\n",
              "14      72\n",
              "20      67\n",
              "16      65\n",
              "8       62\n",
              "9       61\n",
              "11      52\n",
              "19      50\n",
              "13      49\n",
              "60      48\n",
              "15      44\n",
              "18      42\n",
              "40      39\n",
              "24      39\n",
              "30      33\n",
              "23      30\n",
              "32      26\n",
              "25      25\n",
              "21      22\n",
              "26      21\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Phases</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>6899</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>633</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>258</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>158</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>142</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>130</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>111</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>98</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>10</th>\n",
              "      <td>93</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>17</th>\n",
              "      <td>93</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>78</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>72</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20</th>\n",
              "      <td>67</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>16</th>\n",
              "      <td>65</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>62</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>61</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>52</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>19</th>\n",
              "      <td>50</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>13</th>\n",
              "      <td>49</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>60</th>\n",
              "      <td>48</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15</th>\n",
              "      <td>44</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>18</th>\n",
              "      <td>42</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>40</th>\n",
              "      <td>39</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>24</th>\n",
              "      <td>39</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>30</th>\n",
              "      <td>33</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>23</th>\n",
              "      <td>30</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>32</th>\n",
              "      <td>26</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>25</th>\n",
              "      <td>25</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>21</th>\n",
              "      <td>22</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>26</th>\n",
              "      <td>21</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 406
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "#For Enrollment"
      ],
      "metadata": {
        "id": "gG4lcxHOmBUG"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Enrollment'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 489
        },
        "id": "rcpIS-sQlkdv",
        "outputId": "5f7123ae-9f2b-4f14-bdf8-de2df86ea44e"
      },
      "execution_count": 407,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Enrollment\n",
              "OTHER                                                                                                                                                                                     644\n",
              "INTERVENTIONAL                                                                                                                                                                            265\n",
              " United States\"                                                                                                                                                                           214\n",
              "INDUSTRY                                                                                                                                                                                  125\n",
              "\"Study Protocol and Statistical Analysis Plan                                                                                                                                              86\n",
              "                                                                                                                                                                                         ... \n",
              " Number (%) of participants with Grade 2 or higher symptoms (on any occasion from Day 1 to Day 12)                                                                                          1\n",
              " Up to 19 days|Incidence of clinically significant changes in vital signs: Orthostatic hypotension measurements performed as per clinical research unit's standard operating procedure      1\n",
              " 562157                                                                                                                                                                                     1\n",
              " Odense                                                                                                                                                                                     1\n",
              " Provincial healthcare administrative databases                                                                                                                                             1\n",
              "Name: count, Length: 3748, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Enrollment</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>OTHER</th>\n",
              "      <td>644</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>INTERVENTIONAL</th>\n",
              "      <td>265</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>United States\"</th>\n",
              "      <td>214</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>INDUSTRY</th>\n",
              "      <td>125</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>\"Study Protocol and Statistical Analysis Plan</th>\n",
              "      <td>86</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Number (%) of participants with Grade 2 or higher symptoms (on any occasion from Day 1 to Day 12)</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Up to 19 days|Incidence of clinically significant changes in vital signs: Orthostatic hypotension measurements performed as per clinical research unit's standard operating procedure</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>562157</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Odense</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Provincial healthcare administrative databases</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>3748 rows × 1 columns</p>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 407
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Assuming 'df_clear' is your DataFrame\n",
        "# Replace NaN and empty values\n",
        "df_clear = df_clear[df_clear['Enrollment'].notna() & (df_clear['Enrollment'] != '')]\n",
        "df_clear['Enrollment'] = df_clear['Enrollment'].fillna('0')\n",
        "\n",
        "# Convert column to string to standardize\n",
        "df_clear['Enrollment'] = df_clear['Enrollment'].astype(str)\n",
        "\n",
        "# Convert strings to numeric where possible (ignore errors)\n",
        "df_clear['Enrollment'] = pd.to_numeric(df_clear['Enrollment'], errors='coerce')\n",
        "\n",
        "# Dynamically update values based on their frequency\n",
        "name_counts = df_clear['Enrollment'].value_counts()\n",
        "\n",
        "# Loop from 1 to 20 and skip NaN values explicitly\n",
        "for i in range(1, 10):\n",
        "    df_clear['Enrollment'] = df_clear['Enrollment'].apply(\n",
        "        lambda x: i if pd.notna(x) and name_counts.get(x, 0) == i else x\n",
        "    )\n",
        "    name_counts = df_clear['Enrollment'].value_counts()\n",
        "\n",
        "# Convert back to integer (after handling non-convertible values)\n",
        "df_clear['Enrollment'] = df_clear['Enrollment'].fillna(0).astype(int)\n",
        "\n",
        "# Display the cleaned DataFrame\n",
        "print(df_clear)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "rIttcDlPlkaX",
        "outputId": "eaacfbca-ade7-403e-a8fa-8760a917d3de"
      },
      "execution_count": 408,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Status  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                     0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                      0   \n",
            "* Withdrawal from the study by the decision of ...  Day 1 to 3 at 3200m\"                              \"Acute mountain sickness                            severity                                           Difference between acetazolamide and placebo g...  Day 1 to 3 at 3200m|6 min walk distance            Difference in altitude-induced change in the d...  Day 2 at 760m and 3200m|Perceived exertion         Difference in altitude-induced change in the p...  Day 2 at 760m and 3200m|Spirometry                 Difference in altitude-induced change in the s...  Day 2 at 760m and 3200m|Arterial blood gases       Difference in altitude-induced change in arter...  carbon dioxide partial pressure                    and pH between the acetazolamide and placebo g...  Day 2 at 760m and 3200m|Exercise endurance dur...  Difference in altitude-induced change in exerc...  measured by constant load cycling ergometry                   0   \n",
            "PD in NHL: Cheson                                   2007: Appearance of new lesion or increase by ...  Transformation to a more aggressive NHL histol...  From first dose of tirabrutinib in the parent ...  OS is defined as the interval from date of the...  From first dose of tirabrutinib in the parent ... NaN                                                Gilead Sciences                                    NaN                                                ALL                                                \"ADULT                                              OLDER_ADULT\"                                      PHASE1                                             29.0                                               INDUSTRY                                           INTERVENTIONAL                                     Allocation: NON_RANDOMIZED|Intervention Model: ... GS-US-401-1787|2015-001404-58                                  0   \n",
            "78                                                 NCT03593278                                        A Study to Evaluate ACT-246475 Fate in Healthy ... https://clinicaltrials.gov/study/NCT03593278       NaN                                                COMPLETED                                          \"The purpose of this study is to investigate ho...  distributed                                        metabolized (broken down) and eliminated from ...  in this way can be traced in blood                 urine                                              and feces. This study will also investigate ho... NO                                                 Healthy Subjects                                   DRUG: ACT-246475                                   \"Cumulative excretion of total 14C-radioactivit...  Cumulative amount of total 14C-radioactivity e...  Up to 54 days\"                                                0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...             0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...             0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...             0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...             0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                     0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Results  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                      0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                       4   \n",
            "* Withdrawal from the study by the decision of ...  Day 1 to 3 at 3200m\"                              \"Acute mountain sickness                            severity                                           Difference between acetazolamide and placebo g...  Day 1 to 3 at 3200m|6 min walk distance            Difference in altitude-induced change in the d...  Day 2 at 760m and 3200m|Perceived exertion         Difference in altitude-induced change in the p...  Day 2 at 760m and 3200m|Spirometry                 Difference in altitude-induced change in the s...  Day 2 at 760m and 3200m|Arterial blood gases       Difference in altitude-induced change in arter...  carbon dioxide partial pressure                    and pH between the acetazolamide and placebo g...  Day 2 at 760m and 3200m|Exercise endurance dur...  Difference in altitude-induced change in exerc...  measured by constant load cycling ergometry                    0   \n",
            "PD in NHL: Cheson                                   2007: Appearance of new lesion or increase by ...  Transformation to a more aggressive NHL histol...  From first dose of tirabrutinib in the parent ...  OS is defined as the interval from date of the...  From first dose of tirabrutinib in the parent ... NaN                                                Gilead Sciences                                    NaN                                                ALL                                                \"ADULT                                              OLDER_ADULT\"                                      PHASE1                                             29.0                                               INDUSTRY                                           INTERVENTIONAL                                     Allocation: NON_RANDOMIZED|Intervention Model: ... GS-US-401-1787|2015-001404-58                                   0   \n",
            "78                                                 NCT03593278                                        A Study to Evaluate ACT-246475 Fate in Healthy ... https://clinicaltrials.gov/study/NCT03593278       NaN                                                COMPLETED                                          \"The purpose of this study is to investigate ho...  distributed                                        metabolized (broken down) and eliminated from ...  in this way can be traced in blood                 urine                                              and feces. This study will also investigate ho... NO                                                 Healthy Subjects                                   DRUG: ACT-246475                                   \"Cumulative excretion of total 14C-radioactivit...  Cumulative amount of total 14C-radioactivity e...  Up to 54 days\"                                                 0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...              0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...              0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...              0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...              0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                      1   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Conditions  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                   0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                    0   \n",
            "* Withdrawal from the study by the decision of ...  Day 1 to 3 at 3200m\"                              \"Acute mountain sickness                            severity                                           Difference between acetazolamide and placebo g...  Day 1 to 3 at 3200m|6 min walk distance            Difference in altitude-induced change in the d...  Day 2 at 760m and 3200m|Perceived exertion         Difference in altitude-induced change in the p...  Day 2 at 760m and 3200m|Spirometry                 Difference in altitude-induced change in the s...  Day 2 at 760m and 3200m|Arterial blood gases       Difference in altitude-induced change in arter...  carbon dioxide partial pressure                    and pH between the acetazolamide and placebo g...  Day 2 at 760m and 3200m|Exercise endurance dur...  Difference in altitude-induced change in exerc...  measured by constant load cycling ergometry                 0   \n",
            "PD in NHL: Cheson                                   2007: Appearance of new lesion or increase by ...  Transformation to a more aggressive NHL histol...  From first dose of tirabrutinib in the parent ...  OS is defined as the interval from date of the...  From first dose of tirabrutinib in the parent ... NaN                                                Gilead Sciences                                    NaN                                                ALL                                                \"ADULT                                              OLDER_ADULT\"                                      PHASE1                                             29.0                                               INDUSTRY                                           INTERVENTIONAL                                     Allocation: NON_RANDOMIZED|Intervention Model: ... GS-US-401-1787|2015-001404-58                                0   \n",
            "78                                                 NCT03593278                                        A Study to Evaluate ACT-246475 Fate in Healthy ... https://clinicaltrials.gov/study/NCT03593278       NaN                                                COMPLETED                                          \"The purpose of this study is to investigate ho...  distributed                                        metabolized (broken down) and eliminated from ...  in this way can be traced in blood                 urine                                              and feces. This study will also investigate ho... NO                                                 Healthy Subjects                                   DRUG: ACT-246475                                   \"Cumulative excretion of total 14C-radioactivit...  Cumulative amount of total 14C-radioactivity e...  Up to 54 days\"                                              6   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...           0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...           0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                   0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sponsor  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                 0   \n",
            "* Withdrawal from the study by the decision of ...  Day 1 to 3 at 3200m\"                              \"Acute mountain sickness                            severity                                           Difference between acetazolamide and placebo g...  Day 1 to 3 at 3200m|6 min walk distance            Difference in altitude-induced change in the d...  Day 2 at 760m and 3200m|Perceived exertion         Difference in altitude-induced change in the p...  Day 2 at 760m and 3200m|Spirometry                 Difference in altitude-induced change in the s...  Day 2 at 760m and 3200m|Arterial blood gases       Difference in altitude-induced change in arter...  carbon dioxide partial pressure                    and pH between the acetazolamide and placebo g...  Day 2 at 760m and 3200m|Exercise endurance dur...  Difference in altitude-induced change in exerc...  measured by constant load cycling ergometry              0   \n",
            "PD in NHL: Cheson                                   2007: Appearance of new lesion or increase by ...  Transformation to a more aggressive NHL histol...  From first dose of tirabrutinib in the parent ...  OS is defined as the interval from date of the...  From first dose of tirabrutinib in the parent ... NaN                                                Gilead Sciences                                    NaN                                                ALL                                                \"ADULT                                              OLDER_ADULT\"                                      PHASE1                                             29.0                                               INDUSTRY                                           INTERVENTIONAL                                     Allocation: NON_RANDOMIZED|Intervention Model: ... GS-US-401-1787|2015-001404-58                             0   \n",
            "78                                                 NCT03593278                                        A Study to Evaluate ACT-246475 Fate in Healthy ... https://clinicaltrials.gov/study/NCT03593278       NaN                                                COMPLETED                                          \"The purpose of this study is to investigate ho...  distributed                                        metabolized (broken down) and eliminated from ...  in this way can be traced in blood                 urine                                              and feces. This study will also investigate ho... NO                                                 Healthy Subjects                                   DRUG: ACT-246475                                   \"Cumulative excretion of total 14C-radioactivit...  Cumulative amount of total 14C-radioactivity e...  Up to 54 days\"                                           0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...        0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...        0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...        0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...        0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Collaborators  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                      0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                       0   \n",
            "* Withdrawal from the study by the decision of ...  Day 1 to 3 at 3200m\"                              \"Acute mountain sickness                            severity                                           Difference between acetazolamide and placebo g...  Day 1 to 3 at 3200m|6 min walk distance            Difference in altitude-induced change in the d...  Day 2 at 760m and 3200m|Perceived exertion         Difference in altitude-induced change in the p...  Day 2 at 760m and 3200m|Spirometry                 Difference in altitude-induced change in the s...  Day 2 at 760m and 3200m|Arterial blood gases       Difference in altitude-induced change in arter...  carbon dioxide partial pressure                    and pH between the acetazolamide and placebo g...  Day 2 at 760m and 3200m|Exercise endurance dur...  Difference in altitude-induced change in exerc...  measured by constant load cycling ergometry                    0   \n",
            "PD in NHL: Cheson                                   2007: Appearance of new lesion or increase by ...  Transformation to a more aggressive NHL histol...  From first dose of tirabrutinib in the parent ...  OS is defined as the interval from date of the...  From first dose of tirabrutinib in the parent ... NaN                                                Gilead Sciences                                    NaN                                                ALL                                                \"ADULT                                              OLDER_ADULT\"                                      PHASE1                                             29.0                                               INDUSTRY                                           INTERVENTIONAL                                     Allocation: NON_RANDOMIZED|Intervention Model: ... GS-US-401-1787|2015-001404-58                                   0   \n",
            "78                                                 NCT03593278                                        A Study to Evaluate ACT-246475 Fate in Healthy ... https://clinicaltrials.gov/study/NCT03593278       NaN                                                COMPLETED                                          \"The purpose of this study is to investigate ho...  distributed                                        metabolized (broken down) and eliminated from ...  in this way can be traced in blood                 urine                                              and feces. This study will also investigate ho... NO                                                 Healthy Subjects                                   DRUG: ACT-246475                                   \"Cumulative excretion of total 14C-radioactivit...  Cumulative amount of total 14C-radioactivity e...  Up to 54 days\"                                                 0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...              0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...              0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...              0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...              0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                      0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sex  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                            0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                             0   \n",
            "* Withdrawal from the study by the decision of ...  Day 1 to 3 at 3200m\"                              \"Acute mountain sickness                            severity                                           Difference between acetazolamide and placebo g...  Day 1 to 3 at 3200m|6 min walk distance            Difference in altitude-induced change in the d...  Day 2 at 760m and 3200m|Perceived exertion         Difference in altitude-induced change in the p...  Day 2 at 760m and 3200m|Spirometry                 Difference in altitude-induced change in the s...  Day 2 at 760m and 3200m|Arterial blood gases       Difference in altitude-induced change in arter...  carbon dioxide partial pressure                    and pH between the acetazolamide and placebo g...  Day 2 at 760m and 3200m|Exercise endurance dur...  Difference in altitude-induced change in exerc...  measured by constant load cycling ergometry          0   \n",
            "PD in NHL: Cheson                                   2007: Appearance of new lesion or increase by ...  Transformation to a more aggressive NHL histol...  From first dose of tirabrutinib in the parent ...  OS is defined as the interval from date of the...  From first dose of tirabrutinib in the parent ... NaN                                                Gilead Sciences                                    NaN                                                ALL                                                \"ADULT                                              OLDER_ADULT\"                                      PHASE1                                             29.0                                               INDUSTRY                                           INTERVENTIONAL                                     Allocation: NON_RANDOMIZED|Intervention Model: ... GS-US-401-1787|2015-001404-58                         0   \n",
            "78                                                 NCT03593278                                        A Study to Evaluate ACT-246475 Fate in Healthy ... https://clinicaltrials.gov/study/NCT03593278       NaN                                                COMPLETED                                          \"The purpose of this study is to investigate ho...  distributed                                        metabolized (broken down) and eliminated from ...  in this way can be traced in blood                 urine                                              and feces. This study will also investigate ho... NO                                                 Healthy Subjects                                   DRUG: ACT-246475                                   \"Cumulative excretion of total 14C-radioactivit...  Cumulative amount of total 14C-radioactivity e...  Up to 54 days\"                                       1   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...    0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...    0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...    0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...    0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"            0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Age  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                            0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                             0   \n",
            "* Withdrawal from the study by the decision of ...  Day 1 to 3 at 3200m\"                              \"Acute mountain sickness                            severity                                           Difference between acetazolamide and placebo g...  Day 1 to 3 at 3200m|6 min walk distance            Difference in altitude-induced change in the d...  Day 2 at 760m and 3200m|Perceived exertion         Difference in altitude-induced change in the p...  Day 2 at 760m and 3200m|Spirometry                 Difference in altitude-induced change in the s...  Day 2 at 760m and 3200m|Arterial blood gases       Difference in altitude-induced change in arter...  carbon dioxide partial pressure                    and pH between the acetazolamide and placebo g...  Day 2 at 760m and 3200m|Exercise endurance dur...  Difference in altitude-induced change in exerc...  measured by constant load cycling ergometry          0   \n",
            "PD in NHL: Cheson                                   2007: Appearance of new lesion or increase by ...  Transformation to a more aggressive NHL histol...  From first dose of tirabrutinib in the parent ...  OS is defined as the interval from date of the...  From first dose of tirabrutinib in the parent ... NaN                                                Gilead Sciences                                    NaN                                                ALL                                                \"ADULT                                              OLDER_ADULT\"                                      PHASE1                                             29.0                                               INDUSTRY                                           INTERVENTIONAL                                     Allocation: NON_RANDOMIZED|Intervention Model: ... GS-US-401-1787|2015-001404-58                         0   \n",
            "78                                                 NCT03593278                                        A Study to Evaluate ACT-246475 Fate in Healthy ... https://clinicaltrials.gov/study/NCT03593278       NaN                                                COMPLETED                                          \"The purpose of this study is to investigate ho...  distributed                                        metabolized (broken down) and eliminated from ...  in this way can be traced in blood                 urine                                              and feces. This study will also investigate ho... NO                                                 Healthy Subjects                                   DRUG: ACT-246475                                   \"Cumulative excretion of total 14C-radioactivit...  Cumulative amount of total 14C-radioactivity e...  Up to 54 days\"                                       0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...    0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...    0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...    4   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...    0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"            0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Phases  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                               0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                1   \n",
            "* Withdrawal from the study by the decision of ...  Day 1 to 3 at 3200m\"                              \"Acute mountain sickness                            severity                                           Difference between acetazolamide and placebo g...  Day 1 to 3 at 3200m|6 min walk distance            Difference in altitude-induced change in the d...  Day 2 at 760m and 3200m|Perceived exertion         Difference in altitude-induced change in the p...  Day 2 at 760m and 3200m|Spirometry                 Difference in altitude-induced change in the s...  Day 2 at 760m and 3200m|Arterial blood gases       Difference in altitude-induced change in arter...  carbon dioxide partial pressure                    and pH between the acetazolamide and placebo g...  Day 2 at 760m and 3200m|Exercise endurance dur...  Difference in altitude-induced change in exerc...  measured by constant load cycling ergometry             0   \n",
            "PD in NHL: Cheson                                   2007: Appearance of new lesion or increase by ...  Transformation to a more aggressive NHL histol...  From first dose of tirabrutinib in the parent ...  OS is defined as the interval from date of the...  From first dose of tirabrutinib in the parent ... NaN                                                Gilead Sciences                                    NaN                                                ALL                                                \"ADULT                                              OLDER_ADULT\"                                      PHASE1                                             29.0                                               INDUSTRY                                           INTERVENTIONAL                                     Allocation: NON_RANDOMIZED|Intervention Model: ... GS-US-401-1787|2015-001404-58                            0   \n",
            "78                                                 NCT03593278                                        A Study to Evaluate ACT-246475 Fate in Healthy ... https://clinicaltrials.gov/study/NCT03593278       NaN                                                COMPLETED                                          \"The purpose of this study is to investigate ho...  distributed                                        metabolized (broken down) and eliminated from ...  in this way can be traced in blood                 urine                                              and feces. This study will also investigate ho... NO                                                 Healthy Subjects                                   DRUG: ACT-246475                                   \"Cumulative excretion of total 14C-radioactivit...  Cumulative amount of total 14C-radioactivity e...  Up to 54 days\"                                          0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...       0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...       0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...       0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...       8   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"               0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Enrollment  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                   0   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                    0   \n",
            "* Withdrawal from the study by the decision of ...  Day 1 to 3 at 3200m\"                              \"Acute mountain sickness                            severity                                           Difference between acetazolamide and placebo g...  Day 1 to 3 at 3200m|6 min walk distance            Difference in altitude-induced change in the d...  Day 2 at 760m and 3200m|Perceived exertion         Difference in altitude-induced change in the p...  Day 2 at 760m and 3200m|Spirometry                 Difference in altitude-induced change in the s...  Day 2 at 760m and 3200m|Arterial blood gases       Difference in altitude-induced change in arter...  carbon dioxide partial pressure                    and pH between the acetazolamide and placebo g...  Day 2 at 760m and 3200m|Exercise endurance dur...  Difference in altitude-induced change in exerc...  measured by constant load cycling ergometry                 0   \n",
            "PD in NHL: Cheson                                   2007: Appearance of new lesion or increase by ...  Transformation to a more aggressive NHL histol...  From first dose of tirabrutinib in the parent ...  OS is defined as the interval from date of the...  From first dose of tirabrutinib in the parent ... NaN                                                Gilead Sciences                                    NaN                                                ALL                                                \"ADULT                                              OLDER_ADULT\"                                      PHASE1                                             29.0                                               INDUSTRY                                           INTERVENTIONAL                                     Allocation: NON_RANDOMIZED|Intervention Model: ... GS-US-401-1787|2015-001404-58                                0   \n",
            "78                                                 NCT03593278                                        A Study to Evaluate ACT-246475 Fate in Healthy ... https://clinicaltrials.gov/study/NCT03593278       NaN                                                COMPLETED                                          \"The purpose of this study is to investigate ho...  distributed                                        metabolized (broken down) and eliminated from ...  in this way can be traced in blood                 urine                                              and feces. This study will also investigate ho... NO                                                 Healthy Subjects                                   DRUG: ACT-246475                                   \"Cumulative excretion of total 14C-radioactivit...  Cumulative amount of total 14C-radioactivity e...  Up to 54 days\"                                              1   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...           0   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...           0   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                   2   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Funder Type  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                                      10467   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                                                         NaN   \n",
            "* Withdrawal from the study by the decision of ...  Day 1 to 3 at 3200m\"                              \"Acute mountain sickness                            severity                                           Difference between acetazolamide and placebo g...  Day 1 to 3 at 3200m|6 min walk distance            Difference in altitude-induced change in the d...  Day 2 at 760m and 3200m|Perceived exertion         Difference in altitude-induced change in the p...  Day 2 at 760m and 3200m|Spirometry                 Difference in altitude-induced change in the s...  Day 2 at 760m and 3200m|Arterial blood gases       Difference in altitude-induced change in arter...  carbon dioxide partial pressure                    and pH between the acetazolamide and placebo g...  Day 2 at 760m and 3200m|Exercise endurance dur...  Difference in altitude-induced change in exerc...  measured by constant load cycling ergometry                                                  Bishkek   \n",
            "PD in NHL: Cheson                                   2007: Appearance of new lesion or increase by ...  Transformation to a more aggressive NHL histol...  From first dose of tirabrutinib in the parent ...  OS is defined as the interval from date of the...  From first dose of tirabrutinib in the parent ... NaN                                                Gilead Sciences                                    NaN                                                ALL                                                \"ADULT                                              OLDER_ADULT\"                                      PHASE1                                             29.0                                               INDUSTRY                                           INTERVENTIONAL                                     Allocation: NON_RANDOMIZED|Intervention Model: ... GS-US-401-1787|2015-001404-58                                                         United Kingdom\"   \n",
            "78                                                 NCT03593278                                        A Study to Evaluate ACT-246475 Fate in Healthy ... https://clinicaltrials.gov/study/NCT03593278       NaN                                                COMPLETED                                          \"The purpose of this study is to investigate ho...  distributed                                        metabolized (broken down) and eliminated from ...  in this way can be traced in blood                 urine                                              and feces. This study will also investigate ho... NO                                                 Healthy Subjects                                   DRUG: ACT-246475                                   \"Cumulative excretion of total 14C-radioactivit...  Cumulative amount of total 14C-radioactivity e...  Up to 54 days\"                                      Germany|Klinikum der Stadt Ludwigshafen am Rh...   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...                                        Charlestown   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                              66160   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                     INTERVENTIONAL   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                       France|HÃ´pital Nord   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Study Type  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                                             United States\"   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                                                           5   \n",
            "* Withdrawal from the study by the decision of ...  Day 1 to 3 at 3200m\"                              \"Acute mountain sickness                            severity                                           Difference between acetazolamide and placebo g...  Day 1 to 3 at 3200m|6 min walk distance            Difference in altitude-induced change in the d...  Day 2 at 760m and 3200m|Perceived exertion         Difference in altitude-induced change in the p...  Day 2 at 760m and 3200m|Spirometry                 Difference in altitude-induced change in the s...  Day 2 at 760m and 3200m|Arterial blood gases       Difference in altitude-induced change in arter...  carbon dioxide partial pressure                    and pH between the acetazolamide and placebo g...  Day 2 at 760m and 3200m|Exercise endurance dur...  Difference in altitude-induced change in exerc...  measured by constant load cycling ergometry                                                   720040   \n",
            "PD in NHL: Cheson                                   2007: Appearance of new lesion or increase by ...  Transformation to a more aggressive NHL histol...  From first dose of tirabrutinib in the parent ...  OS is defined as the interval from date of the...  From first dose of tirabrutinib in the parent ... NaN                                                Gilead Sciences                                    NaN                                                ALL                                                \"ADULT                                              OLDER_ADULT\"                                      PHASE1                                             29.0                                               INDUSTRY                                           INTERVENTIONAL                                     Allocation: NON_RANDOMIZED|Intervention Model: ... GS-US-401-1787|2015-001404-58                                                         \"Study Protocol   \n",
            "78                                                 NCT03593278                                        A Study to Evaluate ACT-246475 Fate in Healthy ... https://clinicaltrials.gov/study/NCT03593278       NaN                                                COMPLETED                                          \"The purpose of this study is to investigate ho...  distributed                                        metabolized (broken down) and eliminated from ...  in this way can be traced in blood                 urine                                              and feces. This study will also investigate ho... NO                                                 Healthy Subjects                                   DRUG: ACT-246475                                   \"Cumulative excretion of total 14C-radioactivit...  Cumulative amount of total 14C-radioactivity e...  Up to 54 days\"                                                                          Ludwigshafen   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...                                      Massachusetts   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                     United States\"   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                                     B-1902-520-004   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                             Saint-Ãtienne   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Study Design  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                              \"Study Protocol and Statistical Analysis Plan   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                                                         NaN   \n",
            "* Withdrawal from the study by the decision of ...  Day 1 to 3 at 3200m\"                              \"Acute mountain sickness                            severity                                           Difference between acetazolamide and placebo g...  Day 1 to 3 at 3200m|6 min walk distance            Difference in altitude-induced change in the d...  Day 2 at 760m and 3200m|Perceived exertion         Difference in altitude-induced change in the p...  Day 2 at 760m and 3200m|Spirometry                 Difference in altitude-induced change in the s...  Day 2 at 760m and 3200m|Arterial blood gases       Difference in altitude-induced change in arter...  carbon dioxide partial pressure                    and pH between the acetazolamide and placebo g...  Day 2 at 760m and 3200m|Exercise endurance dur...  Difference in altitude-induced change in exerc...  measured by constant load cycling ergometry                                              Kyrgyzstan\"   \n",
            "PD in NHL: Cheson                                   2007: Appearance of new lesion or increase by ...  Transformation to a more aggressive NHL histol...  From first dose of tirabrutinib in the parent ...  OS is defined as the interval from date of the...  From first dose of tirabrutinib in the parent ... NaN                                                Gilead Sciences                                    NaN                                                ALL                                                \"ADULT                                              OLDER_ADULT\"                                      PHASE1                                             29.0                                               INDUSTRY                                           INTERVENTIONAL                                     Allocation: NON_RANDOMIZED|Intervention Model: ... GS-US-401-1787|2015-001404-58                        https://cdn.clinicaltrials.gov/large-docs/59/...   \n",
            "78                                                 NCT03593278                                        A Study to Evaluate ACT-246475 Fate in Healthy ... https://clinicaltrials.gov/study/NCT03593278       NaN                                                COMPLETED                                          \"The purpose of this study is to investigate ho...  distributed                                        metabolized (broken down) and eliminated from ...  in this way can be traced in blood                 urine                                              and feces. This study will also investigate ho... NO                                                 Healthy Subjects                                   DRUG: ACT-246475                                   \"Cumulative excretion of total 14C-radioactivit...  Cumulative amount of total 14C-radioactivity e...  Up to 54 days\"                                                                                 67063   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...                                              02129   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                                                NaN   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...        \"Seoul National University Bundang Hospital   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                                              17217   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                                                    France\"   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Locations  \\\n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                 19   \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                 NaN   \n",
            "* Withdrawal from the study by the decision of ...  Day 1 to 3 at 3200m\"                              \"Acute mountain sickness                            severity                                           Difference between acetazolamide and placebo g...  Day 1 to 3 at 3200m|6 min walk distance            Difference in altitude-induced change in the d...  Day 2 at 760m and 3200m|Perceived exertion         Difference in altitude-induced change in the p...  Day 2 at 760m and 3200m|Spirometry                 Difference in altitude-induced change in the s...  Day 2 at 760m and 3200m|Arterial blood gases       Difference in altitude-induced change in arter...  carbon dioxide partial pressure                    and pH between the acetazolamide and placebo g...  Day 2 at 760m and 3200m|Exercise endurance dur...  Difference in altitude-induced change in exerc...  measured by constant load cycling ergometry               15   \n",
            "PD in NHL: Cheson                                   2007: Appearance of new lesion or increase by ...  Transformation to a more aggressive NHL histol...  From first dose of tirabrutinib in the parent ...  OS is defined as the interval from date of the...  From first dose of tirabrutinib in the parent ... NaN                                                Gilead Sciences                                    NaN                                                ALL                                                \"ADULT                                              OLDER_ADULT\"                                      PHASE1                                             29.0                                               INDUSTRY                                           INTERVENTIONAL                                     Allocation: NON_RANDOMIZED|Intervention Model: ... GS-US-401-1787|2015-001404-58                              63   \n",
            "78                                                 NCT03593278                                        A Study to Evaluate ACT-246475 Fate in Healthy ... https://clinicaltrials.gov/study/NCT03593278       NaN                                                COMPLETED                                          \"The purpose of this study is to investigate ho...  distributed                                        metabolized (broken down) and eliminated from ...  in this way can be traced in blood                 urine                                              and feces. This study will also investigate ho... NO                                                 Healthy Subjects                                   DRUG: ACT-246475                                   \"Cumulative excretion of total 14C-radioactivit...  Cumulative amount of total 14C-radioactivity e...  Up to 54 days\"                                           NaN   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ...   \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...        NaN   \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...        NaN   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...   Gyeonggi   \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...   01246000   \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                 44   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Time taken for Enrollment  \n",
            "Hypothesis: A daily regimen of ketorolac will p...  as measured by the Roland Morris Disability Qu... YES                                                Back Pain Without Radiation|Low Back Pain          DRUG: Ketorolac|DRUG: Ibuprofen|DRUG: Diclofena... \"Change From Baseline to Day 5 in Functional Im...  The change will be assessed by Roland Morris D...  Baseline to 5 days\"                               \"Worst LBP 2 Days After ED Visit                    Participants were called 2 days after ED visit...  using a four point ordinal scale: severe           moderate                                           mild                                               or none.                                           2 days after Emergency department visit|Freque...  Participants were called 2 days after ED visit...  Rarely                                             Sometimes                                                               NaN  \n",
            "34                                                 NCT04382287                                        Comparison of Remineralisation Efficacy of MI P... https://clinicaltrials.gov/study/NCT04382287       NaN                                                COMPLETED                                          \"The present study aimed to compare the reminer...  applied at home twice a day on the anterior up... NO                                                 White Spot Lesion                                  PROCEDURE: Remin ProÂ® and MI Paste PlusÂ®         \"Enamel remineralisation degree                     The remineralisation degree was quantified by ...  by evaluation on the 10th day.                     10 days|Enamel remineralisation degree             The remineralisation degree was quantified by ...  after twice-daily applications                     21 days\"                                                                NaN  \n",
            "* Withdrawal from the study by the decision of ...  Day 1 to 3 at 3200m\"                              \"Acute mountain sickness                            severity                                           Difference between acetazolamide and placebo g...  Day 1 to 3 at 3200m|6 min walk distance            Difference in altitude-induced change in the d...  Day 2 at 760m and 3200m|Perceived exertion         Difference in altitude-induced change in the p...  Day 2 at 760m and 3200m|Spirometry                 Difference in altitude-induced change in the s...  Day 2 at 760m and 3200m|Arterial blood gases       Difference in altitude-induced change in arter...  carbon dioxide partial pressure                    and pH between the acetazolamide and placebo g...  Day 2 at 760m and 3200m|Exercise endurance dur...  Difference in altitude-induced change in exerc...  measured by constant load cycling ergometry                             NaN  \n",
            "PD in NHL: Cheson                                   2007: Appearance of new lesion or increase by ...  Transformation to a more aggressive NHL histol...  From first dose of tirabrutinib in the parent ...  OS is defined as the interval from date of the...  From first dose of tirabrutinib in the parent ... NaN                                                Gilead Sciences                                    NaN                                                ALL                                                \"ADULT                                              OLDER_ADULT\"                                      PHASE1                                             29.0                                               INDUSTRY                                           INTERVENTIONAL                                     Allocation: NON_RANDOMIZED|Intervention Model: ... GS-US-401-1787|2015-001404-58                                            NaN  \n",
            "78                                                 NCT03593278                                        A Study to Evaluate ACT-246475 Fate in Healthy ... https://clinicaltrials.gov/study/NCT03593278       NaN                                                COMPLETED                                          \"The purpose of this study is to investigate ho...  distributed                                        metabolized (broken down) and eliminated from ...  in this way can be traced in blood                 urine                                              and feces. This study will also investigate ho... NO                                                 Healthy Subjects                                   DRUG: ACT-246475                                   \"Cumulative excretion of total 14C-radioactivit...  Cumulative amount of total 14C-radioactivity e...  Up to 54 days\"                                                          NaN  \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ...  \n",
            "68918                                              NCT03106740                                        Evaluating the Role of Neuroinflammation in Low... https://clinicaltrials.gov/study/NCT03106740       IGNITE                                             COMPLETED                                          \"In this research                                   the study team will use brain imaging to evalu... NO                                                 \"Low Back Pain|Back Pain With Radiation|Back Pa...  Chronic\"                                          DRUG: Minocycline Hydrochloride 100mg Capsule|D... \"Changes in brain PET signal                        The investigators will test for the presence o...  2 weeks\"                                          \"Changes in spinal PET signal                       The investigators will test for the presence o...  2 weeks|Daily pain ratings (as measured by the...                       NaN  \n",
            "68939                                              NCT03462667                                        Intensive Preoperative Ostomy Education for the... https://clinicaltrials.gov/study/NCT03462667       StomABC                                            COMPLETED                                          The purpose of this study is to learn if the st... NO                                                 Stoma Ileostomy                                    BEHAVIORAL: Stoma Boot Camp|OTHER: Standard of ... \"Ostomy adjustment scale                            The Ostomy Adjustment Scale evaluates a person...  the better the person's perceived adjustment.      Change from Baseline to 30 Days After Date of ... \"Length of hospital stay                            Measured as the date of admission to discharge.    Date of Admission to Date of Discharge             up to 7 days|Count of un-planned stoma-related...                       NaN  \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty...  ng/mL                                              6 and 12 months|Change in blood LDL-cholestero...                     Korea  \n",
            "68952                                              NCT02465502                                        Regorafenib in Subjects With Antiangiogenic-nai... https://clinicaltrials.gov/study/NCT02465502       NaN                                                COMPLETED                                          To determine the efficacy (as measured by progr... NO                                                 Colorectal Neoplasms                               \"DRUG: Regorafenib (Stivarga                        BAY73-4506)\"                                      \"Percentage of participants without disease pro...  At week 8\"                                        \"Progression-Free Survival (PFS)                    PFS is defined as the date from the first dose...  whichever comes first.                             Approximately 2 months|Overall Survival (OS)       OS is defined as the date from the first dose ...                       NaN  \n",
            "The aim of this study is to evaluate the cumula... NO                                                 Chronic Thromboembolic Pulmonary Hypertension (... DIAGNOSTIC_TEST: Study population                  \"Cumulated incidence of CTEPH                       Cumulated incidence rate of CTEPH after pulmon...  30-day +/- 15 days after inclusion visit\"         \"Cumulated incidence of CTEPH in patients witho...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Cumul...  Cumulated incidence rate of CTEPH in patients ...  30-day +/- 15 days after inclusion visit|Risk ...  Hazard ratio of risk factors independently and...  30-day +/- 15 days after inclusion visit|Compl...  Complication rate of right heart catheterization   30-day +/- 15 days after inclusion visit|Compl...  Complication rate of pulmonary angiography         30-day +/- 15 days after inclusion visit\"                               NaN  \n",
            "\n",
            "[7422 rows x 14 columns]\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "<ipython-input-408-43f3236ba334>:4: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_clear['Enrollment'] = df_clear['Enrollment'].fillna('0')\n",
            "<ipython-input-408-43f3236ba334>:7: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_clear['Enrollment'] = df_clear['Enrollment'].astype(str)\n",
            "<ipython-input-408-43f3236ba334>:10: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_clear['Enrollment'] = pd.to_numeric(df_clear['Enrollment'], errors='coerce')\n",
            "<ipython-input-408-43f3236ba334>:17: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df_clear['Enrollment'] = df_clear['Enrollment'].apply(\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Enrollment'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 460
        },
        "id": "E_sdex3plkXU",
        "outputId": "7c2a28bd-b5b2-464d-a94d-8812225ca1ab"
      },
      "execution_count": 409,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Enrollment\n",
              "0        6253\n",
              "1         547\n",
              "2         199\n",
              "3         108\n",
              "4          95\n",
              "5          72\n",
              "6          67\n",
              "8          32\n",
              "7          21\n",
              "9          18\n",
              "19104      10\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Enrollment</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>6253</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>547</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>199</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>108</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>95</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>72</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>67</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>32</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>21</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>18</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>19104</th>\n",
              "      <td>10</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 409
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Enrollment'] = df_clear['Enrollment'].replace(19104,11)"
      ],
      "metadata": {
        "id": "gAYiUyRXmTlu"
      },
      "execution_count": 410,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Enrollment'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 460
        },
        "id": "-DTuhotduZeu",
        "outputId": "4a0ed8df-40c3-4db0-a518-c531efc76ce6"
      },
      "execution_count": 411,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Enrollment\n",
              "0     6253\n",
              "1      547\n",
              "2      199\n",
              "3      108\n",
              "4       95\n",
              "5       72\n",
              "6       67\n",
              "8       32\n",
              "7       21\n",
              "9       18\n",
              "11      10\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Enrollment</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>6253</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>547</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>199</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>108</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>95</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>72</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>67</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>32</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>21</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>18</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>10</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 411
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [],
      "metadata": {
        "id": "wvnODOmSulXm"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "#For Funder Type"
      ],
      "metadata": {
        "id": "eGd-NsyiuxIh"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Funder Type'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 303
        },
        "id": "W88HDUMYuZcW",
        "outputId": "a8e385eb-c1e6-4e33-9450-12e91286680a"
      },
      "execution_count": 448,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Funder Type\n",
              "0    2219\n",
              "1     178\n",
              "2      43\n",
              "4      19\n",
              "3      14\n",
              "5      11\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Funder Type</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>2219</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>178</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>43</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>19</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>14</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>11</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 448
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "This is for random value assign"
      ],
      "metadata": {
        "id": "2G-bS00hvHTP"
      }
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "joTq_WfbvNbZ"
      },
      "execution_count": 448,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Funder Type'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 303
        },
        "id": "vj6t7viHvNYy",
        "outputId": "bcabf0cd-0512-4922-eaf9-e122543d9273"
      },
      "execution_count": 449,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Funder Type\n",
              "0    2219\n",
              "1     178\n",
              "2      43\n",
              "4      19\n",
              "3      14\n",
              "5      11\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Funder Type</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>2219</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>178</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>43</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>19</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>14</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>11</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 449
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "jt3IoKo53EWM"
      },
      "execution_count": 449,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Funder Type'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 303
        },
        "id": "3-KcWt5b3LsG",
        "outputId": "3af27653-8fe0-4880-eced-85716bf03489"
      },
      "execution_count": 450,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Funder Type\n",
              "0    2219\n",
              "1     178\n",
              "2      43\n",
              "4      19\n",
              "3      14\n",
              "5      11\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Funder Type</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>2219</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>178</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>43</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>19</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>14</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>11</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 450
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Funder Type'].value_counts()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 303
        },
        "id": "dEhL5E4K3UE-",
        "outputId": "17e2000c-800f-4a46-ff14-8b03d2c4abc0"
      },
      "execution_count": 451,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Funder Type\n",
              "0    2219\n",
              "1     178\n",
              "2      43\n",
              "4      19\n",
              "3      14\n",
              "5      11\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Funder Type</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>2219</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>178</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>43</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>19</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>14</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>11</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 451
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "\n",
        "# Assuming 'df_clear' is your DataFrame\n",
        "# Replace NaN and empty values\n",
        "df_clear = df_clear[df_clear['Funder Type'].notna() & (df_clear['Funder Type'] != '')]\n",
        "df_clear['Funder Type'] = df_clear['Funder Type'].fillna('0')\n",
        "\n",
        "# Convert column to string to standardize\n",
        "df_clear['Funder Type'] = df_clear['Study Design'].astype(str)\n",
        "\n",
        "# Convert strings to numeric where possible (ignore errors)\n",
        "df_clear['Funder Type'] = pd.to_numeric(df_clear['Funder Type'], errors='coerce')\n",
        "\n",
        "# Dynamically update values based on their frequency\n",
        "name_counts = df_clear['Funder Type'].value_counts()\n",
        "\n",
        "# Loop from 1 to 20 and skip NaN values explicitly\n",
        "for i in range(1, 10):\n",
        "    df_clear['Funder Type'] = df_clear['Funder Type'].apply(\n",
        "        lambda x: i if pd.notna(x) and name_counts.get(x, 0) == i else x\n",
        "    )\n",
        "    name_counts = df_clear['Funder Type'].value_counts()\n",
        "\n",
        "# Convert back to integer (after handling non-convertible values)\n",
        "df_clear['Funder Type'] = df_clear['Funder Type'].fillna(0).astype(int)\n",
        "\n",
        "# Display the cleaned DataFrame\n",
        "print(df_clear)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "PJstMKqs3LZm",
        "outputId": "657aa9c5-9aa5-45e2-9197-d50ecc834213"
      },
      "execution_count": 452,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Status  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...             0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...             0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                     0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                             0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...             0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                             3   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                             0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...             6   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...             0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...             0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Results  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...              0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...              0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                      0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                              0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...              0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                             12   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                              0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...              0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...              0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...              0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Conditions  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...           0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...           0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                   0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                           0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...           0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                          15   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                           0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...           0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sponsor  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...        3   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...        2   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                        0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...        5   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                        0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                        0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...        0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...        0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...        0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Collaborators  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...              0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...              0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                      0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                              0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...              0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                              0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                              0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...              0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...              0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...              0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sex  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...    0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...    0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure            0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                    0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...    0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                    0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                    0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...    0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...    0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...    0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Age  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...    0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...    0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure            0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                    0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...    0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                    0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                    0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...    0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...    0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...    4   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Phases  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...       0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...       0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure               0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                       0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...       0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                       0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                      24   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...      40   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...       0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...       0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Enrollment  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...           0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...           0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                   0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                           0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...           0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                           3   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                           0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...           0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Funder Type  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...            1   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...            0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                    0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                            0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...            0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                            3   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                            0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...            0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...            0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...            0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Type  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...           0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...           0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                   0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                           0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...           0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                           6   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                           0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...           0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Design  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...             1   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...             0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                     0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                             0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...             0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                             7   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                             0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...             0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...             0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...             0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Locations  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...          0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...          0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                  0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                          0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...          0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                          0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                          0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...          0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...          0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...          0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Time taken for Enrollment  \n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...                          3  \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...                          6  \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                                  2  \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                                          0  \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...                          5  \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ...  \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                                          3  \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                                          0  \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...                          0  \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...                          0  \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...                          0  \n",
            "\n",
            "[2484 rows x 14 columns]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Funder Type'].value_counts()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 303
        },
        "id": "mORencMO3lua",
        "outputId": "a800fe14-2972-44ba-c9f0-cabe4cdfe7c9"
      },
      "execution_count": 453,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Funder Type\n",
              "0    2219\n",
              "1     178\n",
              "2      43\n",
              "4      19\n",
              "3      14\n",
              "5      11\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Funder Type</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>2219</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>178</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>43</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>19</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>14</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>11</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 453
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "J7XoI6PW3lq8"
      },
      "execution_count": 453,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "EIUlOF4o3ln_"
      },
      "execution_count": 453,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "#For Study Type"
      ],
      "metadata": {
        "id": "0tH5AF7DwA60"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Study Type'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 366
        },
        "id": "hv1X1G3evNVz",
        "outputId": "f87e9cba-d9cc-466a-ed79-8120fd79ef4e"
      },
      "execution_count": 454,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Study Type\n",
              "0    2299\n",
              "1     121\n",
              "2      26\n",
              "6      11\n",
              "3      11\n",
              "4       9\n",
              "5       5\n",
              "9       2\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Study Type</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>2299</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>121</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>26</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>11</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>11</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>9</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>5</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>2</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 454
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "\n",
        "# Assuming 'df_clear' is your DataFrame\n",
        "# Replace NaN and empty values\n",
        "df_clear = df_clear[df_clear['Study Type'].notna() & (df_clear['Sex'] != '')]\n",
        "df_clear['Study Type'] = df_clear['Study Type'].fillna('0')\n",
        "\n",
        "# Convert column to string to standardize\n",
        "df_clear['Funder Type'] = df_clear['Study Type'].astype(str)\n",
        "\n",
        "\n",
        "# Convert strings to numeric where possible (ignore errors)\n",
        "df_clear['Study Type'] = pd.to_numeric(df_clear['Study Type'], errors='coerce')\n",
        "\n",
        "# Dynamically update values based on their frequency\n",
        "name_counts = df_clear['Study Type'].value_counts()\n",
        "\n",
        "# Loop from 1 to 20 and skip NaN values explicitly\n",
        "for i in range(1, 21):\n",
        "    df_clear['Study Type'] = df_clear['Study Type'].apply(\n",
        "        lambda x: i if pd.notna(x) and name_counts.get(x, 0) == i else x\n",
        "    )\n",
        "    name_counts = df_clear['Study Type'].value_counts()\n",
        "\n",
        "# Convert back to integer (after handling non-convertible values)\n",
        "df_clear['Study Type'] = df_clear['Study Type'].fillna(0).astype(int)\n",
        "\n",
        "# Display the cleaned DataFrame\n",
        "print(df_clear)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "X27YXBygvNQy",
        "outputId": "7f1275c8-cffc-4b06-f942-ffc80c4a6231"
      },
      "execution_count": 455,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Status  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...             0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...             0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                     0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                             0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...             0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                             3   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                             0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...             6   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...             0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...             0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Results  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...              0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...              0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                      0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                              0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...              0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                             12   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                              0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...              0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...              0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...              0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Conditions  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...           0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...           0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                   0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                           0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...           0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                          15   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                           0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...           0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sponsor  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...        3   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...        2   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                        0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...        5   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                        0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                        0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...        0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...        0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...        0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Collaborators  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...              0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...              0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                      0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                              0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...              0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                              0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                              0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...              0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...              0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...              0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sex  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...    0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...    0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure            0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                    0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...    0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                    0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                    0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...    0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...    0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...    0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Age  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...    0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...    0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure            0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                    0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...    0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                    0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                    0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...    0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...    0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...    4   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Phases  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...       0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...       0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure               0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                       0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...       0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                       0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                      24   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...      40   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...       0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...       0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Enrollment  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...           0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...           0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                   0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                           0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...           0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                           3   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                           0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...           0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Funder Type  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...           0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...           0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                   0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                           0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...           0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                           6   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                           0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...           0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Type  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...           0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...           0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                   0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                           0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...           0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                          11   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                           0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...           0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Design  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...             1   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...             0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                     0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                             0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...             0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                             7   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                             0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...             0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...             0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...             0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Locations  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...          0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...          0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                  0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                          0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...          0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                          0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                          0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...          0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...          0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...          0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Time taken for Enrollment  \n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...                          3  \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...                          6  \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                                  2  \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                                          0  \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...                          5  \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ...  \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                                          3  \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                                          0  \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...                          0  \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...                          0  \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...                          0  \n",
            "\n",
            "[2484 rows x 14 columns]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Study Type'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 303
        },
        "id": "rITN1P1dvNOW",
        "outputId": "7c3ddaf2-6b2a-4868-eb6a-d592ea02dd18"
      },
      "execution_count": 456,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Study Type\n",
              "0     2299\n",
              "1      121\n",
              "2       28\n",
              "11      22\n",
              "9        9\n",
              "5        5\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Study Type</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>2299</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>121</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>28</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>22</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>9</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>5</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 456
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "bFKMJNF3vNK9"
      },
      "execution_count": 456,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "#For Study Design"
      ],
      "metadata": {
        "id": "iaR_yNSLwx5a"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Study Design'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 397
        },
        "id": "KSJssSYRwxo5",
        "outputId": "9e257b3e-34f7-4548-a968-16e58f9540e5"
      },
      "execution_count": 457,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Study Design\n",
              "0    2219\n",
              "1     178\n",
              "2      43\n",
              "4      19\n",
              "3       8\n",
              "5       6\n",
              "8       5\n",
              "6       3\n",
              "7       3\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Study Design</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>2219</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>178</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>43</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>19</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>8</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>6</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>5</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>3</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>3</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 457
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "\n",
        "# Assuming 'df_clear' is your DataFrame\n",
        "# Replace NaN and empty values\n",
        "df_clear = df_clear[df_clear['Study Design'].notna() & (df_clear['Study Design'] != '')]\n",
        "df_clear['Study Design'] = df_clear['Study Design'].fillna('0')\n",
        "\n",
        "# Convert column to string to standardize\n",
        "df_clear['Study Design'] = df_clear['Study Design'].astype(str)\n",
        "\n",
        "# Convert strings to numeric where possible (ignore errors)\n",
        "df_clear['Study Design'] = pd.to_numeric(df_clear['Study Design'], errors='coerce')\n",
        "\n",
        "# Dynamically update values based on their frequency\n",
        "name_counts = df_clear['Study Design'].value_counts()\n",
        "\n",
        "# Loop from 1 to 20 and skip NaN values explicitly\n",
        "for i in range(1, 10):\n",
        "    df_clear['Study Design'] = df_clear['Study Design'].apply(\n",
        "        lambda x: i if pd.notna(x) and name_counts.get(x, 0) == i else x\n",
        "    )\n",
        "    name_counts = df_clear['Study Design'].value_counts()\n",
        "\n",
        "# Convert back to integer (after handling non-convertible values)\n",
        "df_clear['Study Design'] = df_clear['Study Design'].fillna(0).astype(int)\n",
        "\n",
        "# Display the cleaned DataFrame\n",
        "print(df_clear)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "yzhJ_vTfwxmJ",
        "outputId": "7624e85a-e438-4d8c-c598-20bc79449a60"
      },
      "execution_count": 458,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Status  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...             0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...             0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                     0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                             0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...             0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                             3   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                             0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...             6   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...             0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...             0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Results  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...              0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...              0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                      0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                              0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...              0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                             12   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                              0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...              0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...              0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...              0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Conditions  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...           0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...           0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                   0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                           0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...           0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                          15   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                           0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...           0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sponsor  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...        3   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...        2   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                        0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...        5   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                        0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                        0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...        0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...        0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...        0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Collaborators  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...              0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...              0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                      0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                              0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...              0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                              0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                              0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...              0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...              0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...              0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sex  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...    0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...    0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure            0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                    0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...    0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                    0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                    0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...    0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...    0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...    0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Age  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...    0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...    0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure            0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                    0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...    0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                    0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                    0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...    0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...    0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...    4   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Phases  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...       0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...       0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure               0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                       0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...       0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                       0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                      24   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...      40   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...       0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...       0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Enrollment  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...           0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...           0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                   0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                           0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...           0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                           3   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                           0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...           0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Funder Type  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...           0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...           0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                   0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                           0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...           0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                           6   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                           0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...           0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Type  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...           0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...           0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                   0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                           0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...           0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                          11   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                           0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...           0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Design  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...             1   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...             0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                     0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                             0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...             0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                             3   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                             0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...             0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...             0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...             0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Locations  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...          0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...          0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                  0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                          0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...          0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                          0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                          0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...          0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...          0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...          0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Time taken for Enrollment  \n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...                          3  \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...                          6  \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                                  2  \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                                          0  \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...                          5  \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ...  \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                                          3  \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                                          0  \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...                          0  \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...                          0  \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...                          0  \n",
            "\n",
            "[2484 rows x 14 columns]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Study Design'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 303
        },
        "id": "0hcSLaIDwxjL",
        "outputId": "d57e3bf2-c6bc-4938-991a-0755b90e72f1"
      },
      "execution_count": 459,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Study Design\n",
              "0    2219\n",
              "1     178\n",
              "2      43\n",
              "4      19\n",
              "3      14\n",
              "5      11\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Study Design</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>2219</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>178</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>43</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>19</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>14</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>11</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 459
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "#For Locations"
      ],
      "metadata": {
        "id": "4GfBEAo2xZLz"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Locations'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 460
        },
        "id": "kcXpO__yxVwf",
        "outputId": "15b50c0b-3364-4b49-cd0b-3493bc618896"
      },
      "execution_count": 460,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Locations\n",
              "0     2321\n",
              "1      117\n",
              "2       21\n",
              "4        7\n",
              "3        6\n",
              "5        3\n",
              "8        3\n",
              "6        3\n",
              "20       1\n",
              "26       1\n",
              "12       1\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Locations</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>2321</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>117</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>21</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>7</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>6</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>3</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>3</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>3</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>26</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 460
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "\n",
        "# Assuming 'df_clear' is your DataFrame\n",
        "# Replace NaN and empty values\n",
        "df_clear = df_clear[df_clear['Locations'].notna() & (df_clear['Locations'] != '')]\n",
        "df_clear['Locations'] = df_clear['Locations'].fillna('0')\n",
        "\n",
        "# Convert column to string to standardize\n",
        "df_clear['Locations'] = df_clear['Locations'].astype(str)\n",
        "\n",
        "# Convert strings to numeric where possible (ignore errors)\n",
        "df_clear['Locations'] = pd.to_numeric(df_clear['Locations'], errors='coerce')\n",
        "\n",
        "# Dynamically update values based on their frequency\n",
        "name_counts = df_clear['Locations'].value_counts()\n",
        "\n",
        "# Loop from 1 to 20 and skip NaN values explicitly\n",
        "for i in range(1, 10):\n",
        "    df_clear['Locations'] = df_clear['Locations'].apply(\n",
        "        lambda x: i if pd.notna(x) and name_counts.get(x, 0) == i else x\n",
        "    )\n",
        "    name_counts = df_clear['Locations'].value_counts()\n",
        "\n",
        "# Convert back to integer (after handling non-convertible values)\n",
        "df_clear['Locations'] = df_clear['Locations'].fillna(0).astype(int)\n",
        "\n",
        "# Display the cleaned DataFrame\n",
        "print(df_clear)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "ivkwEosJxVtH",
        "outputId": "01d8bffe-9d3f-4e48-c610-f7d1883f65c6"
      },
      "execution_count": 461,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Status  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...             0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...             0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                     0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                             0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...             0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                             3   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                             0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...             6   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...             0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...             0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Results  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...              0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...              0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                      0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                              0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...              0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                             12   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                              0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...              0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...              0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...              0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Conditions  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...           0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...           0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                   0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                           0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...           0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                          15   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                           0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...           0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sponsor  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...        3   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...        2   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                        0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...        5   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                        0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                        0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...        0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...        0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...        0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Collaborators  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...              0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...              0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                      0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                              0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...              0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                              0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                              0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...              0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...              0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...              0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sex  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...    0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...    0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure            0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                    0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...    0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                    0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                    0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...    0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...    0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...    0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Age  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...    0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...    0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure            0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                    0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...    0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                    0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                    0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...    0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...    0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...    4   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Phases  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...       0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...       0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure               0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                       0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...       0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                       0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                      24   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...      40   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...       0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...       0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Enrollment  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...           0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...           0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                   0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                           0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...           0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                           3   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                           0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...           0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Funder Type  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...           0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...           0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                   0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                           0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...           0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                           6   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                           0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...           0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Type  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...           0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...           0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                   0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                           0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...           0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                          11   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                           0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...           0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Design  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...             1   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...             0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                     0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                             0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...             0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                             3   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                             0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...             0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...             0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...             0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Locations  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...          0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...          0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                  0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                          0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...          0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                          0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                          0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...          0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...          0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...          0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Time taken for Enrollment  \n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...                          3  \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...                          6  \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                                  2  \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                                          0  \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...                          5  \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ...  \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                                          3  \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                                          0  \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...                          0  \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...                          0  \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...                          0  \n",
            "\n",
            "[2484 rows x 14 columns]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Locations'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 272
        },
        "id": "5f3aLrGPxVqh",
        "outputId": "e1fbe4d1-6847-4a01-80ea-b698c0a6bfb0"
      },
      "execution_count": 462,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Locations\n",
              "0    2321\n",
              "1     120\n",
              "2      21\n",
              "3      15\n",
              "7       7\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Locations</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>2321</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>120</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>21</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>15</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>7</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 462
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [],
      "metadata": {
        "id": "rjErjZfvxr5l"
      }
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "3xt-CstmxVog"
      },
      "execution_count": 462,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "#For Time taken for Enrollment"
      ],
      "metadata": {
        "id": "uMmwfeQTxwLa"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Time taken for Enrollment'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 491
        },
        "id": "9IOxyuUMxVl4",
        "outputId": "2f715b1a-3ca2-497d-96e0-0518a3467d43"
      },
      "execution_count": 463,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Time taken for Enrollment\n",
              "0     1670\n",
              "1      331\n",
              "2      110\n",
              "3       92\n",
              "4       60\n",
              "6       49\n",
              "5       47\n",
              "8       36\n",
              "7       32\n",
              "9       32\n",
              "20      13\n",
              "12      12\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Time taken for Enrollment</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>1670</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>331</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>110</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>92</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>60</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>49</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>47</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>36</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>32</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>32</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20</th>\n",
              "      <td>13</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>12</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 463
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "\n",
        "\n",
        "# Assuming 'df_clear' is your DataFrame\n",
        "# Replace NaN and empty values\n",
        "df_clear = df_clear[df_clear['Time taken for Enrollment'].notna() & (df_clear['Time taken for Enrollment'] != '')]\n",
        "df_clear['Time taken for Enrollment'] = df_clear['Time taken for Enrollment'].fillna('0')\n",
        "\n",
        "# Convert column to string to standardize\n",
        "df_clear['Time taken for Enrollment'] = df_clear['Time taken for Enrollment'].astype(str)\n",
        "\n",
        "# Convert strings to numeric where possible (ignore errors)\n",
        "df_clear['Time taken for Enrollment'] = pd.to_numeric(df_clear['Time taken for Enrollment'], errors='coerce')\n",
        "\n",
        "# Dynamically update values based on their frequency\n",
        "name_counts = df_clear['Time taken for Enrollment'].value_counts()\n",
        "\n",
        "# Loop from 1 to 20 and skip NaN values explicitly\n",
        "for i in range(1, 10):\n",
        "    df_clear['Time taken for Enrollment'] = df_clear['Time taken for Enrollment'].apply(\n",
        "        lambda x: i if pd.notna(x) and name_counts.get(x, 0) == i else x\n",
        "    )\n",
        "    name_counts = df_clear['Time taken for Enrollment'].value_counts()\n",
        "\n",
        "# Convert back to integer (after handling non-convertible values)\n",
        "df_clear['Time taken for Enrollment'] = df_clear['Time taken for Enrollment'].fillna(0).astype(int)\n",
        "\n",
        "# Display the cleaned DataFrame\n",
        "print(df_clear)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "gAZtYohBxVhq",
        "outputId": "13f809e9-8df1-48e4-8dd1-0d62bc933394"
      },
      "execution_count": 464,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Status  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...             0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...             0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                     0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                             0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...             0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                             3   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                             0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...             6   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...             0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...             0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Results  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...              0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...              0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                      0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                              0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...              0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                             12   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                              0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...              0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...              0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...              0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Conditions  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...           0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...           0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                   0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                           0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...           0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                          15   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                           0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...           0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sponsor  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...        3   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...        2   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                        0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...        5   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                        0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                        0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...        0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...        0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...        0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Collaborators  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...              0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...              0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                      0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                              0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...              0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                              0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                              0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...              0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...              0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...              0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sex  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...    0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...    0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure            0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                    0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...    0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                    0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                    0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...    0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...    0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...    0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Age  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...    0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...    0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure            0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                    0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...    0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                    0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                    0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...    0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...    0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...    4   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Phases  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...       0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...       0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure               0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                       0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...       0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                       0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                      24   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...      40   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...       0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...       0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Enrollment  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...           0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...           0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                   0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                           0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...           0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                           3   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                           0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...           0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Funder Type  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...           0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...           0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                   0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                           0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...           0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                           6   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                           0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...           0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Type  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...           0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...           0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                   0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                           0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...           0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                          11   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                           0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...           0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...           0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...           0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study Design  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...             1   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...             0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                     0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                             0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...             0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                             3   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                             0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...             0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...             0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...             0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Locations  \\\n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...          0   \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...          0   \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                  0   \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                          0   \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...          0   \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ...   \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                          0   \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                          0   \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...          0   \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...          0   \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...          0   \n",
            "\n",
            "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Time taken for Enrollment  \n",
            "213                                                NCT03998176                                        Bictegravir/Emtricitabine/Tenofovir Alafenamide... https://clinicaltrials.gov/study/NCT03998176       BASE                                               COMPLETED                                          This study will evaluate the efficacy and safet... YES                                                HIV-1-infection                                    DRUG: Bictegravir/emtricitabine/tenofovir alafe... \"Percentage of Participants With HIV-1 RNA < 50...  The percentage of participants achieving HIV-1...  which defines a participants virologic respons...  along with study drug discontinuation status.      Week 24\"                                          \"Percentage of Participants With Grade 3 or Gre... The percentage of participants experiencing gra...  Week 24|Percentage of Participants With Grade ...                          3  \n",
            "275                                                NCT06098638                                        Effect of Aerobic and Resisted Exercise on Lipi... https://clinicaltrials.gov/study/NCT06098638       NaN                                                COMPLETED                                          the aim of the study was to investigate the eff... NO                                                 Postpartum Weight Retention                        OTHER: Nutritional recommendation and Faradic s... \"measurement of lipid parameter level of High-d...  It was used to measure the lipid profile param...  12 weeks|measurement of Low-density lipoprotei...  It was used to measure the lipid profile param...  12 weeks|measurement of Triglycerides (TG) mg/dL   t was used to measure the lipid profile parame... 12 weeks\"                                          \"calculation of score of Short Form 36 Health S...                          6  \n",
            "681                                                NCT03234790                                        Human Study to Develop a Signature of Occupatio... https://clinicaltrials.gov/study/NCT03234790       DICE                                               COMPLETED                                          \"Strong scientific understanding of how emissio...  we are recruiting healthy volunteers who are n...  clinically relevant strategy that can be used ...  companies                                          and ultimately workers to better manage their ... NO                                                 Experimental                                       OTHER: Filtered Air Exposure|OTHER: Diesel Exha... \"Serum proteome in response to DE exposure          Serum from each experimental condition will be... 4 hours & 24 hours\"                                \"Urine proteins in response to DE exposure                                  2  \n",
            "The aim of this study is to determine whether a... NO                                                 Knee Osteoarthritis                                BEHAVIORAL: Illness perception conversation|BEH... \"VAS knee pain                                      Knee pain defined as \"\"the average level of pa...  Week two                                           change from baseline\"                             \"The effect of knee pain variability (VAS) prio...  The key secondary objective is to assess if pa...  Week 0                                             Change from week -1|Brief Illness perception q...  The Brief illness perception questionnaire (BI...  Cause                                              Timeline                                           Consequences and Cure-Control. It contains eig... reverse score items 3                               4                                                                          0  \n",
            "889                                                NCT04197778                                        Food Effect Study of DDO-3055 Tablets in Health... https://clinicaltrials.gov/study/NCT04197778       NaN                                                COMPLETED                                          \"The study is a randomized                          open-label                                         two-stage crossover food effect study of singl...  7 subjects in each group. Two stage washout pe... NO                                                 Anemia in Chronic Kidney Disease                   DRUG: DDO-3055 tablet                              \"Area under the concentration-time curve (AUC) ...  up to 2 days|Maximum plasma concentration (Cma...  up to 2 days|Time to maximum observed serum co... up to 2 days|Terminal elimination half-life (T1...  up to 2 days|Apparent total clearance of the d...                          5  \n",
            "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ...  \n",
            "68866                                              NCT04063085                                        The Assessment of the Use of Anti-Adhesion Agen... https://clinicaltrials.gov/study/NCT04063085       NaN                                                COMPLETED                                          The aim of this study is to assess the safety a... NO                                                 Tissue Adhesion|Gynecologic Surgery                DEVICE: PROTAHERE Absorbable Adhesion Barrier|D... \"The incidence of postoperative adhesion at 3 m...  Divide the number of patients with postoperati...  3 months post-operation\"                          \"The incidence of adverse events in each group ...  Divide the number of patients who suffered fro...  14 days                                           3                                                   6                                                                          3  \n",
            "68900                                              NCT03244501                                        Transcranial Static Magnetic Field Stimulation ... https://clinicaltrials.gov/study/NCT03244501       NaN                                                COMPLETED                                          \"The purpose of this study is to see if a new b...  static magnetic field stimulation (tSMS)           which involves holding a static neodymium magn...  can influence normal rhythms of brain activity.\"  NO                                                 Healthy                                            OTHER: Active tSMS|OTHER: Sham tSMS                \"Electroencephalogram (EEG) Spectral Power          Changes in the spectral power of the EEG befor...  2 min eyes-open)                                  during (eyes-open)                                  and after stimulation (eyes-open)                                          0  \n",
            "68907                                              NCT04159571                                        QuitFast: Evaluating Transcranial Magnetic Stim... https://clinicaltrials.gov/study/NCT04159571       NaN                                                COMPLETED                                          \"Cigarette smoking constitutes the greatest pre...  P \\<0.0001; Ashare et al. 2013). Prodigious re... YES                                                Smoking|Smoking Cessation|Craving|Addiction|Add... DEVICE: Real TBS to the vmPFC|DEVICE: Sham cTBS... \"Questionnaire on Smoking Urges Administered Da...  Questionnaire on Smoking Urges (QSU). This 10-...  \"\"I have a desire for a cigarette right now       \"\" and \"\"Nothing would be better than smoking a...  Through study completion                          an average of 8 weeks|Self- Report Assessment o...  This self-reported tobacco product use intervi...                          0  \n",
            "68916                                              NCT03337659                                        A Cluster Randomized Controlled Trial of FICare... https://clinicaltrials.gov/study/NCT03337659       NaN                                                COMPLETED                                          \"In Alberta                                         one in every twelve babies is born preterm. Co...  preterm infants who survive are at higher risk...  jaundice                                           infections                                         feeding problems                                   behavioural problems                               and neuro-developmental disabilities               including cognitive delays                         and visual and hearing impairments. As a result   parents must leave their preterm babies in the ...  parents are often unprepared to look after the...                          0  \n",
            "The study's primary goal is to determine the ef...  combining bone health and cholesterol manageme... NO                                                 \"Osteoporosis                                       Osteopenia|Hypercholesterolemia|Menopausal Ost... DRUG: Pitavastatin                                 \"Change in blood urinary N-Telopeptide of Type ...  nmol BCE/L                                         6 month\"                                          \"Change in blood C-Telopeptide of Type I Collag...  ng/L                                               6 and 12 months|Change in blood Osteocalcin le...  ng/mL                                              6 and 12 months|Change in urinary N-Telopeptid...  nmol BCE/L                                         6 and 12 months|Change in blood Procollagen Ty... ng/mL                                               6 and 12 months|Change in blood LDL-cholestero...                          0  \n",
            "\n",
            "[2484 rows x 14 columns]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Time taken for Enrollment'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 491
        },
        "id": "lRtYguEivNIN",
        "outputId": "fc677966-2197-4a96-eb6c-2da405fcfce8"
      },
      "execution_count": 465,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Time taken for Enrollment\n",
              "0     1670\n",
              "1      331\n",
              "2      110\n",
              "3       92\n",
              "4       60\n",
              "6       49\n",
              "5       47\n",
              "8       36\n",
              "7       32\n",
              "9       32\n",
              "20      13\n",
              "12      12\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Time taken for Enrollment</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>1670</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>331</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>110</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>92</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>60</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>49</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>47</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>36</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>32</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>32</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20</th>\n",
              "      <td>13</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>12</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 465
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "NtlBuIoxx_sQ"
      },
      "execution_count": 465,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "p-W9no-Mx_pr"
      },
      "execution_count": 465,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "iiHNBxGQx_nh"
      },
      "execution_count": 465,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "TQsJwYHKx_k_"
      },
      "execution_count": 465,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "xidK36o6x_if"
      },
      "execution_count": 465,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "VQJSJEorx_gB"
      },
      "execution_count": 465,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "f8jfbrzyx_dP"
      },
      "execution_count": 465,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "dn4IWVcYx_ak"
      },
      "execution_count": 465,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear['Funder Type'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 366
        },
        "id": "y49nz6LduZW6",
        "outputId": "aec9a3f6-2ef7-428d-fabe-af068c14c36a"
      },
      "execution_count": 466,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Funder Type\n",
              "0    2299\n",
              "1     121\n",
              "2      26\n",
              "6      11\n",
              "3      11\n",
              "4       9\n",
              "5       5\n",
              "9       2\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Funder Type</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>2299</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>121</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>26</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>11</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>11</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>9</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>5</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>2</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 466
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "kvU8RPeQuZUZ"
      },
      "execution_count": 466,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "c34b8_KGxvVK"
      },
      "execution_count": 466,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear.dtypes"
      ],
      "metadata": {
        "id": "XxV-07DAgxYV",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 523
        },
        "outputId": "a8194765-3479-41e1-ade0-5e34e4df2ee7"
      },
      "execution_count": 467,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Study Status                  int64\n",
              "Study Results                 int64\n",
              "Conditions                    int64\n",
              "Sponsor                       int64\n",
              "Collaborators                 int64\n",
              "Sex                           int64\n",
              "Age                           int64\n",
              "Phases                        int64\n",
              "Enrollment                    int64\n",
              "Funder Type                  object\n",
              "Study Type                    int64\n",
              "Study Design                  int64\n",
              "Locations                     int64\n",
              "Time taken for Enrollment     int64\n",
              "dtype: object"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>0</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>Study Status</th>\n",
              "      <td>int64</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Study Results</th>\n",
              "      <td>int64</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Conditions</th>\n",
              "      <td>int64</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Sponsor</th>\n",
              "      <td>int64</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Collaborators</th>\n",
              "      <td>int64</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Sex</th>\n",
              "      <td>int64</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Age</th>\n",
              "      <td>int64</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Phases</th>\n",
              "      <td>int64</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Enrollment</th>\n",
              "      <td>int64</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Funder Type</th>\n",
              "      <td>object</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Study Type</th>\n",
              "      <td>int64</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Study Design</th>\n",
              "      <td>int64</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Locations</th>\n",
              "      <td>int64</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Time taken for Enrollment</th>\n",
              "      <td>int64</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> object</label>"
            ]
          },
          "metadata": {},
          "execution_count": 467
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "#For Age"
      ],
      "metadata": {
        "id": "KyMHVDP4lPaA"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear.sample(2)"
      ],
      "metadata": {
        "id": "SOJgHGvigxWA",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 774
        },
        "outputId": "dd17c206-d991-4ca8-a487-6bf0be19910f"
      },
      "execution_count": 468,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Study Status  \\\n",
              "29475                                              NCT03265314                                        \"LeadHer                                           a Gender-specific Teen Pregnancy Prevention Cur... https://clinicaltrials.gov/study/NCT03265314       NaN COMPLETED                                 \"Alternatives For Girls (AFG) is offering LeadH...  MI. The curriculum seeks to demonstrate that g... will show increased use of birth control and re... NO                                                 Teenage Pregnancy                                  BEHAVIORAL: LeadHer|BEHAVIORAL: Sassy Science      \"Avoidance of unprotected sex                      Participants will refrain from having sex or av... Up to 12 months post the beginning of intervent...  Participants decided to have sex  they will use birth control.             0   \n",
              "Improved FEV1/FVC ratio (Forced expiratory volu...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet... Change from Baseline at 3 months|Morbidity & Ex...  Minimisation or absence of hospitalisation and... NaN  6 months|Exacerbations for COPD patients  The prevention of future exacerbations \"\"time ... NaN                                                6 months.|Change of Respiratory function for CO...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Morbidity for... Minimisation or absence of hospitalisation         6 months.\"                                         NaN                               Beker Laboratories                        1   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Study Results  \\\n",
              "29475                                              NCT03265314                                        \"LeadHer                                           a Gender-specific Teen Pregnancy Prevention Cur... https://clinicaltrials.gov/study/NCT03265314       NaN COMPLETED                                 \"Alternatives For Girls (AFG) is offering LeadH...  MI. The curriculum seeks to demonstrate that g... will show increased use of birth control and re... NO                                                 Teenage Pregnancy                                  BEHAVIORAL: LeadHer|BEHAVIORAL: Sassy Science      \"Avoidance of unprotected sex                      Participants will refrain from having sex or av... Up to 12 months post the beginning of intervent...  Participants decided to have sex  they will use birth control.              0   \n",
              "Improved FEV1/FVC ratio (Forced expiratory volu...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet... Change from Baseline at 3 months|Morbidity & Ex...  Minimisation or absence of hospitalisation and... NaN  6 months|Exacerbations for COPD patients  The prevention of future exacerbations \"\"time ... NaN                                                6 months.|Change of Respiratory function for CO...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Morbidity for... Minimisation or absence of hospitalisation         6 months.\"                                         NaN                               Beker Laboratories                         0   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Conditions  \\\n",
              "29475                                              NCT03265314                                        \"LeadHer                                           a Gender-specific Teen Pregnancy Prevention Cur... https://clinicaltrials.gov/study/NCT03265314       NaN COMPLETED                                 \"Alternatives For Girls (AFG) is offering LeadH...  MI. The curriculum seeks to demonstrate that g... will show increased use of birth control and re... NO                                                 Teenage Pregnancy                                  BEHAVIORAL: LeadHer|BEHAVIORAL: Sassy Science      \"Avoidance of unprotected sex                      Participants will refrain from having sex or av... Up to 12 months post the beginning of intervent...  Participants decided to have sex  they will use birth control.           0   \n",
              "Improved FEV1/FVC ratio (Forced expiratory volu...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet... Change from Baseline at 3 months|Morbidity & Ex...  Minimisation or absence of hospitalisation and... NaN  6 months|Exacerbations for COPD patients  The prevention of future exacerbations \"\"time ... NaN                                                6 months.|Change of Respiratory function for CO...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Morbidity for... Minimisation or absence of hospitalisation         6 months.\"                                         NaN                               Beker Laboratories                      0   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Sponsor  \\\n",
              "29475                                              NCT03265314                                        \"LeadHer                                           a Gender-specific Teen Pregnancy Prevention Cur... https://clinicaltrials.gov/study/NCT03265314       NaN COMPLETED                                 \"Alternatives For Girls (AFG) is offering LeadH...  MI. The curriculum seeks to demonstrate that g... will show increased use of birth control and re... NO                                                 Teenage Pregnancy                                  BEHAVIORAL: LeadHer|BEHAVIORAL: Sassy Science      \"Avoidance of unprotected sex                      Participants will refrain from having sex or av... Up to 12 months post the beginning of intervent...  Participants decided to have sex  they will use birth control.        1   \n",
              "Improved FEV1/FVC ratio (Forced expiratory volu...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet... Change from Baseline at 3 months|Morbidity & Ex...  Minimisation or absence of hospitalisation and... NaN  6 months|Exacerbations for COPD patients  The prevention of future exacerbations \"\"time ... NaN                                                6 months.|Change of Respiratory function for CO...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Morbidity for... Minimisation or absence of hospitalisation         6 months.\"                                         NaN                               Beker Laboratories                   0   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Collaborators  \\\n",
              "29475                                              NCT03265314                                        \"LeadHer                                           a Gender-specific Teen Pregnancy Prevention Cur... https://clinicaltrials.gov/study/NCT03265314       NaN COMPLETED                                 \"Alternatives For Girls (AFG) is offering LeadH...  MI. The curriculum seeks to demonstrate that g... will show increased use of birth control and re... NO                                                 Teenage Pregnancy                                  BEHAVIORAL: LeadHer|BEHAVIORAL: Sassy Science      \"Avoidance of unprotected sex                      Participants will refrain from having sex or av... Up to 12 months post the beginning of intervent...  Participants decided to have sex  they will use birth control.              0   \n",
              "Improved FEV1/FVC ratio (Forced expiratory volu...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet... Change from Baseline at 3 months|Morbidity & Ex...  Minimisation or absence of hospitalisation and... NaN  6 months|Exacerbations for COPD patients  The prevention of future exacerbations \"\"time ... NaN                                                6 months.|Change of Respiratory function for CO...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Morbidity for... Minimisation or absence of hospitalisation         6 months.\"                                         NaN                               Beker Laboratories                         0   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Sex  \\\n",
              "29475                                              NCT03265314                                        \"LeadHer                                           a Gender-specific Teen Pregnancy Prevention Cur... https://clinicaltrials.gov/study/NCT03265314       NaN COMPLETED                                 \"Alternatives For Girls (AFG) is offering LeadH...  MI. The curriculum seeks to demonstrate that g... will show increased use of birth control and re... NO                                                 Teenage Pregnancy                                  BEHAVIORAL: LeadHer|BEHAVIORAL: Sassy Science      \"Avoidance of unprotected sex                      Participants will refrain from having sex or av... Up to 12 months post the beginning of intervent...  Participants decided to have sex  they will use birth control.    0   \n",
              "Improved FEV1/FVC ratio (Forced expiratory volu...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet... Change from Baseline at 3 months|Morbidity & Ex...  Minimisation or absence of hospitalisation and... NaN  6 months|Exacerbations for COPD patients  The prevention of future exacerbations \"\"time ... NaN                                                6 months.|Change of Respiratory function for CO...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Morbidity for... Minimisation or absence of hospitalisation         6 months.\"                                         NaN                               Beker Laboratories               0   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Age  \\\n",
              "29475                                              NCT03265314                                        \"LeadHer                                           a Gender-specific Teen Pregnancy Prevention Cur... https://clinicaltrials.gov/study/NCT03265314       NaN COMPLETED                                 \"Alternatives For Girls (AFG) is offering LeadH...  MI. The curriculum seeks to demonstrate that g... will show increased use of birth control and re... NO                                                 Teenage Pregnancy                                  BEHAVIORAL: LeadHer|BEHAVIORAL: Sassy Science      \"Avoidance of unprotected sex                      Participants will refrain from having sex or av... Up to 12 months post the beginning of intervent...  Participants decided to have sex  they will use birth control.    0   \n",
              "Improved FEV1/FVC ratio (Forced expiratory volu...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet... Change from Baseline at 3 months|Morbidity & Ex...  Minimisation or absence of hospitalisation and... NaN  6 months|Exacerbations for COPD patients  The prevention of future exacerbations \"\"time ... NaN                                                6 months.|Change of Respiratory function for CO...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Morbidity for... Minimisation or absence of hospitalisation         6 months.\"                                         NaN                               Beker Laboratories               0   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Phases  \\\n",
              "29475                                              NCT03265314                                        \"LeadHer                                           a Gender-specific Teen Pregnancy Prevention Cur... https://clinicaltrials.gov/study/NCT03265314       NaN COMPLETED                                 \"Alternatives For Girls (AFG) is offering LeadH...  MI. The curriculum seeks to demonstrate that g... will show increased use of birth control and re... NO                                                 Teenage Pregnancy                                  BEHAVIORAL: LeadHer|BEHAVIORAL: Sassy Science      \"Avoidance of unprotected sex                      Participants will refrain from having sex or av... Up to 12 months post the beginning of intervent...  Participants decided to have sex  they will use birth control.       0   \n",
              "Improved FEV1/FVC ratio (Forced expiratory volu...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet... Change from Baseline at 3 months|Morbidity & Ex...  Minimisation or absence of hospitalisation and... NaN  6 months|Exacerbations for COPD patients  The prevention of future exacerbations \"\"time ... NaN                                                6 months.|Change of Respiratory function for CO...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Morbidity for... Minimisation or absence of hospitalisation         6 months.\"                                         NaN                               Beker Laboratories                  0   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Enrollment  \\\n",
              "29475                                              NCT03265314                                        \"LeadHer                                           a Gender-specific Teen Pregnancy Prevention Cur... https://clinicaltrials.gov/study/NCT03265314       NaN COMPLETED                                 \"Alternatives For Girls (AFG) is offering LeadH...  MI. The curriculum seeks to demonstrate that g... will show increased use of birth control and re... NO                                                 Teenage Pregnancy                                  BEHAVIORAL: LeadHer|BEHAVIORAL: Sassy Science      \"Avoidance of unprotected sex                      Participants will refrain from having sex or av... Up to 12 months post the beginning of intervent...  Participants decided to have sex  they will use birth control.           0   \n",
              "Improved FEV1/FVC ratio (Forced expiratory volu...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet... Change from Baseline at 3 months|Morbidity & Ex...  Minimisation or absence of hospitalisation and... NaN  6 months|Exacerbations for COPD patients  The prevention of future exacerbations \"\"time ... NaN                                                6 months.|Change of Respiratory function for CO...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Morbidity for... Minimisation or absence of hospitalisation         6 months.\"                                         NaN                               Beker Laboratories                      0   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Funder Type  \\\n",
              "29475                                              NCT03265314                                        \"LeadHer                                           a Gender-specific Teen Pregnancy Prevention Cur... https://clinicaltrials.gov/study/NCT03265314       NaN COMPLETED                                 \"Alternatives For Girls (AFG) is offering LeadH...  MI. The curriculum seeks to demonstrate that g... will show increased use of birth control and re... NO                                                 Teenage Pregnancy                                  BEHAVIORAL: LeadHer|BEHAVIORAL: Sassy Science      \"Avoidance of unprotected sex                      Participants will refrain from having sex or av... Up to 12 months post the beginning of intervent...  Participants decided to have sex  they will use birth control.           0   \n",
              "Improved FEV1/FVC ratio (Forced expiratory volu...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet... Change from Baseline at 3 months|Morbidity & Ex...  Minimisation or absence of hospitalisation and... NaN  6 months|Exacerbations for COPD patients  The prevention of future exacerbations \"\"time ... NaN                                                6 months.|Change of Respiratory function for CO...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Morbidity for... Minimisation or absence of hospitalisation         6 months.\"                                         NaN                               Beker Laboratories                      0   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Study Type  \\\n",
              "29475                                              NCT03265314                                        \"LeadHer                                           a Gender-specific Teen Pregnancy Prevention Cur... https://clinicaltrials.gov/study/NCT03265314       NaN COMPLETED                                 \"Alternatives For Girls (AFG) is offering LeadH...  MI. The curriculum seeks to demonstrate that g... will show increased use of birth control and re... NO                                                 Teenage Pregnancy                                  BEHAVIORAL: LeadHer|BEHAVIORAL: Sassy Science      \"Avoidance of unprotected sex                      Participants will refrain from having sex or av... Up to 12 months post the beginning of intervent...  Participants decided to have sex  they will use birth control.           0   \n",
              "Improved FEV1/FVC ratio (Forced expiratory volu...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet... Change from Baseline at 3 months|Morbidity & Ex...  Minimisation or absence of hospitalisation and... NaN  6 months|Exacerbations for COPD patients  The prevention of future exacerbations \"\"time ... NaN                                                6 months.|Change of Respiratory function for CO...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Morbidity for... Minimisation or absence of hospitalisation         6 months.\"                                         NaN                               Beker Laboratories                      0   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Study Design  \\\n",
              "29475                                              NCT03265314                                        \"LeadHer                                           a Gender-specific Teen Pregnancy Prevention Cur... https://clinicaltrials.gov/study/NCT03265314       NaN COMPLETED                                 \"Alternatives For Girls (AFG) is offering LeadH...  MI. The curriculum seeks to demonstrate that g... will show increased use of birth control and re... NO                                                 Teenage Pregnancy                                  BEHAVIORAL: LeadHer|BEHAVIORAL: Sassy Science      \"Avoidance of unprotected sex                      Participants will refrain from having sex or av... Up to 12 months post the beginning of intervent...  Participants decided to have sex  they will use birth control.             0   \n",
              "Improved FEV1/FVC ratio (Forced expiratory volu...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet... Change from Baseline at 3 months|Morbidity & Ex...  Minimisation or absence of hospitalisation and... NaN  6 months|Exacerbations for COPD patients  The prevention of future exacerbations \"\"time ... NaN                                                6 months.|Change of Respiratory function for CO...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Morbidity for... Minimisation or absence of hospitalisation         6 months.\"                                         NaN                               Beker Laboratories                        0   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Locations  \\\n",
              "29475                                              NCT03265314                                        \"LeadHer                                           a Gender-specific Teen Pregnancy Prevention Cur... https://clinicaltrials.gov/study/NCT03265314       NaN COMPLETED                                 \"Alternatives For Girls (AFG) is offering LeadH...  MI. The curriculum seeks to demonstrate that g... will show increased use of birth control and re... NO                                                 Teenage Pregnancy                                  BEHAVIORAL: LeadHer|BEHAVIORAL: Sassy Science      \"Avoidance of unprotected sex                      Participants will refrain from having sex or av... Up to 12 months post the beginning of intervent...  Participants decided to have sex  they will use birth control.          0   \n",
              "Improved FEV1/FVC ratio (Forced expiratory volu...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet... Change from Baseline at 3 months|Morbidity & Ex...  Minimisation or absence of hospitalisation and... NaN  6 months|Exacerbations for COPD patients  The prevention of future exacerbations \"\"time ... NaN                                                6 months.|Change of Respiratory function for CO...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Morbidity for... Minimisation or absence of hospitalisation         6 months.\"                                         NaN                               Beker Laboratories                     0   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Time taken for Enrollment  \n",
              "29475                                              NCT03265314                                        \"LeadHer                                           a Gender-specific Teen Pregnancy Prevention Cur... https://clinicaltrials.gov/study/NCT03265314       NaN COMPLETED                                 \"Alternatives For Girls (AFG) is offering LeadH...  MI. The curriculum seeks to demonstrate that g... will show increased use of birth control and re... NO                                                 Teenage Pregnancy                                  BEHAVIORAL: LeadHer|BEHAVIORAL: Sassy Science      \"Avoidance of unprotected sex                      Participants will refrain from having sex or av... Up to 12 months post the beginning of intervent...  Participants decided to have sex  they will use birth control.                          3  \n",
              "Improved FEV1/FVC ratio (Forced expiratory volu...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet... Change from Baseline at 3 months|Morbidity & Ex...  Minimisation or absence of hospitalisation and... NaN  6 months|Exacerbations for COPD patients  The prevention of future exacerbations \"\"time ... NaN                                                6 months.|Change of Respiratory function for CO...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Change of Res...  Evaluation of respiratory function by spiromet...  Change from Baseline at 3 months|Morbidity for... Minimisation or absence of hospitalisation         6 months.\"                                         NaN                               Beker Laboratories                                     0  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-16c17a79-8a95-4f3c-92ea-bbf92332973d\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th>Study Status</th>\n",
              "      <th>Study Results</th>\n",
              "      <th>Conditions</th>\n",
              "      <th>Sponsor</th>\n",
              "      <th>Collaborators</th>\n",
              "      <th>Sex</th>\n",
              "      <th>Age</th>\n",
              "      <th>Phases</th>\n",
              "      <th>Enrollment</th>\n",
              "      <th>Funder Type</th>\n",
              "      <th>Study Type</th>\n",
              "      <th>Study Design</th>\n",
              "      <th>Locations</th>\n",
              "      <th>Time taken for Enrollment</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>29475</th>\n",
              "      <th>NCT03265314</th>\n",
              "      <th>\"LeadHer</th>\n",
              "      <th>a Gender-specific Teen Pregnancy Prevention Curriculum for Girls 15-19\"</th>\n",
              "      <th>https://clinicaltrials.gov/study/NCT03265314</th>\n",
              "      <th>NaN</th>\n",
              "      <th>COMPLETED</th>\n",
              "      <th>\"Alternatives For Girls (AFG) is offering LeadHer as a gender-specific teen pregnancy prevention curriculum to girls between the ages of 14-19 years old who live in Wayne County</th>\n",
              "      <th>MI. The curriculum seeks to demonstrate that girls who participate in LeadHer will show increased rates of avoidance of unprotected sex</th>\n",
              "      <th>will show increased use of birth control and reduced rates of pregnancy. LeadHer will run over a 6-session period covering topics designed to prevent teen pregnancy and develop girls into leaders. The sessions will be co-led by youth (Peer Educators).\"</th>\n",
              "      <th>NO</th>\n",
              "      <th>Teenage Pregnancy</th>\n",
              "      <th>BEHAVIORAL: LeadHer|BEHAVIORAL: Sassy Science</th>\n",
              "      <th>\"Avoidance of unprotected sex</th>\n",
              "      <th>Participants will refrain from having sex or avoid sex without protection.</th>\n",
              "      <th>Up to 12 months post the beginning of intervention.|Use of birth control</th>\n",
              "      <th>Participants decided to have sex</th>\n",
              "      <th>they will use birth control.</th>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>1</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>3</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Improved FEV1/FVC ratio (Forced expiratory volume in one second/ Forced vital capacity) compared to baseline (in %)</th>\n",
              "      <th>Change from Baseline at 3 months|Change of Respiratory function for Asthma patients</th>\n",
              "      <th>Evaluation of respiratory function by spirometry to detect a decreased FEV1 (Forced expiratory volume in one second) variability compared to baseline (in %)</th>\n",
              "      <th>Change from Baseline at 3 months|Morbidity &amp; Exacerbations for COPD patients</th>\n",
              "      <th>Minimisation or absence of hospitalisation and The prevention of future exacerbations \"\"time to onset of the 1st exacerbation in six (06) months\"\"</th>\n",
              "      <th>NaN</th>\n",
              "      <th>6 months|Exacerbations for COPD patients</th>\n",
              "      <th>The prevention of future exacerbations \"\"time to onset of the 1st exacerbation in six (06) months\"\"</th>\n",
              "      <th>NaN</th>\n",
              "      <th>6 months.|Change of Respiratory function for COPD patients</th>\n",
              "      <th>Evaluation of respiratory function by spirometry to detect variation of PEF (Peak expiratory flow) compared to baseline (in %)</th>\n",
              "      <th>Change from Baseline at 3 months|Change of Respiratory function for COPD patients</th>\n",
              "      <th>Evaluation of respiratory function by spirometry to detect variation of FEV (Forced expiratory volume) compared to baseline (in %)</th>\n",
              "      <th>Change from Baseline at 3 months|Morbidity for long COVID patients</th>\n",
              "      <th>Minimisation or absence of hospitalisation</th>\n",
              "      <th>6 months.\"</th>\n",
              "      <th>NaN</th>\n",
              "      <th>Beker Laboratories</th>\n",
              "      <td>1</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-16c17a79-8a95-4f3c-92ea-bbf92332973d')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-16c17a79-8a95-4f3c-92ea-bbf92332973d button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-16c17a79-8a95-4f3c-92ea-bbf92332973d');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-f9175bc9-64e8-486d-8cc0-6c5e4a4fb2cf\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-f9175bc9-64e8-486d-8cc0-6c5e4a4fb2cf')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-f9175bc9-64e8-486d-8cc0-6c5e4a4fb2cf button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "summary": "{\n  \"name\": \"df_clear\",\n  \"rows\": 2,\n  \"fields\": [\n    {\n      \"column\": \"Study Status\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0,\n        \"min\": 0,\n        \"max\": 1,\n        \"num_unique_values\": 2,\n        \"samples\": [\n          1,\n          0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Study Results\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0,\n        \"min\": 0,\n        \"max\": 0,\n        \"num_unique_values\": 1,\n        \"samples\": [\n          0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Conditions\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0,\n        \"min\": 0,\n        \"max\": 0,\n        \"num_unique_values\": 1,\n        \"samples\": [\n          0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Sponsor\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0,\n        \"min\": 0,\n        \"max\": 1,\n        \"num_unique_values\": 2,\n        \"samples\": [\n          0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Collaborators\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0,\n        \"min\": 0,\n        \"max\": 0,\n        \"num_unique_values\": 1,\n        \"samples\": [\n          0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Sex\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0,\n        \"min\": 0,\n        \"max\": 0,\n        \"num_unique_values\": 1,\n        \"samples\": [\n          0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Age\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0,\n        \"min\": 0,\n        \"max\": 0,\n        \"num_unique_values\": 1,\n        \"samples\": [\n          0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Phases\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0,\n        \"min\": 0,\n        \"max\": 0,\n        \"num_unique_values\": 1,\n        \"samples\": [\n          0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Enrollment\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0,\n        \"min\": 0,\n        \"max\": 0,\n        \"num_unique_values\": 1,\n        \"samples\": [\n          0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Funder Type\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"0\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Study Type\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0,\n        \"min\": 0,\n        \"max\": 0,\n        \"num_unique_values\": 1,\n        \"samples\": [\n          0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Study Design\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0,\n        \"min\": 0,\n        \"max\": 0,\n        \"num_unique_values\": 1,\n        \"samples\": [\n          0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Locations\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0,\n        \"min\": 0,\n        \"max\": 0,\n        \"num_unique_values\": 1,\n        \"samples\": [\n          0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Time taken for Enrollment\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 2,\n        \"min\": 0,\n        \"max\": 3,\n        \"num_unique_values\": 2,\n        \"samples\": [\n          0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 468
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_clear.info()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "C0FKX9eQ2b1W",
        "outputId": "bfd59432-0215-46ce-b999-69ef6e75e760"
      },
      "execution_count": 469,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "<class 'pandas.core.frame.DataFrame'>\n",
            "MultiIndex: 2484 entries, ('213', 'NCT03998176', 'Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE', 'https://clinicaltrials.gov/study/NCT03998176', 'BASE', 'COMPLETED', 'This study will evaluate the efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected patients who actively use illicit substances. The study will also evaluate retention in care and adherence to B/F/TAF by self-report and pharmacokinetic analysis.', 'YES', 'HIV-1-infection', 'DRUG: Bictegravir/emtricitabine/tenofovir alafenamide', '\"Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm', ' The percentage of participants achieving HIV-1 RNA \\\\< 50 copies/mL at Week 24 analyzed by the snapshot algorithm', ' which defines a participants virologic response status using only the viral load at the predefined time point within an allowed window of time', ' along with study drug discontinuation status.', ' Week 24\"', '\"Percentage of Participants With Grade 3 or Greater Adverse Events', ' The percentage of participants experiencing grade 3 or greater adverse events at Week 24', ' Week 24|Percentage of Participants With Grade 3 or Greater Adverse Events') to (\"The study's primary goal is to determine the effects of a 12-month pitavastatin regimen on bone metabolism markers in this population. This research could significantly contribute to developing more effective osteoporosis treatments for postmenopausal women\", ' combining bone health and cholesterol management strategies.\"', 'NO', '\"Osteoporosis', ' Osteopenia|Hypercholesterolemia|Menopausal Osteoporosis\"', 'DRUG: Pitavastatin', '\"Change in blood urinary N-Telopeptide of Type I Collagen levels compared to baseline after 6 months', ' nmol BCE/L', ' 6 month\"', '\"Change in blood C-Telopeptide of Type I Collagen levels', ' ng/L', ' 6 and 12 months|Change in blood Osteocalcin levels', ' ng/mL', ' 6 and 12 months|Change in urinary N-Telopeptide of Type I Collagen levels', ' nmol BCE/L', ' 6 and 12 months|Change in blood Procollagen Type 1 N-Terminal Propeptide levels', ' ng/mL', ' 6 and 12 months|Change in blood LDL-cholesterol levels')\n",
            "Data columns (total 14 columns):\n",
            " #   Column                     Non-Null Count  Dtype \n",
            "---  ------                     --------------  ----- \n",
            " 0   Study Status               2484 non-null   int64 \n",
            " 1   Study Results              2484 non-null   int64 \n",
            " 2   Conditions                 2484 non-null   int64 \n",
            " 3   Sponsor                    2484 non-null   int64 \n",
            " 4   Collaborators              2484 non-null   int64 \n",
            " 5   Sex                        2484 non-null   int64 \n",
            " 6   Age                        2484 non-null   int64 \n",
            " 7   Phases                     2484 non-null   int64 \n",
            " 8   Enrollment                 2484 non-null   int64 \n",
            " 9   Funder Type                2484 non-null   object\n",
            " 10  Study Type                 2484 non-null   int64 \n",
            " 11  Study Design               2484 non-null   int64 \n",
            " 12  Locations                  2484 non-null   int64 \n",
            " 13  Time taken for Enrollment  2484 non-null   int64 \n",
            "dtypes: int64(13), object(1)\n",
            "memory usage: 32.4+ MB\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "Sf6zt_TZ2bxk"
      },
      "execution_count": 469,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "quwHlamA2bu0"
      },
      "execution_count": 469,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "EH2lVUCa2bok"
      },
      "execution_count": 469,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "#Remove Funder Type"
      ],
      "metadata": {
        "id": "2SIgNeOe0WYQ"
      }
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "9Y7dCDDM0WPV"
      },
      "execution_count": 469,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "4Jd5BCBk0WM9"
      },
      "execution_count": 469,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "#Train Test split"
      ],
      "metadata": {
        "id": "1wR4NTfC1xqh"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from sklearn.model_selection import train_test_split\n",
        "\n",
        "\n",
        "x=df_clear.drop('Time taken for Enrollment',axis=1)\n",
        "y=df_clear['Time taken for Enrollment']\n",
        "\n",
        "x_train , x_test , y_train , y_test = train_test_split(x, y, test_size=0.2, random_state=42)"
      ],
      "metadata": {
        "id": "GrvkW2Qp1xiV"
      },
      "execution_count": 470,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "x_train.shape"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "er8zrbqs1xfL",
        "outputId": "58d91f5d-f6e9-4ad5-8ec6-40a76f924f9f"
      },
      "execution_count": 471,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "(1987, 13)"
            ]
          },
          "metadata": {},
          "execution_count": 471
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "309l7I3r1xcL"
      },
      "execution_count": 471,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "eHyXSIBL1xZ9"
      },
      "execution_count": 471,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "o3D6oCDj1xXG"
      },
      "execution_count": 471,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "#Standeerd Scaling"
      ],
      "metadata": {
        "id": "U_GxF5K81eB7"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from sklearn.preprocessing import StandardScaler\n",
        "\n",
        "scale = StandardScaler()\n",
        "\n",
        "StandardScaler_x_train = scale.fit_transform(x_train)\n",
        "StandardScaler_x_test = scale.transform(x_test)"
      ],
      "metadata": {
        "id": "oowC8TCD0WKw"
      },
      "execution_count": 472,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "sns.displot( df_clear['Age'], kde=True , bins=30)\n",
        "plt.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 506
        },
        "id": "CCuX0M0e0WFf",
        "outputId": "82d4ceb3-919e-4f20-fdbe-ec6533877372"
      },
      "execution_count": 480,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 500x500 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "sns.displot( df_clear['Sex'], kde=True , bins=30)\n",
        "plt.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 506
        },
        "id": "FtrZKHa10WC2",
        "outputId": "bc65292b-a48a-4234-9865-bbce811bda81"
      },
      "execution_count": 481,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 500x500 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "sns.displot( df_clear['Funder Type'], kde=True , bins=30)\n",
        "plt.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 507
        },
        "id": "IlVcL1Io0V-R",
        "outputId": "f1e99748-570c-4f7f-d533-ccb98e719192"
      },
      "execution_count": 482,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 500x500 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "sns.displot( df_clear['Time taken for Enrollment'], kde=True , bins=30)\n",
        "plt.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 506
        },
        "id": "COlUWTKk5StK",
        "outputId": "05ce767a-95ba-473d-f115-48a123ef4a21"
      },
      "execution_count": 483,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 500x500 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "sns.displot( df_clear['Locations'], kde=True , bins=30)\n",
        "plt.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 506
        },
        "id": "3q5VAfSN5Sqp",
        "outputId": "4421ddf5-57cb-4080-9535-7828e2cb4c2d"
      },
      "execution_count": 484,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 500x500 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "NvALRDhT5Sky"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "uTPdaZPv5-rQ"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "w7F8KIcZ5-la"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "X1r2q6ne5-jD"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "ikHIu0l-5-gV"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "OJEHJp2r5-co"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "Ab9mERRu5-aM"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "#Apply Algorithem"
      ],
      "metadata": {
        "id": "xhk9R4O057mc"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "#DecisionTree"
      ],
      "metadata": {
        "id": "yFT8dpE46K5x"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from sklearn.tree import DecisionTreeClassifier\n",
        "\n",
        "DFT= DecisionTreeClassifier()\n",
        "DFT.fit(StandardScaler_x_train, y_train)\n",
        "\n",
        "y_pred = DFT.predict(x_train)\n",
        "\n",
        "accuracy_score(y_train, y_pred)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "LOUyT-kS6Ctz",
        "outputId": "c6e2aded-476f-4c4f-da59-250926e3eb2d"
      },
      "execution_count": 485,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "0.6542526421741318"
            ]
          },
          "metadata": {},
          "execution_count": 485
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "4B92nW-D6Cn6"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "#Cross validation\n",
        "cross_val_score(DFT, StandardScaler_x_train , y_train , cv=5).mean()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "f9ekIusF5_wr",
        "outputId": "6dc4d9f2-19a9-4068-f137-6f4eaf765d78"
      },
      "execution_count": 487,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "0.626569877093275"
            ]
          },
          "metadata": {},
          "execution_count": 487
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "#RandomForest"
      ],
      "metadata": {
        "id": "FdoZ7SSM6Nn9"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "\n",
        "from sklearn.ensemble import RandomForestClassifier\n",
        "\n",
        "RFC = RandomForestClassifier()\n",
        "RFC.fit(StandardScaler_x_train, y_train)\n",
        "\n",
        "y_pred = RFC.predict(StandardScaler_x_test)\n",
        "\n",
        "accuracy_score(y_test, y_pred)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "0861HXeE5_uT",
        "outputId": "99aacfb2-b77e-4c43-c31c-cec016d49db3"
      },
      "execution_count": 488,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "0.6559356136820925"
            ]
          },
          "metadata": {},
          "execution_count": 488
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "#Cross validation\n",
        "\n",
        "cross_val_score(RFC, StandardScaler_x_train , y_train , cv=5).mean()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "HCSTkL5G5_rz",
        "outputId": "16948cbe-08d6-4d11-9c5d-ba0bd66b9533"
      },
      "execution_count": 489,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "0.6341189575079428"
            ]
          },
          "metadata": {},
          "execution_count": 489
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "#Logestric regraction"
      ],
      "metadata": {
        "id": "iJUJrjCT6mvQ"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from sklearn.linear_model import LogisticRegression\n",
        "\n",
        "LOR = LogisticRegression()\n",
        "LOR.fit(StandardScaler_x_train, y_train)\n",
        "\n",
        "\n",
        "y_pred = LOR.predict(StandardScaler_x_test)\n",
        "accuracy_score(y_test, y_pred)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "R3wQGY2w5_pc",
        "outputId": "f4b7e124-dfdf-4c40-b91f-0bd0eb9a065e"
      },
      "execution_count": 490,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "0.670020120724346"
            ]
          },
          "metadata": {},
          "execution_count": 490
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "cross_val_score(LOR, StandardScaler_x_train , y_train , cv=5).mean()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "a3deaGn45_lK",
        "outputId": "77af611f-6bb7-4690-c933-feac618d40b4"
      },
      "execution_count": 491,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "0.6628090072528892"
            ]
          },
          "metadata": {},
          "execution_count": 491
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "Y2kngxO25_ir"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "TG771NED5_cr"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "yWWEO4sF5_aF"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "zJh3EUkb5Sgr"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "Nu6AWiit5Sd5"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "CVotDgB55SZx"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "eGwMWmTi5SWp"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "4PqJ9-7v5ST9"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "WlTyZcL8zcTd"
      },
      "execution_count": 476,
      "outputs": []
    }
  ]
}